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Computational medicinal chemistry is a rapidly growing field of modern science. Mathematics 
and computational sciences have long played a dominant role in our understanding of physics, chemis-
try, and other life sciences. However, the wholesale application of computational methods in medicine, 
more specifically in drug design, is relatively recent. Currently, the intriguing questions of molecular in-
teractions, conformational molecular behavior, protein folding, cell signaling, cell movement, genomics, 
ecology, infectious diseases, and diseases development are being successfully tackled with and analyzed 
using mathematical and computational methods.
This thesis is based upon studies conducted during the period between March 2005 and August 
2009 at the Molecular Modeling group (2005-2007), Universidad Nacional de San Luis, Argentina, and 
at the Molecular Neurobiology group (2007-2009), Rijksuniversiteit Groningen, The Netherlands. These 
studies have been funded by the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), 
Argentina and by the Rijksuniversiteit Groningen, The Netherlands. The thesis consists of a total of 
eight chapters, five of which correspond to papers published in various international journals, and the 
material for yet another chapter is in preparation to be submitted for publication. These chapters cover 
various aspects of computational medicinal chemistry applied to peptide compounds with potentials to 
become a drug. The majority of these papers are written jointly with other scientists, some of whom are 
more theoretical chemists than biologists, while some are more biologists that theoretical chemists. In 
the first chapter, however, I have given a general introduction to peptides in medicinal chemistry and a 
survey of the new technological/scientific approaches. Thus, chapter 1 has been written in such a way 
that it is relatively easy to read for any person who possesses a minimum scientific knowledge. This is 
also valid for chapter 8, General discussion & future perspectives.
Besides my profound scientific background, I am deeply interested in several forms of art, 
among these however, visual art, especially painting is the form that allows me to express myself as an 
artist. My affinity for art and my scientific education give me a creative and analytical approach to life 
that I wanted to reflect in this thesis. Therefore, parallel to the hard scientific content presented in this 
thesis, I have decided on a more personal form of presentation, introducing each chapter with a paint-
ing. Thus, my relation to creative work can also be presented with the help of artistic suggestions in 
harmony with scientific content. The creation of these paintings, including the cover painting, has been 
based on selected key words, the inspirational words, related to the research topic of each chapter. Far 
from making a literal interpretation of the inspirational words, these painting are a collection of life-
experiences collected during my stay in Groningen. All these art works have been made “alla prima” 
(Italian for “at once”), which is a style of painting where, instead of building colors up with layers or 
glazing over an underpainting, the whole painting is completed while the paint is still wet. The charm 
of alla prima is that it retains the fresh and spontaneous feelings that come as one paints. It seems to me 
the most intuitive way to paint.
This thesis is my ultimate attempt to harmonically conjugate art and science into a personal 
project. Of course, no such project can be free from errors and incompleteness, which with time and 
more hard work can be improved in a near future. ■
M.F. Masman, 5th May 2010, Groningen.“Every portrait that is painted with feeling is a portrait of the artist, not of the sitter”
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“Bitter-sweetly and paradoxically, the disappointment 
of a left hand allows  the right hand to come”
(M.F. M.)   General introduction:
Peptides as a promising source of therapeutic agents
Marcelo F. Masman
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Chapter 1
Although the important role that pep-
tides and proteins play in almost all biological 
processes was already known by 20th’s century 
scientists, its far fetching consequences were not 
fully understood nor appreciated by most or-
ganic and medicinal chemists at that time. This 
was partly due to the still limited knowledge of 
synthetic amino acids, peptides and peptidomi-
metic compounds. The lack of appreciation of the 
stereo-structural and conformational properties 
of amino acids as building blocks of peptides and 
proteins was probably another reason. However, 
this has changed considerably thanks to the sci-
entific progress of the 20th century. One of the 
most likely reasons for this to happen was the increas-
ing need to produce peptides on a larger scale to study 
their characteristics. This became more urgent after the 
discovery of many new compounds of this kind with 
extremely important biochemical activities, such as 
peptide hormones, neurotransmitters, enzymes, cy-
tokines, growth factors, adhesion proteins, glycopro-
teins, receptors, antigenic sites, antibodies, structural 
proteins, oncogenes, ion channels and so on. In parallel 
major progress in peptide synthesis at the end of the 
20th century (in fact at the end of 1980s) served as a 
stimulus to create and use large peptide libraries. The 
solid-phase method of peptide chemistry initiated by 
Merrifield introduced a tremendous step forward in the 
synthesis of peptides (Merrifield 1986; Merrifield 1963). 
The subsequent development of multiple peptide syn-
thesis by Geysen and colleagues (Geysen 1985; Geysen 
et al. 1984; Geysen et al. 1987), and the “tea bag method” 
by Houghten and coworkers (Houghten 1985) have 
clearly changed the perspectives in the potential use of 
these compounds in the medicinal chemistry field.
Nowadays, at the beginning of the 21st 
century, we may be on the brink of a therapeu-
tic revolution partly as a result of the accelerated 
advance of complex computational techniques 
on the medicinal chemistry field. The use of 
peptides as therapeutic drugs has rapidly grown 
over the last decades, and this trend is likely to be 
continued due to our burgeoning knowledge on 
the activity-structure relationship. It is now well 
known that peptides regulate most physiological 
processes, acting at some sites as endocrine or 
paracrine signals and at others as neurotransmit-
ters or growth factors.  Peptides are already being 
used therapeutically in such diverse areas as neurology, 
endocrinology and haematology (Edwards et al. 1999).
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One of the fist problems that medicinal 
chemists face in the process of peptide drug dis-
covery is the fact that most peptides cannot be 
administered orally since they are rapidly broken 
down by gastrointestinal enzymes, thus requir-
ing subcutaneous  or intravenous application. 
Therefore, great efforts are focused on alternative 
routes of delivery of this type of drugs, including 
inhalation, buccal, intranasal and transdermal 
routes, as well as novel delivery systems such as 
the use of protective liposomes. An exciting fu-
ture area of drug research relate to peptides for 
treatment of brain disorders (Fulop et al. 2004; 
Granic et al. 2009; Hetenyi et al. 2002b; Juhasz et 
al. 2009; Permanne et al. 2002; Soto et al. 1996; 
Soto et al. 1998; Tjernberg et al. 1997; Tjernberg et 
al. 1996). Peptidergic drugs for combatting brain 
diseases are subject to dual problems of local-
ized targeted delivery, and the blood-brain bar-
rier (BBB) that prevent peptide compounds from 
gaining ready access to the required site of action, 
although some solutions are appearing at the ho-
rizon of peptide chemistry. Additional clinical 
value is created with the development of rational 
drug design and specific synthetic modification of 
the peptide molecular structure in order to endow 
the analog ideally with only one specific activity. 
This way new peptides or peptidomimetic com-
pounds can express the desired specific biological 
property. Moreover, by following such rational 
approaches and designs the resistance of the pep-
tide to enzymatic break-down can be increased. 
The most frequently applied approach to render 
a peptide resistant to enzymatic attack has been 
by replacement or modification of chemical func-
tional groups, such as N- and C-terminal groups, 
disulfide bond, N-alkylation,  N-arylation, etc. 
The nature of these changes is usually such that 
the hydrophobicity of the peptide is enhanced, 
and as a result the compounds may permeate into 
the cell instead of remaining in the extracellu-
lar system, or may be transported over the BBB 
membranes. However, it is important to realize 
that if these agents cannot be broken down in vivo 
due to an extreme resistance to enzymatic attack 
and accumulate intracellularly, their clinical ap-
plication may cause undesirable consequences in 
patients. Generally speaking however, chemical 
modifications on the peptide molecular structure 
based on conformational considerations, rather 
than on an empirical or intuitive approach, in 
principle should lead to analogs with the required 
properties and biological activity.
Nevertheless, peptides thus far have 
not played a major commercial role as therapeu-
tic agents, at least not at industrial levels, with 
certain exceptions such as insulin and adreno-
corticotropic hormone (ACTH). However, this 
situation may rapidly change as more and more 
naturally occurring or synthetic low molecular 
weight peptides with interesting biological activi-
ties are being discovered or designed.
Attractive examples of rational design of 
potential peptidergic drugs are the neurohypoph-
yseal hormones (Kotelchuck et al. 1972; Marks and 
Walter 1972; Pliska et al. 1967; Urry and Walter 
1971; Walter et al. 1972; Walter et al. 1971; Walter 
and Shlank 1971; Walter et al. 1974), captopril 
and derivatives (Atkinson and Robertson 1979; 
Bull et al. 1985; Ondetti et al. 1979; Patchett et al. 
1980; Wyvratt and Patchett 1985), antifungal pep-
tides (Carotenuto et al. 2007; Cutuli et al. 2000; 
Grieco et al. 2003; Grieco et al. 2005; Masman 
et al. 2009b; Masman et al. 2006; Masman et al. 
2008), anti amyloid peptides or so-called “β-sheet 
breakers” (Fulop et al. 2004; Granic et al. 2009; 
Hetenyi et al. 2002b; Juhasz et al. 2009; Soto et 
al. 1996; Soto et al. 1998; Tjernberg et al. 1997; 
Tjernberg et al. 1996), amongst others. In the case 
of neurohypophyseal hormones their proposed 
preferred conformations (Urry and Walter 1971; 
Walter et al. 1972) suggest that substitutions of 
amino-acid residues in the corners of the 3-turns 
of the hormones (positions 3, 4, 7, and 8, which 
are not primarily involved in the intramolecular 
stabilization of the peptide backbone and, there-
fore, are available for intermolecular interactions) 4 
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would lead to analogs with a selectively modified 
activity profile. By these modifications certain ac-
tivities will be enhanced while others will be di-
minished or even abolished in these compounds 
(Walter et al. 1971; Walter and Shlank 1971; Walter 
et al. 1974). This example is given to illustrate the 
importance of knowing and understanding the 
conformational behavior as well as the structur-
al intricacies of a potential peptide drug. It is at 
this stage where computational chemistry shows 
its invaluable help in the field of the medicinal 
chemistry.
Peptides, as many other drugs, act by 
binding to specific cell surface receptors. The per-
fect therapeutic agent would be a small-molecular-
mass chemical compound that mimics the natural 
receptor ligand, cheap to manufacture, stable at 
normal storage conditions, with known pharma-
cokinetic and pharmacodynamics, and reach the 
site of action after an easy and non-invasive e.g. 
oral administration. However, receptors are large 
protein complexes with many potential binding 
sites, whereas peptides have a complex secondary 
and tertiary structure, both of which determine 
the peptide’s specificity as well as its sensitivity. 
As a consequence of the complex requirements of 
peptide drugs, the production of successful pep-
tidomimetics using chemical libraries is largely 
unsuccessful. Therefore, large part of the design 
of peptide drugs still relies on the native peptide 
for therapeutic purposes, as will be addressed in 
further chapters of this thesis.
It is well-known that the discovery of 
new lead structures is one of the principal bot-
tlenecks in medicinal chemistry. In this sense 
peptides could be an interesting source of new 
structures for further developments. Because of 
the aforementioned one may ask: why peptides? 
Peptides constitute a class of organic molecules 
that interact with, essentially, all the rest of the 
known chemical world: peptides can control, 
catalyze and modulate most biological processes 
and are highly compatible with and generally 
nontoxic to living systems. In addition, synthet-
ic peptide chemistry is perhaps the most recent 
highly developed domain of biological chemistry, 
with high-yield stereospecific synthetic method-
ologies.
The list of peptides as potential thera-
peutic drugs is huge and space limitations do 
not permit to discuss them all. It is beyond the 
scope of this chapter to focus on peptide therapies 
such as luteinizing-hormone-releasing hormone 
(LHRH), growth hormone, arginine vasopres-
sin or the very interesting peptide, cyclosporine 
(Borel 1989a, b; Borel et al. 1989; Lee et al. 1990). 
Instead, we will shortly address some exciting ar-
eas of research as well as recent developments in 
the use of more established peptide therapies.
Historically, it is well known that in-
sulin was the first peptide to be isolated and ad-
ministered therapeutically, and is still the most  
commonly prescribed peptide. However, it is 
needed yet to find novel analogues and chemical 
mimics, as well as new methods of administra-
tion. Manipulation of the insulin molecule has al-
lowed the development of shorter-acting insulin 
analogs e.g. Lispro insulin which can be rapidly 
absorbed, readily dissociates into insulin mono-
mers, and produces plasma levels that more close-
ly mimic the normal postprandial insulin profile. 
Thus, Lispro can be injected immediately prior to 
a meal, unlike conventional short-acting insulin 
analogs that should be injected half an hour ear-
lier (Puttagunta and Toth 1998).
Peptide antibiotics have been under in-
vestigation for a number of years. Currently one 
family of antibiotic peptides is been distributed, 
the polymyxins, namely; polymyxin B and colis-
tin (polymyxin E). Colistin is occasionally given 
by injection to treat Pseudomonas aeruginosa in 
patients with cystic fibrosis, though more fre-
quently aerosol preparations have been used (Diot 
et al. 1997). Polymyxin B is just used as a topi-
cal preparation for local eye and ear infections. 
Both antibiotics are prescribable for local skin  5  
chapter 1
infections. Several classes of other antibiotic pep-
tides including defensins, protegrins, magainins, 
tachyplesins, cecropins, mutacins and clavanins 
are under investigation. The inability of present 
non-peptide antibiotics to kill certain bacteria, 
make it likely that antibiotic peptides will form an 
important part of our fight to defeat multi-drug 
resistance in the twenty-first century.
At the neurological level, especially in 
the central nervous system (CNS), there have 
been described more than 100 peptides acting as 
neurotransmitters, neuromodulators and growth 
hormones. Amongst them, it is worthy to mention 
the angiotensins, neuromedin B, gastrin releas-
ing peptide, bradisin, calcitonin, β-endorphin, 
Leu-encephalin, Met-encephalin, endothelins, 
gastrin, neuropeptide Y, oxitocine, somatostatin, 
substance P, vasopressin, glucagon, etc. In the 
field of medicinal chemistry, there are numer-
ous examples of drugs that were developed on 
the basis of peptide structures. Amongst the best 
known examples we should mention the encepha-
lin and endorphins mimicking drugs, agonists of 
cholecystokinin, agonists and inhibitors of angio-
tensin-converting enzyme (ACE), etc. The better 
known peptide neurotransmitters are, without 
any doubt, the encephalins and the endorphins. 
Thus, the synthesis of peptidomimetic analogues 
with a better agonist activity, higher stability and 
potentially orally administrated is one of the most 
explored subjects in medicinal chemistry. 
Another well-known example is the de-
velopment of captropril and the anti-hypertensive 
drugs acting on angiotensin-converting enzyme 
(or ACE, dipeptidyl carboxi-peptidase I). In 1965, 
Ferreira reported that a mixture of peptides of the 
venom of the South American pit viper Bothops 
jararaca potentiated the action of bradykinin 
by inhibition of some bradykininase activity 
(Ferreira and Rocha e Silva 1965). Bakhle and co-
workers subsequently showed that these peptides 
also inhibited the conversion of angitensin I to 
angiotensin II (Bakhle et al. 1969). Thus, nine ac-
tive peptides were isolated from this venom; the 
structure of a pentapeptide (Pyr-Lys-Trp-Ala-
Pro, where Pyr stands for L-pyroglutamate) was 
identified (Ferreira et al. 1970a). This peptide was 
shown to inhibit the conversion of angitensin I to 
II and bradykinin degradation in vitro (Ferreira 
et al. 1970b) and in vivo (Stewart et al. 1971). The 
structures of six more related peptides were de-
termined by Ondetti and coworkers (Ondetti et 
al. 1971). Some of these peptides have shown a 
significant in vivo potency and were effective in 
lowering blood pressure. Although none of these 
peptides were effective when administrated oral-
ly, they laid the foundation for the design of orally 
active ACE inhibitors nowadays worldwide used.
From the above mentioned finding it ap-
pears that peptides are an excellent new source to 
obtain novel drugs. However, we must be aware 
that there are also serious limitations with respect 
to the use of peptides as new drugs. In terms of 
drug bioavailability, stability, pharmacokinetics 
and pharmacodynamics, most peptides are as 
bad as proteins, and in general do not make good 
drugs unless modifications have been performed 
on their structures. It is clear that in general pep-
tides possess significant limitations to be used di-
rectly as drugs; however many of these peptides 
are excellent starting structures to develop new 
drugs with novel and specific mechanisms of ac-
tion and therefore developing new effective and 
safer therapeutic agents.
Without any doubt, the knowledge 
gained over the last decades regarding electronic 
molecular structure, as well as conformational 
behavior of peptide compounds is one of the 
fundamental factors that have allowed peptides 
to be, nowadays, an important source of new po-
tential therapeutic agents with a wide variety of 
biological activity. This knowledge of the confor-
mational/electronic structure would not be acces-
sible without the great support of computational 
techniques to molecular modeling.6 
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  Molecular Modeling: A Powerful Tool To Study Peptides  1.2 The key to successfully analyzing the 
complex relationship between structure and 
function of peptides requires data and informa-
tion from both experimental and computational 
technologies and the integration of fundamental 
principles from a range of disciplines like for ex-
ample molecular pharmacology, physical chemis-
try, computational chemistry, medicinal chemis-
try and molecular biology amongst others. All in 
all, modern medicinal chemistry has become an 
extremely multidisciplinary field in which chem-
istry, pharmacology, biomedical science, medi-
cine and theoretical physical-chemistry has to be 
integrated.
The ultimate goal of the medicinal 
chemist is to discover by rational design a mol-
ecule which will produce a desired biological 
activity without producing undesirable collat-
eral effects. In this sense it must be noted that 
although the present available techniques of mo-
lecular modeling have allowed more “rational” 
and planned researches with respect to those de-
veloped in the last century, they are still far from 
perfect. One may be forced to seek compromises 
in view of the complexity of the biological system 
and individual variations. On a more positive 
note, however, molecular modeling studies using 
theoretical calculations can be used to select pep-
tides having high probability of success as useful 
drugs after an adequate chemical modification. 
Since the number of peptides and peptide mimet-
ics to choose from synthetic or natural sources 
is astronomically large, any methodology which 
increases the odds of success is greatly welcomed.
Molecular modeling; a powerful tool to study 
peptides.
One of the first references of the use 
of molecular modeling in drug design is from 
1955 (Marshall 1996). Since then, computational 
techniques have initiated a revolution in drug 
design. Researchers use computational tech-
niques to model the therapeutic target in order 
to determine the essential characteristics that the 
new drug must possess. These characteristics are 
known as a pharmacofore. Once a pharmacofore 
is determined and defined, we may proceed on 
one of two routes. Part of this process may in-
volve performing quantitative structure-activity 
relationship (QSAR) analysis on a given set of 
data. Also, based on the pharmacophore, one may 
“invent” potential compounds that may perform 
the required function. Calculations of these “vir-
tual compounds” can be produced, and “virtual 
tests” can be run to assess its suitability before an 
expensive, and sometimes difficult, synthesis at-
tempt is made. Once the candidate compound has 
been determined, molecular modeling can help 
to determine which ones are the most promising 
compounds. Virtual experiments are cheaper, 
faster and safer than real experiments, and data 
can help us eliminate compounds that will not 
successfully perform the required task.
In spite of the technological advances, 
the key information that permits rational ap-
proaches to drug design is knowledge of the 
etiology of a given disease, or at least of the bio-
chemical process which is disturbed. The genetic 
revolution had added a major new dimension to 
the role of computational chemistry in the me-
dicinal chemistry field. The search for key targets 
in genes offers computational medicinal chemists 
the opportunity to fight many diseases at their 
bio-molecular source. Thus, the so-called struc-
ture-based drug design (SBDD) describes the de-
sign of the therapeutic agent (ligand) based on the 
structure of the target or receptor molecule. In 
SBDD, the modeler seeks a molecule to comple-
ment the active site of a 3D structured molecular 
target, which is typically determined from X-ray, 
nuclear magnetic resonance (NMR), or protein 
homology modeling studies. Once the 3D struc-
ture of a receptor protein’s active site is known, 
modelers use that knowledge to find or design a 
corresponding ligand, the potential new drug.  7  
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The active site must be characterized to determine 
the location of the major functional groups, which 
are typically hydrophobic and hydrogen bonding 
sites. Once the geometry and functional features 
of the active site are known, modelers look for 
the “inverse” shape and feature to describe the 
ligand’s complementary structure.
Modern simulation methods enable to 
study the properties of larger and more complex 
systems than before. Dynamics simulations pro-
vide a tremendous amount of information that 
is not available from a static approach of the sys-
tem. For example, a protein might “open up” to 
reveal an apparently inaccessible active cleft that 
enables a ligand or potential drug candidate to 
bind. Simulating the movements and conforma-
tional behaviors of molecules reveals a deep un-
derstanding of intermolecular interactions and 
the motions responsible for controlling biological 
and chemical activity. While the traditional lock 
and key model for protein-ligand docking is use-
ful as a first approximation for ligand interaction, 
highly accurate docking requires the consider-
ation of conformational changes on the ligand 
and/or the receptor. In addition, solvent effects 
may play a crucial role in the binding of ligands 
(Suvire et al. 2001; Zamora et al. 2003).
In today’s medicinal chemistry labora-
tory, modeling and simulation methods are an 
integral part of developing drugs that optimally 
bind to receptor with great selectivity and im-
proved efficacy. Having an accurate picture of 
what happens at the molecular level includes an 
understanding of how atoms move. By incorpo-
rating simulations into the drug design process, it 
is possible not only help to optimize the potency 
of existing lead compounds, but de novo drug de-
sign.
The exponential increase in power 
and software availability that has occurred with 
molecular modeling in just the past 20 years is 
very promising. Faster computers with superior 
graphics capabilities will become more inexpen-
sive, and molecular modeling software packages 
will be more user friendly. It is clear that the role 
of computational simulation in drug discovery 
analyzing 3D structures of targets gives an un-
precedented insight into the conformational be-
havior and mechanics of drug binding and bio-
logical activity that can be available for almost 
any scientist.
The goal of determining the stereoelec-
tronic feature of a peptide from its constituent 
amino acid sequence stems from the universal 
acceptance that the activity of a peptide is a di-
rect consequence of its folded or unfolded mo-
lecular configuration and its physicochemical 
properties. The capability of describing and un-
derstanding the structure-activity relationship of 
peptides is essential to obtain successful results. 
Nevertheless, the conformational study of pep-
tides is extremely complex due to the structural 
diversity that they posses, not only in terms of 
chemical functionality, but also in terms of con-
formational space research. Each peptide build-
ing block, namely amino acids, has mainly two 
conformational spaces to be taken into account: 
the backbone (φ-ψ Ramachandran space) and the 
side-chain groups (χ space), both of which have a 
considerable high conformational flexibility (fig-
ure 1.1). Hence, a simple hexapeptide not only 
has its unique chemical structure but also has 
hundreds or even tens of thousands of available 
conformations at physiological temperature. In 
fact, it is well established that not only one but 
several of this possible conformational struc-
ture can trigger the activation signal in a given 
biological system, depending on the surrounding 
environment (solvent, temperature, pressure, pH, 
salt strength, concentration, etc) as well as on the 
molecular interactions with the corresponding 
receptor molecule.
Once the biologically relevant struc-
ture of a given peptide is obtained it is necessary 
to carry out an electronic study which has to be 
done at the highest level of theory possible, in 8 
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and Truhlar 1981). More positive potentials re-
flect nucleus predominance, while less positive 
values represent rearrangements of electronic 
charges and lone pairs of electrons. The funda-
mental application of this study is the analysis of 
non-covalent interactions (Politzer and Truhlar 
1981) mainly by investigating the electronic distri-
bution in the molecule. Thus, this methodology 
was used to evaluate the electronic distribution 
around the molecular surface for peptides report-
ed in this thesis.
It is clear that an astronomical increase 
of computing power will become available in the 
foreseeable future. A retrospective and prospec-
tive view about the developments of softwares 
and hardwares from 1950 to 2050 was previ-
ously reported showing the amazing increase in 
the computer capabilities (Chasse et al. 2001). 
Furthermore, it becomes clear that such an un-
precedented increase in computing capability will 
make it possible to produce more accurate theo-
retical results than can be measured experimen-
tally at a substantially lower cost. It was estimated 
that this will occur around 2020 (Enriz 2005).
In the present thesis, the studies on 
synthesis, bioassays and molecular modeling of 
small-size peptides have been directed towards 
two problems that are of great interest in today’s 
medicinal chemistry; (i) the search of new pep-
tides with antifungal activities and (ii) the devel-
opment of novel anti-amyloid peptides with po-
tential therapeutic properties for  the treatment of 
Alzheimer’s disease. Hereinafter, a brief descrip-
tion, as well as the importance and necessity of 
the above mentioned study goals is given.
1.3
Figure 1.1: Schematic representation of an L-amino acid 
containing peptide. The ω dihedral angles represent the 
torsion of the peptide linkage itself. All ω dihedral angles 
are represented in their trans (ω ≈ 180º) configuration. The 
main dihedral angles that define the peptide backbone (φ 
and ψ) are also shown. R stands for the side chain moiety 
which can include multiple χ dihedral angles depending 
on the nature of the residue, e.g.: the side chain of the resi-
due Arg has 5 χ torsions while the side chain of a residue 
Gly does not possess this type of dihedral angle.
order to have the optimal description of its elec-
tronic distribution. Of course, to achieve this 
goal it is mandatory to use quantum mechanics 
approaches. Knowledge of the stereoelectronic at-
tributes and properties of peptides will contribute 
significantly to the elucidation of the molecular 
mechanism involved in the biological activity. 
Molecular Electrostatic Potentials (MEPs), which 
are the visualization of the molecular electrostatic 
fields, offer an informative description of the ca-
pacity of peptides to generate stereoelectrostatic 
forces. MEPs have been shown to provide reliable 
information, both on the interaction sites of mol-
ecules with point charges and on the compara-
tive reactivity of those sites (Murray and Politzer 
1998; Naray-Szabo and Ferenczy 1995; Politzer 
  The need for new antifungal drugs
Fungal infections have continued to 
be a major medical problem during the past two 
decades especially involving immunocompro-
mised patients (Georgopapadakou and Tkacz 
1995; McNeil et al. 2001; Pfaller and Diekema 
2007; Walsh et al. 2004). Invasive fungal infec-
tions, as well as dermatomycoses produced by 
fungal organisms with even low virulence can be 
life-threatening (Nagiec et al. 1997) for patients 
such as neonates, cancer patients receiving che-
motherapy, organ transplant patients, and burn 
patients, apart from those with acquired immu- 9  
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nodeficiency syndrome (AIDS). Other risk factors 
include corticosteroid and antibiotic treatments, 
diabetes, lesions of epidermis and dermis, mal-
nutrition, neutropenia and surgery (Walsh et al. 
2004). Many fungal infections are caused by op-
portunistic pathogens that may be endogenous 
(Candida infections) or acquired from the envi-
ronment (Cryptococcus and/or Aspergillus infec-
tions). Patients with significant immunosuppres-
sion frequently develop Candida esophaguitis. 
Criptococcosis, caused by the encapsulated yeast 
Cryptococcus neoformans, which has been the 
leading cause of fungal mortality among HIV-
infected patients. This organism has predilec-
tion for the central nervous system and leads to 
severe, life-threatening meningitis. In addition, 
an increasing number of normal individuals, in-
cluding children in third-world nations that suf-
fer deficient sanitation and education, have fungal 
infections, specially those involving the skin and 
mucosal surfaces (Ablordeppey et al. 1999; Freixa 
et al. 1998).
Although it appears that many drugs 
are available for the treatment of systemic and su-
perficial mycoses, there are in fact only a limited 
number of efficacious antifungal drugs (Walsh et 
al. 2004). Many of the drugs currently available 
have undesirable effects or are very toxic (e.g.: 
amphotericin B); are fungistatic and not fun-
gicidal (e.g.: azoles), or can lead to the develop-
ment of resistance as in flucytocine (also called 
5-fluorocytosine or 5-FC) (White et al. 1998). 
Amphotericine B, developed in the late 50’s, still 
remains a widely used antifungal drug, most re-
cently gaining renewed life through lipid based 
formulations. According to Polak ideal drugs to 
cure fungal infections have not been discovered 
yet (Polak 1999). Certain conditions are required 
for a compound to be a good antifungal agent: it 
must be fungicidal rather than fungistatic and 
have a good broad spectrum of activity, a mini-
mum emergence of resistant strains, and a selec-
tive mechanism of action. In addition, the agent 
should have minor toxic side effects and good 
availability (Ablordeppey et al. 1999; Polak 1999; 
Zacchino et al. 2003). In the meantime, resistance to 
currently available antifungal agents continues to grow 
(Bartroli et al. 1998a). Although combination therapy 
has emerged as a good alternative to bypass these dis-
advantages (Bartroli et al. 1998b; Polak 1999), there 
is a real need for a next generation of safer and more 
potent antifungal agents (Bartroli et al. 1998b; Walsh 
et al. 2004). This event resulted in the identification of 
novel molecules, which could result useful for a future 
development.
In the course of a screening program for 
new and selective antifungal compounds, the molecu-
lar modeling group of the National University of San 
Luis, Argentina has previously reported the antifungal 
activity of different compounds obtained from natu-
ral (Bisogno et al. 2007; Freile et al. 2003; Zacchino et 
al. 1999; Zacchino et al. 1997; Zacchino et al. 1998) and 
synthetic (Giannini et al. 2004; Karolyhazy et al. 2003; 
Kouznetsov et al. 2000; Kouznetsov et al. 2008; Lopez 
et al. 2001; Sortino et al. 2007; Suvire et al. 2006; Vargas 
M et al. 2003; Villagra et al. 2003) sources. Among them 
a series of 4-aryl-or 4-alkyl-N-arylamino-1-butenes 
(“homoallylamines”) and related tetrahydroquinolines 
and quinolines (Kouznetsov et al. 2000; Vargas M et al. 
2003) display a range of antifungal properties against 
dermatophytes, fungi that produce most of the derma-
tomycoses in humans. This study was extended intro-
ducing a new series of 4-N-arylamino-1-butenes con-
taining the pyridinyl or quinolinyl moieties at C4 and 
other structurally related compounds (Kouznetsov et 
al. 2008). Regarding their mode of action, active com-
pounds showed in vitro inhibitory activities against  
(1,3) β-D-Glucan-synthase and mainly against chitin-
synthase, enzymes that catalyze the synthesis of ma-
jor fungal cell wall polymers (Kouznetsov et al. 2008; 
Sortino et al. 2007; Suvire et al. 2006). Since fungal but 
not mammalian cells possess a cell wall, these struc-
tures appeared as promising leads for the development 
of selective antifungal compounds. Other classes of 
structure possessing interesting potential as antifungal 
agents are the peptides. Some of the most relevant an-
tecedents about these compounds are discussed in the 
next section.10 
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  Cationic peptides acting as antifungal compounds
With an understanding of the pivotal 
role that cationic host defense (antimicrobial) 
peptides play in preventing infections by micro-
bial pathogens in many organisms, it has been 
proposed that these peptides might form the 
foundation for a new class of clinically useful an-
timicrobials. To date, more than 700 peptides (in 
virtually all species of life) have been described 
that not only kill pathogenic microorganisms, 
including Gram-positive and Gram-negative 
bacteria, viruses, protozoa and fungi, but also 
play a central role in recruiting and promoting 
elements of the innate immune system (Bowdish 
and Hancock 2005; Brown and Hancock 2006; 
Hancock 2001; Hancock 1997). This enormous 
peptide diversity is achieved through several 
structural classes, whereby all peptides, regardless 
of class, share a net positive charge and approxi-
mately 50 % hydrophobic residues, which confers 
the ability to fold into amphiphilic conformation 
upon interaction with membranes (Zasloff 2002). 
Although, it was in the early 80’s when the use 
of amphipathic structures from the structural 
analyses of complement toxins was settled as a 
non-enzymatic way of cell membrane disruption 
(Bhakdi et al. 1983; Bhakdi and Tranum Jensen 
1983), its mechanisms of action, at the molecular 
level, was not fully understood by then.
A major motivation for therapeutic pep-
tide use is their diverse potential application: they 
can be used as single antifungal, in combination 
with other antifungals for a synergistic effect, 
or as immunomodulatory and/or endotoxin-
neutralizing compounds (Powers and Hancock  
2003). Although the potency of these amtimicro-
bial peptides against the more susceptible patho-
gens is normally not as strong as certain conven-
tional antifungals, one of their major strengths is 
their ability to kill multi-drug-resistant fungi at 
similar concentrations.
Some natural peptides have been re-
cently reported as antifungal compounds; they 
showed to inhibition of a broad spectrum of 
pathogens and microorganisms (Bulet and 
Stöcklin 2005; Hancock et al. 1995; Hancock and 
Lehrer 1998; Lee et al. 2003). It has been reported 
that a group of cationic antimicrobial peptides 
are major players in the innate immune response. 
These peptides are very ancient elements of the 
immune response of all species of life, and the 
induction pathways for these compounds in ver-
tebrates, insects and plants (Boman et al. 1993; 
Ganz and Lehrer 1995; Hoffmann et al. 1999; 
Zasloff 1992) are highly conserved. Furthermore, 
it is becoming increasingly apparent that cationic 
antimicrobial peptides have many potential roles 
in inflammatory responses, which represent an 
orchestration of the mechanisms of innate im-
munity.
Small cationic peptides are abundant 
in nature and have been described as “nature´s 
antibiotics” or “cationic antimicrobial peptides” 
(Hancock 2001; Hancock and Patrzykat 2002). 
These peptides are 12-50 amino acids long with a 
net positive charge of +2 or +9, which is due to 
an excess of basic arginine and lysine residues, 
and approximately 50% hydrophobic amino acids 
(Hancock 2001). These molecules are also folded 
in three dimensions so that they have both a hy-
drophobic face comprising non-polar amino acid 
side-chains, and a hydrophilic face of polar and 
positively charged residues: these molecules are 
amphipathic.  Despite these two similarities these 
compounds vary considerably in length, amino acid 
sequence, and secondary structure. The different spa-
tial orderings include small β-sheets stabilized by di-
sulphide bridges, amphipathic α-helices and, less com-
monly, extended and loop structures.
In this thesis two families of peptides with 
antifungal properties have been studied: (i) pep-
tides that are structurally related of the α-MSH hor-
mone (chapters 2, 3) and (ii) pepdides analogues of 
Penetratin, a cell penetrating peptides (CPP) of 16 ami-
no acid long (chapter 4). 11  
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1.5
  Alzheimer disease, the phantom threat
Alzheimer’s disease  (AD) is a com-
plex multifactorial neurodegenerative syndrome 
characterized by the patient’s memory loss and 
impairment of cognitive abilities. This devastat-
ing disease affects more than 37 million people 
worldwide and, as a consequence of the worlds 
aging population, the prevalence of AD is expect-
ed to increase in an exponential fashion within 
decades (Blennow et al. 2006; Melnikova 2007; 
Pratico and Delanty 2000). AD is the most stud-
ied amyloid-based disease, whose main hallmarks 
are characterized by pathological high levels of 
brain lesions (senile plaques) and neurofibrillary 
tangles in dead and dying neurons, and also by 
abnormally elevated numbers of amyloid deposits 
in the walls of cerebral blood vessels (Haass and 
Selkoe 2007; Holtzman and Mobley 1991). 
This degenerative brain syndrome was 
described by first time by the German neurolo-
gist and psychiatrist Alois Alzheimer in 1906. 
A. Alzheimer was a specialist of neuropathology 
who by observation of postmortem human brain 
tissue described the possible hallmarks of a de-
generative syndrome which leads to a progressive 
decline in memory with concomitant abatement 
of thinking, comprehension and learning capa-
bilities (Citron 2004). Thus, Alzheimer is cred-
ited with identifying the first published case of 
“pre-senile dementia”, which the influential E. 
Kraepelin would later name as Alzheimer’s dis-
ease. AD accounts for most cases of dementia that 
are diagnosed after the age of 60 (Verdon et al. 
2007; WHO-WebSite 2009). Numerous hypoth-
eses have been put forward to explain the etiology 
of AD but for the vast majority of AD patients the 
cause of this disease remains unknown. However 
the best known and acknowledged hypothesis is 
the so-called amyloid hypothesis (figure 1.2). 
This hypothesis is based on the fact that the ma-
jor component of senile plaques is a small pep-
tide of 39-43 amino acids called β-amyloid (Aβ). 
Aβ40 is the most prevalent species, while Aβ42 is 
the more toxic one; other lengths are rare. Aβ is 
produced through endoproteolysis of the amyloid 
precursor protein (APP) which was first cloned 
and characterized in the late eighties (Muller-
Hill and Beyreuther 1989). During the patho-
genesis of AD the equilibrium of Aβ generation 
and Aβ clearance is disturbed, which eventually 
leads to elevated Aβ levels, increased Aβ aggre-
gation and impaired memory function (Citron 
2004; Wasling et al. 2009). Due to the above de-
scribed processes AD is at least at the molecular 
level, a protein/peptide misfolding disease. For 
several years it was believed that the fibrillar fi-
nal product, namely the plaques itself, of the am-
yloid-cascade was the main responsible element 
of the neuronal toxicity of Aβ aggregates. Recent 
evidence however for the involvement of soluble, 
non-fibrillar Aβ in AD has been gathered through 
four distinct experimental approaches that utilize 
(i) synthetic Aβ peptides; (ii) cell culture systems 
in which APP is over-expressed; (iii) APP trans-
genic mice; and (iv) human CSF and postmortem 
brain. In the case of human brain, it has long been 
recognized that amyloid plaque number does not 
correlate well with severity of dementia (Dickson 
et al. 1995; Katzman 1986; Terry et al. 1991); indeed 
this has been frequently cited as a critical flaw in 
the amyloid cascade hypothesis.
By using aqueous buffer free of deter-
gents or chaotropes, Kuo et al. isolated a range of 
non-fibrillar forms of Aβ from both AD and con-
trol human brain (Kuo et al. 1996), with the major 
contribution coming from low-n oligomers rang-
ing from dimers to octamers (up to ca. 100 kDa 
oligomers). In a complementary study, McLean 
and colleagues extracted samples of frontal cor-
tex and putamen in PBS and after centrifugation 
and western blot analysis of the supernates from 
AD brain, the presence of variable proportions 
of monomeric, dimeric and trimeric Aβ species 
was revealed (McLean et al. 1999). Moreover, it 
was demonstrated that synthetic Aβ peptides 
are toxic to hippocampal and cortical neurons, 
both in vitro and in vivo (Busciglio et al. 1992; 12 
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Deshpande et al. 2006; Hartley et al. 1999; Hoshi 
et al. 2003; Lambert et al. 1998; Pike et al. 1991). 
Despite the above mentioned, it is important to 
be aware of the fact that Aβ is a natural biological 
product and is present in the brain and cerebro-
spinal fluid (CSF) of normal humans throughout 
life (Haass et al. 1992b; Ida et al. 1996; Seubert 
et al. 1992; Vigo-Pelfrey et al. 1993; Walsh et al. 
2000) and just the mere presence of this product 
in brain does not necessarily lead to AD.  Further 
evidence supporting soluble forms of Aβ as the 
principal mediators of neuronal toxic challenge 
comes from a report using PDAPP mice in which 
Aβ-mediated deficits of memory were reversed 
by a single intraperitoneal injection of an anti-
Aβ antibody (Dodart et al. 2002). Using another 
well-characterized APP transgenic mouse model, 
Tg2576, Lesne and colleagues searched for the ap-
pearance of an Aβ species that coincided with the 
first observed changes in spatial memory (Lesne 
et al. 2006). It has been previously documented 
that the same Tg2576 mice show impaired perfor-
mance in a hippocampal dependent contextual 
fear conditioning assay, decreased spine density in 
the dentate gyrus, and impairment of long-term 
potentiation (LTP) at ages long before the first  
apparent detection of Aβ dodecamer (Dineley et 
al. 2002; Jacobsen et al. 2006; Lesne et al. 2006). 
Thus, while the appearance of dodecamer corre-
lates with the impairment of spatial memory in 
Tg2576 mice, it does not correlate with changes in 
other forms of memory, nor does it correlate with 
changes in synaptic form and function. Therefore, 
it seems likely that other lower-n oligomers may 
be responsible for the observed effects. We ad-
dress the conformational behavior of low-n oligo-
mers (specifically tri- and penta- Aβ42 aggregates) 
in aqueous solution in chapter 5 by using an in 
silico approach.
Expressing overt fear of dementia in 
the later phase of life, the dark humour about 
Alzheimer’s disease, making so-called fun when 
someone starts to forget facts of daily life or mild 
signs of loss of decorum, signs of late onset de-
pression, leads me to use a term like “the phantom 
threat” for this devastating human disease. When 
considering the current statistics on prospective 
projections of AD in our societies it is only logi-
cal that one feels certain threat by the possibility 
of becoming a victim of this disease, especially 
due to the very silent and almost asymptomatic 
beginning of it. Obviously, one of the first ques-
tions I would like to address is:  which are the 
therapeutic possibilities that exist currently to 
deal with this threat? And what are the possibili-
ties to design a new putative drug to fight against 
the phantom threat?
  Acetylcholinesterase inhibitors, the first generation of promising therapeutics agents
In the beginning of the ‘80s, biochemical 
and neuropathological evidences revealed the im-
plications of the degeneration of basal forebrain, 
acetylcholinergic neurons in AD (Bartus 2000; 
Bartus et al. 1982), which became the basis of the 
so-called ‘‘cholinergic hypothesis’’. According to 
this hypothesis, the deterioration of cholinergic 
neurons in the basal forebrain and the associated 
loss of cholinergic neurotransmission in the cere-
bral cortex and other areas, significantly contrib-
ute to the neurodegeneration in AD (Bartus et al. 
1982). Since acetylcholine in the forebrain was long 
known to be essential to memory function and 
attention, the so-called “cholinergic hypothesis” of 
AD held that cholinergic dysfunction in AD pa-
tients causes cognitive decline and that dementia 
therefore might be mitigated by the augmentation 
of acetylcholine activity in brain. The most logical 
therapeutic objective was to boost the levels of the 
transmitter, acetylcholine, by inhibiting its cata-
bolic enzyme, acetylcholinesterase. Historically, 
acetylcholinesterase inhibitors were the first 
group of drugs marketed for AD treatment. 
Nowadays, several acetylcholinesterase inhibitors  13  
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are marketed and investigated for the treatment 
of mild-to-moderate dementia (Silvestri 2009). 
They have been demonstrated to mildly improve, 
relative to placebo, various cognitive and func-
tional capacities (Scarpini and Cogiamanian 
2003; Scarpini et al. 2003), and there is evidence 
that they may slow down the pathogenesis of AD 
(Hashimoto et al. 2005). Furthermore, a new drug 
called memantine, an inhibitor of the ionotropic 
receptor NMDA sensitive to the neurotransmit-
ter glutamate, was recently approved for use in 
moderate-to-severe dementia (Koch et al. 2005). 
However, due to the severe damage that multiple 
neuronal systems undergo in AD, the benefits of 
agents that selectively target the activity of certain 
neurotransmitters offer poor and only temporary 
improvements. The limitations of the current gen-
eration of AD therapies led to recent reports not 
encouraging drugs like donepezil, rivastigmine, 
galantamine or memantine for the treatment of 
dementia (Kmietowicz 2005a, b; Mayor 2006). 
Even though, the improvements are modest and 
mainly acting at the symptomatic level of the dis-
ease, these drugs offered, and still do, hope to pa-
tients and their families. Nevertheless, they must 
eventually face the reality that the drugs cannot 
halt the unyieldingly severe deterioration of the 
patient’s mental capacities. Fortunately, several 
extensive research programs on the fundamental 
molecule based pathogenesis of AD reveal prom-
ising new strategies for arresting the disease.
  Targeting the amyloid hypothesis, a new generation of therapeutics agents
The amyloid  cascade hypothesis 
was proposed in 1991 by John Hardy and David 
Allsop. This hypothesis states that the deranged 
metabolism of APP is the initiating event in AD 
pathogenesis, subsequently leading to the ag-
gregation of Aβ, specifically Aβ42, since Aβ was 
identified in the 8o’s as the main component of 
amyloid plaques (Glenner 1980a, b; Glenner and 
Wong 1984). Formation of neuritic plaques would 
then give rise to further pathological events, in-
cluding the disruption of synaptic connections, 
which would lead to a reduction in neurotrans-
mitters, death of tangle-bearing neurons and fi-
nally dementia (Hardy and Allsop 1991). As it was 
discussed in section 1.5, at the beginning it was 
believed that the fibrillar final product, namely 
the plaques itself, of the amyloid cascade was the 
main element responsible of the neuronal toxicity 
of Aβ. Nevertheless, recent evidence convincingly 
shows the involvement of soluble Aβ aggregates 
(see section 1.5 of this thesis). Thus, this hypoth-
esis serves different points where the disease can 
be, at least in part, arrested at the very beginning 
of the molecular trigger events (figure 1.2).
Five major points of interference are 
easily seen on the pathway of this hypothesis; (i) 
blocking the Aβ production, (ii) preventing the 
self-assembly of Aβ monomers (aggregation), (iii) 
promoting the Aβ catabolism, (iv) stimulating the 
Aβ clearance and (v) blocking the cytotoxicity of 
multimeric Aβ aggregates. A brief description of 
each of the above mentioned points now will be 
given.
1.7.1  Blocking the Aβ production. This ap-
proach aims to decrease the biological production 
of Aβ by controlling the cleavage of the APP. APP is 
usually cleaved within the Aβ sequence by the enzyme 
α-secretase, which splits Aβ, leading the non-amy-
loidogenic pathway (figure 1.3A). Alternatively, this 
protein can be also cleaved by the enzyme β-secretase 
(β-amyloid cleaving enzyme, or BACE) and γ-secretase 
at the Aβ N- and C-termini, respectively, thus yield-
ing monomeric Aβ (figure 1.3B). These Aβ monomers 
may then aggregate and form neurotoxic products. This 
amyloidogenic pathway is the core of the amyloid cas-
cade (figure 1.2). Therefore, the main targets of this 
approach are obviously the cleavage enzymes α-, β-, 
and γ-secretases. Most pharmacological efforts to re-
duce the production of Aβ have been directed towards 
inhibiting β- or γ-secretase by the action of peptide and 
non-peptide inhibitors (Black et al. 2005; Brunkan and 
Goate 2005; Eriksen et al. 2003; Kornacker et al. 2005; 14 
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Figure 1.2: Schematic representation of the amyloid hypothesis. Five major points of interference are shown on the path-
way of this hypothesis; (1) blocking the Aβ production (section 1.7.1), (2) preventing the self-assembly of Aβ monomers 
(aggregation, section 1.7.2), (3) promoting the Aβ catabolism (section 1.7.3), (4) stimulating the Aβ clearance (section 1.7.4) 
and (5) blocking the cytotoxicity of multimeric Aβ aggregates (section 1.7.5).
Lanz et al. 2005; Maiorini et al. 2002; Pollack and Lewis 
2005; Silvestri 2009; Singer et al. 2005). Even though 
blocking the γ-secretase complex lowers Aβ formation 
in experimental systems, this can also play an impor-
tant role in the receptor/signalling system of the protein 
Notch. The reduction of Notch activity could interfere 
with important cellular proliferation and differentia-
tion pathways (Pollack and Lewis 2005). Reducing Aβ 
production by enhancing α-secretase cleavage also is 
a plausible, yet complex, strategy (Lichtenthaler and 
Haass 2004), and there is evidence that statins, which 
might reduce the risk of AD, partly act in this manner 
(Parvathy et al. 2004).
1.7.2 Preventing the self-assembly of Aβ mono-
mers. This strategy aims to interfere with the aggrega-
tion of Aβ into oligomeric and/or fibrillar assemblies 
(Mason et al. 2003). Several attempts to design a drug 
with these properties have been devoted to this aspect 
of the pathogenesis e.g.: Tramiprosate (Alzhemed™) 
which recently reached phase III clinical trials (Aisen 
2005). Although it is a theoretically very appealing 
tactic, impeding protein–protein interactions can be 
extremely difficult pharmacologically (Walker and 
LeVine Iii 2002). On the other hand, it is very important 
to mention that there is a need of interrupting the Aβ 
self-assembly process very early in the cascade, since 
inhibiting just the fibril formation conceivably could 
cause the accumulation of prefibrillar soluble oligo-
mers and thereby could exacerbate neurocytotoxicity.
1.7.3 Promoting the Aβ catabolism. As many 
other peptides, Aβ can be broken down by endopep-
tidases, notably neprilysin and insulin-degrading en-
zyme (IDE) (Tanzi et al. 2004). There is evidence that 
by increasing the activity of these enzymes in APP-
transgenic mice reduces brain Aβ levels and senile 
plaque load (Leissring et al. 2003). However, it is impor-
tant to be mindful that selective up-regulation of en-
zymatic activity can be dangerously problematic, since 
other substrates might be adversely affected. Therefore, 
to interfere the enzymatic liberation of Aβ remains a 
more attractive approach.
1.7.4 Stimulating the Aβ clearance. This is a 
very ambitious and auspicious strategy for halting AD 
pathogenesis. Either immunologically (Billings et al.  15  
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Figure 1.3: Schematic representation APP and its metabo-
lites biochemical pathways relevant to Alzheimer’s disease 
(not drawn to scale). The non-amyloidogenic (A) and the 
amyloidogenic (B) biochemical pathways are depicted. In 
pathway A, α-secretase cleaves in the middle of the Aβ 
region to release a large soluble APP fragment, α-APPs. 
The C-terminal C83 peptide is metabolized to p3 and C59 
(APP intracellular domain) by γ-secretase. In pathway B, 
β-secretase releases a large soluble fragment, β-APPs. The 
C-terminal C99 peptide is then metabolized to Aβ and C59 
by γ-secretase. β-Secretase inhibitors block the formation 
of β-APPs and C99; γ-secretase inhibitors block the forma-
tion of p3, Aβ and C59.
2005; Gilman et al. 2005; Hock et al. 2003) or by en-
hancing the transcellular efflux (Cirrito et al. 2005; Lam 
et al. 2001; Vogelgesang et al. 2004; Zerbinatti and Bu 
2005) of Aβ out of the brain, this approach has shown 
some promising results. However, some adverse events, 
particularly aseptic meningoencephalitis, have hin-
dered the clinical application of Aβ-immunotherapy in 
AD (Orgogozo et al. 2003a), but the effectiveness of im-
munisation in preclinical models justifies the current 
intensity of research on this matter. Nevertheless, this 
approach should be undertaken cautiously.
1.7.5 Blocking the cytotoxicity of multimeric 
Aβ aggregates. The biochemical pathways of how Aβ 
multimers aggregate exert their neurocytotoxic effects 
remains uncertain, and thus several hypothesis have 
been proposed. Two plausible possibilities have drawn 
mayor attention; (i) abnormal interactions of globular 
oligomers with cellular elements (Demuro et al. 2005) 
and (ii) the formation of membrane pores that act as 
anomalous ion channels (Quist et al. 2005). Thus, selec-
tive Aβ-channel-blocking agents could be useful for a 
future AD therapy if Aβ pores are proven to form in 
membranes of degeneration-prone cells. On the other 
hand, for instance, if a drug can be designed with the 
property of binding Aβ oligomers and by this mean to 
inactive their cytotoxicity properties, this drug should 
be able to bind selectively Aβ and specifically soluble 
low-n Aβ oligomers. This last opens an attractive field 
of opportunities to design peptidergic drugs based on 
the natural sequence of Aβ.
I would like to remark that so far none 
of the above mentioned strategies have led to 
more than promising treatments of AD, either 
by reducing the symptomatic implications or by 
slowing down the course of the disease. The de-
finitive cure of this phantom threat seems to be as 
phantasmagoric as the disease itself.
 A β -toxicity offsetting peptides
Due to the great incidence that AD has 
over the human aging population, there is an 
evident need of therapeutic agents that could at 
least significantly delay the progressive course of 
the disease (Hardy and Selkoe 2002; Wolfe 2002). 
Currently, several research groups attempt to de-
velop therapies that aim at reducing Aβ produc-
tion, enhancing its clearance and/or preventing 
or retarding the amyloidogenesis processes, as it 
was briefly discussed in section 1.7 of this thesis. 
Particularly appealing is the use of peptides or 
peptidomimetic molecules derived from the same 
Aβ sequence (Granic et al. 2009; Soto et al. 1998; 
Tjernberg et al. 1996; Wolfe 2002). Promising pu-
tative treatments may be those designed to inhibit 
steps that precede  Aβ peptide aggregation, by 16 
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blocking production of the toxic soluble Aβ oligo-
mers in the first place, or by reversing, somehow, 
the toxic effect of these oligomers. In fact, some 
short peptide derivatives from Aβ peptide have 
already been reported to specifically interact with 
Aβ and cause interferences in its neurotoxic ef-
fects. Leu-Pro-Phe-Phe-Asp (Soto et al. 1996; Soto 
et al. 1998), Lys-Leu-Val-Phe-Phe (Hetenyi et al. 
2002b; Tjernberg et al. 1997; Tjernberg et al. 1996), 
Arg-Ile-Ile-Gly-Leu-NH2 (Fulop et al. 2004) and 
Leu-Pro-Tyr-Phe-Asp-NH2 (Datki et al. 2003; 
Datki et al. 2004; Granic et al. 2009; Juhasz et al. 
2009; Szegedi et al. 2005) are some of the promis-
ing starting points to develop potential drugs that 
can somehow reverse the devastating impact of 
Aβ aggregates. Specifically, the case of Leu-Pro-
Tyr-Phe-Asp-NH2 is addressed in chapter 6. In 
order to increase the anti-amyloidogenic proper-
ties of these peptides, some groups have recently 
explored a new strategy consisting of the intro-
duction of N-methyl amino acids in these se-
quences (Cruz et al. 2005; Gordon and Meredith 
2003; Gordon et al. 2001; Gordon et al. 2002). 
N-Methyl amino acids have been used in several 
systems to control or prevent the aggregation of 
β-sheet and β-strand peptides (Chitnumsub et al. 
1999; Clark et al. 1998; Doig 1997; Hughes et al. 
2000; Nesloney and Kelly 1996; Rajarathnam et 
al. 1994). The main goal is to block the hydrogen 
bond network that stabilizes the β-sheet amyloid 
structure and hopefully inhibit the formation of 
toxic oligomers and/or amyloid aggregates. A se-
ries of N-Methyl amino acids containing peptides 
has been described in chapter 7.
I would like to propose the use of the 
term Aβ-Toxicity Offsetting Peptides (Aβ-TOP), 
since to our opinion some of the peptides men-
tioned in this section have been erroneously 
named as β-sheet breaker peptides. The term 
β-sheet breaker peptides was introduced firstly by 
C. Soto and coworkers (Soto et al. 1998), thus this 
term was widely used for almost all peptides de-
rived of the Aβ sequence as a generic term. Some 
studies using CD spectrometry studies have been 
carried out on some of these so-called β-sheet 
breaker peptides (Datki et al. 2004; Hetenyi et al. 
2002a; Hetenyi et al. 2002b; Laczko et al. 2008) 
but none of them so far have demonstrated proof 
at the molecular level of the β-sheet breaking 
properties of these peptides. Thus, we propose the 
use of this novel term based on the fact that this 
peptides, somehow, can protect neuron cells from 
the toxicity of Aβ, even though the mechanisms 
of how Aβ oligomers exert their toxicity are not 
yet clear and fully understood.
  Scope of this thesis
Finally, I would like to spend a few 
words on the principal scope of this interdisci-
plinary thesis topic. It must be pointed out that 
we are looking not for another potential peptide 
drug, which can be made relatively easily, or even 
a more or less sophisticated potential peptider-
gic drug requiring a more laborious synthesis. In 
any case, we are not aiming to find a panacean 
compound, which might be a definite cure for a 
given disease. For many chronic diseases, like the 
two conditions that are the focus of this thesis, 
we need a totally new form of therapy, as peni-
cillin, beta-blockers or H2-antagonists were in 
their time. Of course, everybody is looking for, 
and hoping to obtain these “panacean drugs”. 
We have to remain realistic and we have to be 
content with only a partial approach to these 
ideal drugs, at least for the time being. Our aim 
is therefore more modest. Thus, we would like 
to place the minimum requirement to be able to 
generate a series of compounds that will provide 
the necessary guidelines to set out the route to a 
better understanding of the molecular bases of a 
given disease, in this case; fungal infections and 
Alzheimer’s disease, by the useful approach of 
molecular modeling combined with techniques 
of molecular biology techniques. The question 
is: how do we generate this sort of compounds? 
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Structure based drug design (SBDD) provides a 
way to escape from molecular roulette, and this 
promising strategy represents a new chemothera-
peutic revolution; however, at the moment there 
is no strategy (even the most rational one) totally 
free from serendipity.
On the other hand there are many 
sources where we can look for new structures to 
obtain new potential candidates to convert to 
leader compounds. It appears that the study of 
peptide structures as a starting point is a promis-
ing source in order to obtain such “leader struc-
tures”.
In this thesis the results of synthesis, 
bioassays and molecular modeling on small-size 
peptides are presented. The structures obtained 
displayed potential applications on two burning 
topics in medicinal chemistry (i) the developing 
of new structures possessing antifungal activity 
and (ii) the development of new peptides display-
ing effective activity against Aβ toxicity. In these 
studies both theoretical and experimental tools 
have been used.
A brief description of what the reader 
will find in the following chapters of this multi-
disciplinary thesis is given here. Chapters 2 and 
3 address the antifungal properties of peptides re-
lated to the sequence of the α-MSH. In chapter 
2 the synthesis, in vitro evaluation and conforma-
tional study of the tetrapeptide His-Phe-Arg-Trp-
NH2 and related derivatives acting as antifungal 
agents, specifically against Cryptococcus neo-
formans, are reported. Chapter 3 discusses the 
implications in the antifungal properties of the 
octapeptide His-Phe-Lys-Trp-Gly-Arg-Phe-Val-
NH2 based on the conformational and electronic 
study, as well as the synthesis and in vitro evalu-
ation. Chapter 4 presents also the synthesis, in 
vivo evaluation, conformational and electronic 
investigations of a series of cell penetrating pep-
tides of 16 amino acid residues named penetratin 
and their derivatives.
Chapter 5 explores the contributions 
of the different structural elements of the trimeric 
and pentameric full-length Aβ42 aggregates in 
solution to their stability and conformational dy-
namics. In chapter 6 the neuroprotect  ive prop- the neuroprotective prop-
erties of the pentapeptide Leu-Pro-Tyr-Phe-Asp-
NH2 in vitro, as well as its memory preserving 
capacity against Aβ42-induced learning deficits in 
vivo is investigated. Also, a conformational study 
and docking experiments were used to reveal part 
of the putative its mechanism of action. Finally, 
chapter 7 presents a novel N-Methyl amino acid 
containing peptide with anti-Aβ toxicity prop-
erties Ac-Lys-(Me)Ile-Ile-(Me)Gly-Leu-NH2. A 
complete in silico design, as well as its in vitro 
neuroprotective properties and memory preserv-
ing capacity against Aβ42-induced learning defi-
cits in vivo are reported. ■“Kiko”
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Chapter 2
Abstract
The synthesis, in vitro evaluation and conformational study of His-Phe-Arg-Trp-NH2 and related deriva-
tives acting as antifungal agents are reported. Among them, His-Phe-Arg-Trp-NH2 and His-Tyr-Arg-
Trp-NH2 exhibited antifungal activity against Cryptococcus neoformans. Antifungal activity of these 
compounds appears to be closely related to the α-MSH effect. A conformational and electronic study 
allows us to propose a biologically relevant conformation for these tetrapeptides acting as antifungal 
agents. In addition, these theoretical calculations permit us to determine the minimal structural re-
quirements to produce the antifungal response and may provide a guide for the design of compounds 
with this biological activity.
 Bioorganic and Medicinal Chemistry (2006) 14, 7604-7614 21  
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  Introduction
In the early 1980s, it was believed that 
virtually any fungal infection could be success-
fully treated with the wide range of available an-
tifungal agents. Nevertheless, this belief was soon 
proved to be false (Garber 2001). The continuing 
increase in the incidence of fungal infections to-
gether with the gradual rise in resistance mainly 
to azoles in the last two decades highlighted the 
need to search novel compounds not tested pre-
viously in antifungal assays (Fromtling 1999; 
Kontoyiannis et al. 2003; Polak 1999; Zacchino et 
al. 2003). This event resulted in the identification 
of novel molecules of diverse structures, which  
could prove useful for a future development. 
Among them, some natural peptides have been 
recently reported as antifungal compounds. They 
showed to inhibit a broad spectrum of pathogens 
and microorganisms (Bulet and Stöcklin 2005; 
Hancock et al. 1995; Hancock and Lehrer 1998; Lee 
et al. 2003) and possess a very important charac-
teristic, since they do not usually induce bacterial 
resistance (Hancock 1997). Regarding their struc-
tural features, they are cationic, but differing con-
siderably in other characteristics such as size and 
presence of disulfide bonds and structural motifs 
(Epand et al. 1995; Epand and Vogel 1999).
Most of these peptides are believed to 
exert their antimicrobial activities either form-
ing multimeric pores in the lipid bilayer of the 
cell membranes(Hancock 1997), or interacting 
with DNA or RNA after penetration into the cell 
(Boman et al. 1993; Cabiaux et al. 1994; Park et 
al. 1998). Nevertheless, α-melanocyte stimulat-
ing hormone (α-MSH) and its C-terminal tripep-
tide Lys-Pro-Val, which showed antimicrobial 
activity against two representative pathogens: 
Staphylococcus aureus and Candida albicans 
(Cutuli et al. 2000), appear to act through a mech-
anism substantially different from that of other 
natural antimicrobial peptides. Previous research 
suggests that the candidacidal effect of α-MSH 
is linked to the cAMP production in C. albicans 
2.1 and the adenylyl cyclase inhibitor ddAdo partly 
reversed the candidacidal effect of the peptide 
(Cutuli et al. 2000; Grieco et al. 2003; Grieco et 
al. 2005). It was suggested by Eberle and Schwyzer 
that α-MSH might have two message sequences, 
the first active sequence centered around the cen-
tral tetrapeptide His-Phe-Arg-Trp and the second 
active site centered around the C-terminal tripep-
tide Ac-Lys-Pro-Val-NH2 (Eberle et al. 1975; Eberle 
and Schwyzer 1975, 1976). Thus, we focussed our 
attention on both sequences in order to evaluate 
their potential antifungal effects.
As part of our ongoing program aimed 
at identifying novel antifungal agents, we have re-
ported several natural and synthetic compounds 
(Freile et al. 2003; Giannini et al. 2004; Karolyhazy 
et al. 2003; Lopez et al. 2005; Lopez et al. 2001; 
Suvire et al. 2006; Urbina et al. 2000; Vargas M et 
al. 2003; Zacchino et al. 1999; Zacchino et al. 1997) 
exhibiting antifungal activities against different 
human pathogenic fungi. However, peptide struc-
tures had not been tested during this program 
until now. In the present study we report the de-
sign, synthesis and antifungal activity of novel 
small-size peptides: fifteen tripeptides structur-
ally related to Lys-Pro-Val (the 11-13 sequence of 
α-MSH) and thirteen tetrapeptides structurally 
related to His-Phe-Arg-Trp (the 6-9 sequence of 
α-MSH). We tested these peptides against vari-
ous human pathogenic strains including yeasts, 
filamentous as well as dermatophyte fungi. In ad-
dition, a conformational and electronic study on 
the most representative peptides reported here 
was carried out in order to determine a possible 
biologically relevant conformation for these com-
pounds acting as antifungal agents. Thus, one 
of the goals of this study was to identify a topo-
graphical and/or substructural template, which  
may be the starting structure for the design of 
new antifungal compounds.22 
his-phe-arg-trp-nh2 | α-msh
Scheme 2.1: Sequence of the peptides studied in chapter 2.
Ac-Lys-Pro-Val-NH2  (1)  His-Phe-Arg-Trp-NH2  (16) 
Ac-Lys-Pro-Val-OH  (2)  His-Tyr-Arg-Trp-NH2  (17) 
Lys-Pro-Val-NH2  (3)  His-Phe-Lys-Trp-NH2  (18) 
Lys-Pro-Val-OH  (4)  His-Tyr-Lys-Trp-NH2  (19) 
Ac-Lys-Phe-Val-NH2  (5)  His-Phe-D-Arg-Trp-NH2  (20) 
Lys-Phe-Val-NH2  (6)  His-D-Phe-Arg-Trp-NH2  (21) 
Lys-Phe-Val-OH  (7)  His-D-Phe-Lys-Trp-NH2  (22) 
Ac-Arg-Pro-Val-NH2  (8)  Ac-His-Phe-Arg-Trp-NH2  (23) 
Arg-Pro-Val-NH2  (9)  Ac-His-Tyr-Arg-Trp-NH2  (24) 
Arg-Pro-Val-OH  (10)  Ac-His-Phe-Lys-Trp-NH2  (25) 
Ac-His-Pro-Val-NH2  (11)  Ac-His-Tyr-Lys-Trp-NH2  (26) 
Ac-Lys-Gly-Ala-NH2  (12)  Ac-Trp-Arg-Phe-His-NH2  (27) 
Ac-Lys-Gly-Gly-NH2  (13)  For-His-Phe-Arg-Trp-NH2  (28) 
Ac-Lys-Ala-Ala-NH2  (14)     
Ac-Val-Pro-Lys-NH2  (15)     
  Results and discussion
2.2.1 Chemistry
Peptides 1-28 were prepared by manu-
ally solid-phase synthesis on a p-methylbenzhy-
drylamine resin (1 g MBHA, 0.39 mmol/g) and 
Merrifield resin (1 g, 1%, 200-400 mesh) with 
standard methodology using Boc-strategy. The 
peptides were cleaved from the resin with simul-
taneous side chain deprotection by acidolysis with 
anhydrous hydrogen fluoride containing 2% anis-
ole, 8% dimethyl sulfide and indole. Details of the 
synthesis are given in Section 2.4.1 (Synthetic 
methods)
2.2.2  Antifungal activity
To carry out the antifungal evaluation, 
concentrations of peptides up to 250 μg/ml were 
incorporated to growth media following the 
guidelines of the National Committee of Clinical 
and Laboratory Standards for yeasts (Pfaller 
2002a) and for filamentous fungi (Pfaller 2002b). 
Compounds producing no inhibition of fungal 
growth at 250 μg/ml level were considered inac-
tive.
In a first step we focussed our atten-
tion on the activity of the sequence Ac-Lys-Pro-
Val-NH2 (peptide 1, scheme 2.1), which has been 
reported as relevant for both receptor activation 
(Hruby et al. 1987) and antimicrobial activity 
(Cutuli et al. 2000). However, this tripeptide did 
not show any antifungal activity to the concen-
trations reported here against any of the strains 
of the fungal panel (yeasts: Saccharomyces cerevi-
siae and Cryptococcus neoformans; hialohypho-
mycetes: Aspergillus flavus, A. niger and A. fu-
migatus; dermatophytes: Microsporum gypseum, 
Trichophyton rubrum and Trichophyton mentag-
rophytes). It should be noted that compound 1 has 
been previously reported as antifungal against a 
strain of C. albicans (Cutuli et al. 2000). However, 
compound  1 was inactive against all the fungi 
tested here. Next, fourteen tripeptides with differ-
ent residues (peptides 2-15) were tested against the 
panel of opportunistic pathogenic fungi. It can be 
observed that none of these tripeptides showed 
antifungal activity against hialohyphomycetes 
or dermatophytes yeasts. It should be noted that 
peptide 6 was inactive against all the fungi tested 
here. This result is in agreement with those previ-
ously reported for peptide 6, by Grieco et al. who 
reported only 2.7 % of inhibition of C. albicans for 
this tripeptide (Grieco et al. 2005).
In a second step of our study we focused 
on the tetrapeptide His-Phe-Arg-Trp-NH2 (16), 
which is common to all melanocortin peptides 
and is important for binding to the known mel-
anocortin receptors (Hruby et al. 1987). A very 
interesting result was that this tetrapeptide dis-
played a moderate but significant antifungal ac-
tivity against C. neoformans (table 2.1) as well as 
against dermatophyte fungi (MICs values of 125, 
250 and 250 μg/ml against T. mentagrophytes, M. 
gypseum and T. rubrum, respectively). Peptide 16 
was the only peptide reported here showing anti-
fungal activity against dermatophytes.
The next step consisted in testing twelve 
tetrapeptides structurally related to peptide 16 
(peptides 17-28), in which different replacements 
in the His-Phe-Arg-Trp-NH2 sequence were per-
formed to determine the contribution of each ami-
no acid to the antifungal activity. None of these 
tetrapeptides displayed significant effect against 
C. albicans, Saccharomyces cerevisiae, Aspergillus 
2.2 23  
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Peptide  Structure  MIC (Pg/ml) 
16  His-Phe-Arg-Trp-NH2  125 
17  His-Tyr-Arg-Trp-NH2  125 
18  His-Phe-Lys-Trp-NH2  250 
19  His-Tyr-Lys-Trp-NH2  250 
20  His-Phe-D-Arg-Trp-NH2  250 
21  His-D-Phe-Arg-Trp-NH2  250 
22  His-D-Phe-Lys-Trp-NH2  250 
23  Ac-His-Phe-Arg-Trp-NH2 >250 
24  Ac-His-Tyr-Arg-Trp-NH2 >250 
25  Ac-His-Phe-Lys-Trp-NH2 >250 
26  Ac-His-Tyr-Lys-Trp-NH2 >250 
27  Ac-Trp-Arg-Phe-His-NH2 >250 
28  For-His-Phe-Arg-Trp-NH2 >250 
Standard drugs 
Amphotericin B  0.25 
Ketoconazole  0.25 
Table 2.1: Antifungal activity (MIC) of tetrapeptide His-
Phe-Arg-Trp-NH2 and derivatives against Cryptococcus 
Neoformans ATCC 32264
  Generated
a  Accepted
b 
Pep  Elec.  Ran.  Ther.  Total  Elec.  Ran.  Ther.  Total 
# F
c  # F0.20%
d  % P
e 
16  3808  57095  80 60983 576 4359  65 5000 442  55  86.76 
17  4592  65724  125 70441 651 4240  109 5000 436  51  87.84 
18  4602  73490  235 78327 653 4168  179 5000 512  66  86.12 
19  5403  78159  225 83787 747 4074  179 5000 449  37  87.72 
23  6158  94316  340 100814 536 4199  265 5000 715  45  79.64 
24  6517  91519  247 98283 743 4078  179 5000 623  59  82.22 
25  7514  102050  499 110063 448 4190  362 5000 786  49  78.82 
26  7104  95865  382 103351 518 4206  276 5000 659  51  81.94 
a Number of conformations generated electrostatically, randomly and thermally during the conformational search. 
b Number of conformations accepted from those generated electrostatically, randomly and thermally during the conformational search. 
c #F: Total number of conformational families as result of the clustering run. 
d # F0.20%: Number of conformational families with populations above 0.20%  
e % P: Sum of the per cent relative population of # F0.20% 
Table 2.2: Selected conformational search and clustering results for peptides 16-19 and 23-26 optimized at the EDMC/SRFOPT/
ECCEP/3 level of theory
spp. and dermatophytes. However, six of these tet-
rapeptides (compounds 17-22) displayed antifun-
gal activity only against Cryptococcus neoformans 
(table 2.1).  This is an important finding because 
cryptococcosis remains an important life-threat-
ening complication for immunocompromised 
hosts and new compounds acting against this 
fungus are actually welcome (Polak 1999).
From the structure-activity analysis of 
the active peptides, it appears that the position 
of His and Trp-NH2 in the amino acid sequence 
is essential for such activity, whereas the position 
of Phe and Arg are not. Replacement of the Phe 
residue in position 2 by Tyr (16 → 17) was possible 
without any loss of activity. Replacing Arg in posi-
tion 3 by Lys was tolerated but with loss of activity 
(compare 16 with 18). Peptide 19 showed that the 
replacement of the two central residues was toler-
ated but with loss of activity. An identical result 
was obtained replacing Arg with D-Arg (compare 
16 with 20). Our results indicate that replacement 
of Phe by Tyr gives a peptide as potent as the start-
ing structure, whereas replacing Phe by its isomer 
D-Phe gives an active tetrapeptide but with loss of 
activity (compare 16 with 21 and 22). In addition, 
all the acetylated (peptides 23-27) and formylated 
(28) derivatives were inactive compounds.
In order to better understand the above 
experimental results and to establish some basis 
to obtain more active compounds, we performed 
a conformational and electronic study on the 
most representative peptides reported here, using 
theoretical calculations.
2.2.3  Conformational and electronic study 
of his-phe-arg-trp-nh2 and analogues
Linear peptides are highly flexible and 
therefore the determination of the biologically 
relevant conformations is not an easy task. It is 
necessary to perform an exhaustive conforma-
tional analysis for these structures. Therefore, 
eight tetrapeptides (16-19 and 23-26) were select-
ed for energy calculations.24 
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Figure 2.1: Stereoview of overlapping of conformer 1 for 
peptide 16 (red), conformer 1 for analogue 17 (bleu), con-
former 19 for analogue 18 (green) and conformer 19 for 
analogue 19 (yellow). All hydrogens are omitted for clarity.
Figure 2.2: Stereoview of overlapping of conformer 1 for 
peptide 16 (red), conformer 1 for analogue 18 (green) and 
conformer 2 for analogue 19 (yellow). All hydrogens are 
omitted for clarity.
 
Theoretical calculations were carried 
out as described in section 2.4.4 Computational 
methods. These results are summarized in table 
2.2 and tables 2.1S-2.8S (available in appendix A 
as supplementary material). Calculations yielded 
a large set of conformational families for each pep-
tide studied. The total number of conformations 
generated for each peptide varied between 60983 
and 110063, and the number of those accepted was 
5000 for all the cases. In the clustering procedure, 
an R.M.S.D (Root Mean Square Deviation) of 0.75 
Å and a ΔE of 20 kcal mol-1 were used. The num-
ber of families after clustering varied between 435 
and 789. The total number of families accepted 
with a relative population higher than 0.20 % var-
ied between 37 and 66. Their populations sum up 
to ca 80% of all conformations for each case (see 
table 2.2)
All low-energy conformers of tetrapep-
tides studied here were then compared to each  
other. The comparison involved the spatial ar-
rangements, relative energy and populations. It 
was found that all the active tetrapeptides 16-19 
possess similar low-energy conformers. Figure 
2.1 shows a spatial view of most populates and 
energetically preferred conformations of com-
pounds 16 and 17. These conformations have been 
overlapped with conformation number 19 ob-
tained for compounds 18 and 19 (tables 2.1S-2.8S 
in appendix A). The conformers shown in figure 
2.1 are very close to one another considering the 
values of the dihedral angles for their backbones 
as well as comparing the dihedral angles defining 
the mutual spatial arrangement of side chains. 
It is worth mentioning that the families 
19 are not the preferred forms for peptides 18 and 
19, which possess 1.62 and 2.13 kcal mol-1 above 
their respective global minimum, and also they 
are not the most populated forms. In other words, 
compounds 18 and 19 can adopt a very similar 
spatial ordering to those obtained for peptides 
16 and 17 but this is not possible without some 
energetic cost. Figure 2.2 gives a spatial view of 
the preferred conformations obtained for com-
pounds 16, 18 and 19. It is clear that there is not 
a complete conformational overlapping between 
these conformers. In this case, a good fit among 
the two first amino acids (His-Phe in peptides 16 
and 18 and His-Tyr in peptide 19) was obtained, 
but there is not a good overlapping between the 
two last amino acids (Arg-Trp for 16 and Lys-Trp 
in peptides 18 and 19). Interesting enough, com- 25  
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Figure 2.3: Electrostatic potential-encoded electron density surfaces of peptides 16 (a), 17 (b), 18 (c) and 19 (d). The sur-
faces were generated with Gaussian 03 after RHF/6-31G(d) single-point calculations. The coloring represents electrostatic 
potential with red indicating the strongest attraction to a positive point charge and blue indicating the strongest repulsion.
pounds 18 and 19 displayed half of the antifungal 
activity in comparison with compounds 16 and 
17. Thus, our results let us speculate that the dif-
ferent antifungal effect could be explained by this 
conformational difference.
Molecular recognition and the con-
verse concept of specificity (Sarai 1989) are ex-
plained in mechanistic and reductionistic terms 
by a stereo-electronic “complementarity” be-
tween the ligand and the receptor (North 1989). 
In this context it is obvious that the knowledge 
of the stereo-electronic attributes and properties 
of His-Phe-Arg-Trp-NH2 and its analogues will 
contribute significantly to the elucidation of the 
mechanism of action at the molecular level or at 
least, to determine a possible pharmacophoric 
pattern for these compounds acting as antifun-
gal compounds. The intermolecular forces that 
contribute to both affinity and specificity can be 
schematically classified as hydrophobic and elec-
trostatic ones. Therefore, Molecular Electrostatic 
Potentials (MEPs) are of particular value because 
they permit the visualization and assessment of 
the capacity of a molecule to interact electrostati-
cally with a putative binding site (Carrupt et al. 
1991; Greeling et al. 1996; Politzer and Truhlar 
1981). MEPs can be interpreted in terms of a ste-
reoelectronic pharmacophore condensing all 
available information on the electrostatic forces 
underlying affinity and specificity.
Once the low-energy conformations 
for the most active tetrapeptides reported here 
were obtained and in an attempt to find the po-
tentially reactive sites for the ligands, we evalu-
ated the electronic aspects of the molecules using 
MEPs. Figure 2.3 shows the MEPs obtained for 
compounds 16-19. These results account for the 
general characteristics of the electronic behavior 
of active tetrapeptides reported here. The general 
pattern is similar for all of the active systems. The 26 
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Figure 2.4: Spatial view of the preferred conformations 
obtained for peptides 16 (a), 23 (b), 17 (c) and 24 (d) using 
EDMC calculations. The hydrogen bonds are denoted by 
dotted lines.

Figure 2.5: Electrostatic potential-encoded electron den-
sity surface of peptide 23. The surface was generate with 
Gaussian 03 after RHF/6-31G(d) single-point calculation. 
The color-coded is shown at the left.
MEPs exhibit clear minimum values (deep red 
zones) in the vicinity of the lone pair of nitrogen 
atom of His and near the carbonyl groups of the 
backbone. There are positive regions near the Arg 
residue (peptides 16 and 17) or Lys residue (pep-
tides 18 and 19) and at the amino terminal group. 
Also three clear hydrophobic zones might be ap-
preciated near the aromatic rings of His, Phe (or 
Tyr) and Trp.
All the acetylated derivatives tested here 
were inactive compounds. Figure 2.4b shows the 
spatial view obtained for the preferred confor-
mation of peptide 23. This conformer displays a 
very different spatial ordering with respect to the 
preferred conformation obtained for compound 
16 (figure 2.4a). While for active compounds, a 
partially extended (β-strand) conformation for 
the backbone is the preferred form, for peptide 
23 the preferred form for the backbone is a folded 
conformation which is stabilized through hydro-
gen bonds. The interaction shown in figure 2.4b 
is a bifurcated hydrogen bond between the car-
bonyl system of the acetyl group and the guani-
dine group of Arg residue.
This stabilizing interaction might be 
better appreciated in figure 2.5. The different 
electronic distributions obtained for the acety-
lated peptides with respect to those attained for 
compounds 16-19 might be well appreciated com-
paring figures 2.3 with 2.5. All the acetylated and 
formylated derivatives (peptides 24-28) displayed 
a conformational behavior closely related to that 
obtained for compound 23. Figures 2.4c and d 
give a comparative spatial view between the pre-
ferred conformations of peptide 17 and its acety-
lated derivative (compound 24). On the basis of 
our results, we can conclude that the lack of anti-
fungal activity of these acetylated peptides could 
be explained at least in part, by their different 
conformational and electronic behaviors.
It is worthwhile to compare the biologi-
cally active conformation for the backbone of the 
His-Phe-Arg-Trp-NH2 proposed in this study to 
that previously reported for the same sequence 
from proton NMR studies in aqueous solution 
(Sugg et al. 1986). Sugg et al. reported that the ob-
served topology was consistent with non hydro-
gen-bonded β-like structure (φ=139º and ψ=135º 
for L-amino acids) as the predominant solution 
conformation. This conformation is closely relat-
ed to those obtained for the different conformers 
of the active peptides reported here. In figure 2.6 
we overlapped the conformation reported by Sugg 
et al. (in white) with three representative confor-
mations obtained for peptide 16. In the case of 
conformer 11 (figure 2.6a) a complete overlap, 
not only with the backbone but also with the vici- 27  
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Figure 2.6: Overlapped stereoviews of the backbone conformation from Sugg et al in white and various conformations for 
compound 16 in red: (a) conformer 11, (b) conformer 5 and (c) conformer 1. All hydrogens are omitted for clarity.
 Conclusions 2.3
nal side-chains was obtained. For conformers 5 
and 1 (figure 2.6b and c) although there is not 
a complete fit, the resemblance is still apparent.
At this stage of our study, some general 
trends might be established: (i) the smallest frag-
ments with measurable antifungal activity were 
His-Phe-Arg-Trp-NH2 and its derivatives 17-22. 
It has been shown that the minimal sequence 
possessing α-MSH-like activity is the central 
tetrapeptide His6-Phe7-Arg8-Trp9 (Hruby et al. 
1987). This “core” sequence was suggested to be 
the “message” fragment for α-MSH, the rest of 
the molecule being regarded as the “address” se-
quence (Otsyka and Inouye 1964).
 (ii) For the α-MSH activity, the impor-
tance of His6 was demonstrated by the fact that 
Ac-α-MSH7-10-NH2 lacked measurable activity. 
Trp9 was also critical for biological activity as 
demonstrated by the lack of biological activity of 
Ac-α-MSH6-8. Our results suggest that the pres-
ence of His and Trp-NH2 sequence appears to be a 
structural requirement for the antifungal activity 
as well. In contrast, our results indicate that Phe 
and Arg could be replaced.
(iii) A. Catania’s group suggested that 
the antimicrobial effects of α-MSH are exerted 
through a unique mechanism different from that 
of other natural antimicrobial peptides (Cutuli et 
al. 2000; Grieco et al. 2003; Grieco et al. 2005). 
They suggested that the candidacidal effect of 
α-MSH is linked to the cAMP-inducing activity. 
Our results may be regarded as an additional sup-
port for that hypothesis.
(iv) It is interesting that the tetrapeptides 
16-22, being the smallest fragment with antifun-
gal activity, contains three aromatic residues. In 
this regard, aromatic amino acids are common 
in the active site of many hormones and are often 
considered critical for biological activity (Sabesan 
and Harper 1983). Thus, our conformational and 
electronic study indicates that a predominant 
β-conformation without internal stabilizing hy-
drogen bond could be the “biologically relevant 
conformation” for these compounds.
We synthesized small-size peptides 
(tri and tetrapeptides) with different residues 
and tested their antifungal activity. Among the 
compounds tested, His-Phe-Arg-Trp-NH2 and 
analogues displayed antifungal activities mainly 
against Cryptoccoccus neoformans. The antifun-
gal activity of these compounds appears to be 
closely related to the α-MSH effect. These results 
are in a complete agreement with those previous-
ly reported by Grieco et al. against Candida albi-
cans (Cutuli et al. 2000; Grieco et al. 2003; Grieco 
et al. 2005).
A detailed conformational and elec-
tronic study supported by theoretical calculations 
helped us to identify a possible “biologically rele-
vant conformation” and understand the minimal 
structural requirements for the antifungal actions 28 
his-phe-arg-trp-nh2 | α-msh
of tetrapeptides reported here. Our results are 
very encouraging in that they show a great poten-
tial of His-Phe-Arg-Trp-NH2 and analogues as a 
truly novel class of antifungal compounds partic-
ularly against the yeast Cryptococcus neoformans.
Although it is desirable to develop 
compounds having a broad spectrum of activ-
ity, it is also important to bear in mind that 
long treatments of fungal infections with the 
same broad spectrum antifungal agent may lead 
to a high resistance to the available antifungal 
agents (Ghannoum and Rice 1999). Thus, one of 
the strategies for overcoming this problem is the 
treatment of fungal infections with the appropri-
ate narrow spectrum agent when the ethological 
agent is known (Didomenico 1999). The selective 
antifungal activity reported in this paper for pep-
tides 16-22 (and among them for compounds 16 
and 17 in particular) opens an interesting field of 
research, which deals with the discovery and fur-
ther development of new antifungal peptides use-
ful for treating cryptococcosis, an important life-
threatening infection for immuno-compromised 
hosts.
  Experimental section
2.4.1  Synthetic methods
Solid phase synthesis of the peptides (His-Phe-
Arg-Trp-NH2, His-D-Phe-Arg-Trp-NH2, His-Tyr-Arg-Trp-
NH2, His-Phe-Lys-Trp-NH2, His-D-Phe-Lys-Trp-NH2, 
His-Tyr-Lys-Trp-NH2, His-Phe-D-Arg-Trp-NH2, His-D-
Phe-D-Arg-Trp-NH2, His-Phe-D-Lys-Trp-NH2, Arg-Pro-
Val-NH2, Lys-Phe-Val-NH2, Lys-Pro-Val-NH2, Ac-Arg-
Pro-Val-NH2, Ac-Lys-Phe-Val-NH2, Ac-Val-Pro-Lys-NH2, 
Ac-His-Pro-Val-NH2, Ac-Lys-Pro-Val-NH2, Ac-Lys-Gly-
Gly-NH2, Ac-Lys-Gly-Ala-NH2, Ac-Lys-Ala-Gly-NH2, 
Ac-His-Phe-Arg-Trp-NH2, For-His-Phe-Arg-Trp-NH2, 
Ac-Trp-Arg-Phe-His-NH2, Ac-His-Tyr-Arg-Trp-NH2, 
Ac-His-Phe-Lys-Trp-NH2, Ac-His-Tyr-Lys-Trp-NH2, Lys-
Pro-Val-OH, Arg-Pro-Val-OH, Lys-Phe-Val-OH, Ac-Lys-
Pro-Val-OH) were carried out manually on a p-
methylbenzhydrylamine resin (1 g MBHA, 0.39 
mmol/g) and Merrifield resin (1 g, 1%, 200-400 
mesh), respectively with standard methodology 
using Boc-strategy. Side chain protecting groups 
were as follows: Arg(Tos), His(Tos), Lys(2Cl-Z), 
Tyr(2Br-Z). All protected amino acids were cou-
pled in CH2Cl2 (5 ml) using DCC (2.5 equiv.) and 
HOBt (2.5 equiv.) until completion (3 h) judged 
by Kaiser ninhydrin test. After coupling of the 
appropriate amino acid, Boc deprotection was 
effected by use of TFA/CH2Cl2 (1:1, 5 ml)) for 5 
min first then repeated for 25 min. Following 
neutralization with 10% TEA/CH2Cl2 three 
times (5-5 ml of each), the synthetic cycle was 
repeated to assemble the resin-bond protected 
peptide. The peptides were cleaved from the resin 
with simultaneous side chain deprotection by 
acidolysis with anhydrous hydrogen fluoride (5 
ml) containing 2% anisole, 8% dimethyl sulfide 
and indole at 5°C for 45 min. The crude peptides 
were dissolved in aqueous acetic acid and lyophi-
lized. Preparative and analytical HPLC of the 
crude and the purified peptides were performed 
on an LKB Bromma apparatus (for preparative 
HPLC, column: Lichrosorb RP C18, 7 µm, 250x16 
mm; gradient elution: 30-100%, 70 min; mobile 
phase: 80% acetonitrile, 0.1% TFA; flow rate: 4 
ml/min, 220 nm, for analytical HPLC, column: 
Phenomenex Luna 5C18, 250x4.6 mm; mobile 
phase: 80% acetonitrile, o.1% TFA; flow rate: 1.2 
ml/min, 220 nm). ESI-MS: Finnigan TSQ 7000 
(table 2.3).
2.4.2  Microorganisms and media
For the antifungal evaluation, strains 
from the American Type Culture Collection 
(ATCC), Rockville, MD, USA and CEREMIC (C), 
Centro de Referencia Micológica, Facultad de 
Ciencias Bioquímicas y Farmacéuticas, Suipacha 
531-(2000)-Rosario, Argentina were used: 
Candida albicans ATCC 10231, Saccharomyces 
cerevisiae ATCC 9763, Cryptococcus neoformans 
ATCC 32264, Aspergillus flavus ATCC 9170, 
2.4 29  
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Pep.  Sequence 
Retention 
factor 
Gradient elution 
(min)  (%) 
 1.  His-Phe-Arg-Trp-NH2  12.912  5-60 (20 min) 
 2.  His-D-Phe-Arg-Trp-NH2  6.510  20-50 (15 min) 
 3.  Lys-Pro-Val-NH2  9.962  0-25 (15 min) 
 4.  His-Phe-Lys-Trp-NH2  8.048  20-50 (15 min) 
 5.  His-Tyr-Arg-Trp-NH2  6.523  20-50 (20 min) 
 6.  Arg-Pro-Val-NH2  5.552  5-50 (20 min) 
 7.  Lys-Phe-Val-NH2  10.570  5-50 (20 min) 
 8.  His-Phe-D-Lys-Trp-NH2  8.343  10-70 (20 min)  
 9.  His-D-Phe-D-Arg-Trp-NH2  9.598  10-70 (20 min) 
10.  His-Phe-D-Arg-Trp-NH2  9.079  10-70 (20 min) 
11.  His-Tyr-Lys-Trp-NH2  9.004  10-70 (20 min) 
12.  His-D-Phe-Lys-Trp-NH2  6.068  20-50 (15 min) 
13.  Ac-Lys-Gly-Gly-NH2  7.434  5-80 (20 min) 
14.  For-His-Phe-Arg-Trp-NH2  12.750  10-45 (15 min)  
15.  Ac-Lys-Phe-Val-NH2  11.878  5-80 (25 min) 
16.  Ac-Lys-Gly-Ala-NH2  5.674  0-30 (10 min) 
17.  Ac-Lys-Pro-Val-OH  8.311  10-45 (15 min) 
18.  Ac-Lys-Pro-Val-NH2  8.153  5-25 (10 min) 
19.   Ac-His-Tyr-Lys-Trp-NH2  8.919  15-45 (15 min) 
20.  Ac-His-Phe-Lys-Trp-NH2  12.703  5-80 (25 min) 
21.  Ac-His-Pro-Val-NH2  6.533  10-35 (10 min) 
22.  Ac-Val-Pro-Lys-NH2  8.364  5-35 (10 min) 
23.  Ac-Trp-Arg-Phe-His-NH2  11.770  5-80 (20 min) 
24.  Ac-His-Tyr-Arg-Trp-NH2  7.297  20-50 (10 min) 
25.  Ac-His-Phe-Arg-Trp-NH2  8.785  20-50 (10 min) 
26.  Ac-Arg-Pro-Val-NH2  8.781  5-80 (25 min) 
27.  Ac-Lys-Ala-Ala-NH2  6.235  0-40 (20 min) 
28.  Lys-Pro-Val-OH  8.945  0-30 (15 min) 
29.  Arg-Pro-Val-OH  9.254  5-20 (15 min) 
30.  Lys-Phe-Val-OH  11.109  5-50 (20 min) 

Table 2.3: HPLC data of the synthesized peptides
Aspergillus fumigatus ATCC 26934, Aspergillus 
niger ATCC 9029 and Trichophyton mentagro-
phytes ATCC 9972, Trichophyton rubrum C 113, 
Microsporum gypseum C 115.
Strains were grown on Sabouraud-
chloramphenicol agar slants for 48 h at 30 oC, 
maintained on slopes of Sabouraud-dextrose agar 
(SDA, Oxoid) and subcultured every 15 days to 
prevent pleomorphic transformations. Inocula of 
cell or spore suspensions were obtained according 
to reported procedures and adjusted to 105 cells/
spores with colony forming units (CFU) /mL 
(Wright et al. 1983).
2.4.3  Antifungal susceptibility testing
Minimal Inhibitory Concentration 
(MIC) of each compound was determined by 
using broth microdilution techniques accord-
ing to the guidelines of the National Committee 
for Clinical Laboratory Standards for yeasts 
(M27-A2) (Pfaller 2002a) and for filamentous 
fungi (M38-A).(Pfaller 2002b) MIC values were 
determined in RPMI-1640 (Sigma, St Louis, Mo, 
USA) buffered to pH 7.0 with MOPS. The starting 
inocula were 1x103 to 5x103 CFU/ml. Microtiter 
trays were incubated at 35 oC for yeasts and hialo-
hyphomycetes and at 28-30 oC for dermatophyte 
strains in a moist, dark chamber, and MICs were 
visually recorded at 48 h for yeasts, and at a time 
according to the control fungus growth, for the 
rest of fungi. 
For the assay, stock solutions of peptides 
were two-fold diluted with RPMI 250-1 µg/ml 
(final volume = 100 µl) and a final DMSO con-
centration ≤ 1%. A volume of 100 µl of inoculum 
suspension was added to each well with the excep-
tion of the sterility control where sterile water was 
added to the well instead. MIC was defined as the 
minimum inhibitory concentration of pure com-
pound which resulted in total inhibition of the 
fungal growth. Ketoconazole, Terbinafine and 
Amphotericin B were used as positive controls. 
2.4.4  Computational methods
2.4.4.1  EDMC calculations
The conformational space of each  
peptide was explored using the method previ-
ously employed by Liwo et al. that included the 
Electrostatically Driven Monte Carlo (EDMC) 
method (Liwo et al. 1996b; Ripoll and Scheraga 
1988, 1990). Conformational energy was evalu-
ated using the ECEPP/3 force field (Némethy et 
al. 1992). This force field employs rigid valence 
geometry. Hydration energy was evaluated us-
ing a hydration-shell model with a solvent sphere 
radius of 1.4 Å and atomic hydration parameters 
that have been optimized using nonpeptide data 
(SRFOPT) (Vila et al. 1991; Williams et al. 1992). 
In this model in addition to a sum of electrostatic, 
non-bonding, hydrogen-bond and torsional en-
ergy terms, the total conformational energy in-
cludes terms accounting for loop closing and pep-
tide solvation. The conformation with minimized 30 
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energy was subsequently perturbed by changing 
its torsional φ and ψ angles using the Monte Carlo 
method (Li and Scheraga 1987). Piela’s algorithm 
(Piela and Scheraga 1987), which was also applied 
at this stage, greatly improves the acceptance 
coefficient. In this algorithm φ and ψ angles are 
changed in a manner which allows the corre-
sponding peptide group to find the most proper 
orientation in the electrostatic field of the rest of 
the peptide chain. The energy of the new confor-
mation is minimized, compared to the previous 
one and may be accepted or discarded on the 
basis of energy and/or geometry. If the new en-
ergy-minimized conformation is similar in shape 
and in energy to the starting conformation, it is 
discarded. Otherwise, the energy of the new con-
formation is compared to the energy of the par-
ent conformation. If the new energy is lower, the 
new conformation is accepted unconditionally, 
otherwise the Metropolis criterion (Metropolis et 
al. 1953) is applied in order to accept or reject the 
new conformation. If the new conformation is ac-
cepted, it replaces the starting one; otherwise an-
other perturbation of the parent conformation is 
tried. A temperature jump may be included if the 
perturbation is not successful for an arbitrarily 
chosen number of iterations. The process is iter-
ated, until a sufficient number of conformations 
has been accepted. Sidor et al. has described this 
procedure in a very detailed fashion (Sidor et al. 
1999).
In order to explore the conformational 
space extensively, we carried out 10 different runs, 
each of them with a different random number, for 
each peptide studied. Since the EDMC procedure 
uses random numbers, there is a need to initial-
ize the random number generator by providing 
an integer. Therefore, we collected a total of 5000 
accepted conformations for each peptide studied. 
Each EDMC run was terminated after 500 ener-
gy-minimized conformations had been accepted. 
The parameters controlling the runs were the fol-
lowing: a temperature of 298.15 K was used for 
the simulations. A temperature jump of 50000 K 
was used;  the maximum number of allowed rep-
etitions of the same minimum was 50; the maxi-
mum number of electrostatically-predicted con-
formations per iteration was 400; the maximum 
number of random-generated conformations per 
iteration was 100; the fraction of random/elec-
trostically-predicted conformations was 0.30; the 
maximum number of steps at one increased tem-
perature was 20; and the maximum number of 
rejected conformations until a temperature jump 
is executed was 100. Only trans peptide bonds (ω 
≈ 180°) were considered.
The ensemble of obtained conforma-
tions was then clustered into families using the 
program ANALYZE (Meadows et al. 1994b; Post 
et al. 1990; Scheraga et al. 1983), which applies the 
minimal-tree clustering algorithm for separation, 
using all heavy atoms, energy threshold of 20 kcal 
mol-1 and R.M.S.D. of 0.75 Å as separation criteria. 
This procedure allows for substantial reduction of 
the number of conformations and eliminates rep-
etitions.
2.4.4.2  Molecular electrostatic poten-
tials
The electronic study of the peptides 
was carried out using Molecular Electrostatic 
Potentials (MEPs). MEPs have shown to provide 
reliable information, both on the interaction sites 
of molecules with point charges and on the com-
parative reactivities of these sites (Carrupt et al. 
1991; Greeling et al. 1996; Politzer and Truhlar 
1981). These MEPs were calculated using RHF/6-
31G(d) wave function from the  Gaussian 03 pro-
gram (Frisch et al. 2003). EDMC coordinates 
were imported to generate the wave functions; 
thus, RHF/6-31G(d) single-point calculations 
were performed from Gaussian 03 program. All 
MEPs graphical presentations were created using 
Molekel (Flükiger et al. 2000). ■ 31  
chapter 2
Acknowledgements
This work is part of the Hungarian-Argentine Intergovernmental S & T Cooperation Programme. 
This research was supported by grants from Universidad Nacional de San Luis and grants to S.A.Z. and 
R.D.E. (Agencia de Promoción Científica y Tecnológica de la Argentina PICT R 260) and it is part of the 
Iberoamerican Project X.7 PIBEAFUN (Search and development of new antifungal part of the Iberoameri-
can Program of Science and Technology for the Development (CYTED). R.D. Enriz is a member of the 
CONICET (Argentina) staff. The authors thank É.Menyhárth and I. Nógrádi for the technical assistance of 
peptide synthesis, as well as for the support of OTKA TS049817 and RET 08/2004 grants.“The opportunist”
oil on paper (320x450 mm)
M.F. Masman 2010
03
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Abstract
The synthesis, in vitro evaluation and conformational study of His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
and analogues acting as antifungal agents are reported. Among them, His-Phe-Lys-Trp-Gly-Arg-Phe-
Val-NH2 exhibited remarkable antifungal activity against Cryptococcus neoformans, Candida albicans 
and Candida tropicalis. A conformational and electronic study allows us to propose a biologically rel-
evant conformation for these octapeptides acting as antifungal agents. In addition, these theoretical cal-
culations allow us to determine the minimal structural requirements to produce the antifungal response 
and can provide a guide for the design of compounds with this biological activity. Antifungal activity of 
these compounds appears to be closely related to the α-MSH effect. 
Bioorganic and Medicinal Chemistry (2008) 16:4347-4358. 35  
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 Introduction
The prevalence of systemic and dermal 
fungal infections has significantly increased dur-
ing the past two decades and remains an impor-
tant cause of great morbi-mortality of immuno-
compromised patients (Vicente et al. 2003). In a 
recent study, McNeil et al. found a dramatic in-
crease in mortality from 1980 to 1997 due to my-
coses originated in multiple causes which were 
mainly associated with Candida, Aspergillus and 
Cryptococcus spp. Infections (McNeil et al. 2001). 
Added to these fungal spp., new emerging fungal 
pathogens appear every year as the cause of mor-
bidity and life-threatening infections in the im-
munocompromised hosts (Pfaller and Diekema 
2007; Walsh et al. 2004).
Although different antifungal agents are 
available for the treatment of fungal infections, 
some of them have undesirable side effects, are 
ineffective against new or re-emerging fungi or 
develop resistance mainly due to the broad use of 
antifungal agents (Pfaller and Diekema 2004). As 
a consequence, there is an urgent need of a next 
generation of new antifungal agents, which may 
overcome the above disadvantages.
Natural and synthetic peptides have 
gained attention as potential new antifungal 
agents (Epand and Vogel 1999; Maloy and Kari 
1995; Tossi et al. 2000; Weinberg et al. 1998). They 
have shown to inhibit a broad spectrum of patho-
gens and microorganisms (Bulet and Stöcklin 
2005; Hancock et al. 1995; Hancock and Lehrer 
1998)  and possess the important characteristic 
that they do not usually induce bacterial or fungal 
resistance (Hancock 1997). Most of these peptides 
are believed to exert their antimicrobial activi-
ties either forming multimeric pores in the lipid 
bilayer of the cell membranes (Hancock 1997), or 
interacting with DNA or RNA after penetration 
into the cell (Boman et al. 1993; Cabiaux et al. 
1994; Park et al. 1998). In contrast, α-melanocyte 
stimulating hormone (α-MSH) and its C-terminal 
tripeptide Lys-Pro-Val, which showed antimicro-
bial activity against the two representative patho-
gens Staphylococcus aureus and Candida albicans 
(Cutuli et al. 2000), appear to act through a mech-
anism substantially different from that of other 
natural antimicrobial peptides.
Catania et al. have reported the antifun-
gal activity of several peptides (Carotenuto et al. 
2007; Cutuli et al. 2000; Grieco et al. 2003; Grieco 
et al. 2005). They have indicated that the antimi-
crobial effects of α-MSH are exerted through a 
unique mechanism different from that of other 
natural peptides, suggesting that the candida-
cidal effect of these compounds is linked to the 
cAMP-inducing activity. As part of our ongoing 
program aimed at identifying novel antifungal 
compounds (Kouznetsov et al. 2000; Suvire et 
al. 2006; Vargas M et al. 2003), we have recently 
reported the synthesis and antifungal properties 
of His-Phe-Arg-Trp-NH2 and structurally related 
tetrapeptides (Masman et al. 2006). In this paper, 
we report the synthesis and conformational anal-
ysis of His6-Phe7-Arg8-Trp9-Gly10-Lys11-Pro12-Val13-
NH2 (1), which is the 6-13 sequence of α-MSH and 
structurally related octapeptides with antifungal 
properties. The aim of our work is to develop 
more potent antifungal peptides and to under-
stand the conformational features that enhance 
potency and selectivity and their relation to the 
amino acid sequence. For this purpose, ten new 
analogues with single or double replacements 
within the α-MSH(6-13) sequence were designed, 
prepared and tested (peptides 2-11 in table 3.1).
For the α-MSH activity, the importance 
of the presence of His6 has been previously demon-
strated by the fact that Ac-α-MSH7-10-NH2 lacked 
measurable activity (Hruby et al. 1987). Trp9 was 
also critical for activity as demonstrated by the 
lack of biological activity of Ac-α-MSH6-8-NH2 
(Hruby et al. 1987). Recently, we reported that the 
presence of His6 and Trp9 residues appears to be a 
structural requirement for the antifungal activity 
as well. In contrast, our results indicated that Tyr 
3.136 
his-phe-arg-trp-gly-lys-pro-val-nh2 | α-msh
and Lys could replace Phe7 and Arg8, respectively. 
It is well known that the receptor binding and 
transducing properties of melanocortins depend 
on separate structural and conformational char-
acteristics (Eberle 1988). For example, Phe7 plays 
a key role in receptor binding whereas Lys11 and 
Pro12 are more important for receptor stimulation 
(Eberle 1988). Thus, the positions 7, 8, 11 and 12 
were systematically mutated in the series present-
ed here. The resulting peptides were tested against 
three human pathogenic strains (C. albicans, C. 
neoformans  and C. tropicalis). In addition, an 
exhaustive conformational and electronic study 
on all the peptides reported here was carried 
out in order to determine a possible biologically 
relevant conformation for these compounds act-
ing as antifungal agents. To determine the rela-
tive importance of some amino acid residues in 
the α-MSH(6-13) sequence to produce antifungal 
activity, systematic replacement at the N- and 
C- terminus (6-9 and 11-13 sequences) were un-
dertaken. Parallel conformational and electronic 
study explored the stereoelectronic aspects of this 
series.
  Results and discussion
The principal goal was to find α-MSH 
analogues with greater antifungal activity and 
to reach a better understanding of the peptide 
structure-antifungal relationship through de-
sign, synthesis and testing of novel octapeptide 
analogues in which several modifications were 
made. As starting structure, we chose the se-
quence α-MSH(6-13), His-Phe-Arg-Trp-Gly-Lys-
Pro-Val-NH2, which contains the invariant “core” 
sequence His-Phe-Arg-Trp (6-9), common to all 
melanocortin receptors (Hruby et al. 1987), and 
the sequence Lys-Pro-Val (11-13), which has been 
reported to be relevant to antimicrobial activ-
ity (Cutuli et al. 2000). Previously, we tested the 
antifungal activity of tetrapeptide His-Phe-Arg-
Trp-NH2 and Lys-Pro-Val-NH2 against a panel of 
pathogenic fungi (Masman et al. 2006). Lys-Pro-
Val-NH2 did not show antifungal activity; in con-
trast, the tetrapeptide His-Phe-Arg-Trp displayed 
a moderated but significant antifungal effect, in 
particular against C. neoformans (Masman et 
al. 2006). To better characterize the structure-
antifungal activity relationship of octapeptides 
1-11 reported here, the present research explored 
influences of amino acid substitutions on its an-
tifungal activity.
3.2.1  Antifungal activity
To carry out the antifungal evaluation, 
concentrations of peptides at 100 and 200 μM 
were incorporated to growth media according 
with the Experimental Section. Compounds pro-
ducing no inhibition of fungal growth at 200 μM 
level were considered inactive.
In a first step of our study, we fo-
cused our attention on the C-terminal extreme 
(α-MSH(11-13) sequence), synthesizing and evalu-
ating compounds 1-4. Our results showed that oc-
tapeptide 1 did not inhibit C. albicans up to a con-
centration = 200 µM (table 3.1).  This result is in 
contrast to that of Grieco et al. who reported that 
peptide 1 possessed a moderate inhibitory activ-
ity against C. albicans (59.4 %) at 100 µM (Grieco 
et al. 2005). Peptide 1 did not inhibit C. tropicalis 
either, but showed a low inhibitory effect against 
C. neoformans (24 %) at 200 μM. The replacement 
of Pro12 by Phe in peptide 2 produced an enhance-
ment of the antifungal activity against all fungi 
tested mainly at 200 µM. These results were in 
agreement with those of Grieco et al. who report-
ed a higher inhibitory effect for peptide 2 in com-
parison to peptide 1 against C. albicans (Grieco 
et al. 2005). The replacement of Pro12 of peptide 1 
by Tyr in peptide 3 gave a higher enhancement of 
activity (compare 3 with 2 and 1) only against C. 
neoformans. We then replaced Lys11 in 2 by Arg 
obtaining peptide 4 which displayed an enhance-
ment of the antifungal activity at 200 µM in the 
three fungi tested.
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C. neoformans  C. albicans  C. tropicalis 
Pep.  Sequence 
200 PM  100 PM  200 PM  100 PM  200 PM  100 PM 
1   His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2  24 ± 5  9 ± 2  0   0  0  0 
2  His-Phe-Arg-Trp-Gly-Lys-Phe-Val-NH2  77 ± 30  15 ± 3  61 ± 23  5 ± 2  19 ± 10  9 ± 3 
3  His-Phe-Arg-Trp-Gly-Lys-Tyr-Val-NH2  99 ± 1  58 ± 1  43 ± 10  0  21 ± 10  0 
4  His-Phe-Arg-Trp-Gly-Arg-Phe-Val-NH2  94 ± 6  72 ± 7  80 ± 0.6  1 ± 0.2  64 ± 12  1 ± 3 
5  His-Phe-Lys-Trp-Gly-Lys-Phe-Val-NH2  97 ± 3  38 ± 6   72 ± 8  0  22 ± 5  0 
6  His-Phe-Lys-Trp-Gly-Arg-Phe-Val-NH2  97 ± 4  98 ± 3  100 ± 0.4  80 ± 1  92 ± 4  58 ± 6 
7  His-Phe-Lys-Trp-Gly-Lys-Tyr-Val-NH2  83 ± 20  50 ± 6  15 ± 12  0  0  0 
8  His-Tyr-Lys-Trp-Gly-Arg-Phe-Val-NH2  89 ± 5  47 ± 4  11 ± 3  0  23 ± 8  0 
9  His-Tyr-Lys-Trp-Gly-Lys-Tyr-Val-NH2  63 ± 15  42 ± 1  0  0  3 ± 3  0 
10  His-Tyr-Lys-Trp-Gly-Lys-Phe-Val-NH2  41 ± 10  25 ± 1  0  0  1 ± 2  0 
11  His-Tyr-Arg-Trp-Gly-Lys-Phe-Val-NH2  35 ± 10  21 ± 7  10 ± 6  0  1 ± 3  0 
Amphotericin B  100  100  100  100  100  100 
Table 3.1: Antifungal activity (% inhibition = mean ± SD) of peptides against Cryptococcus neoformans ATCC 32264, 
Candida albicans ATCC 10231 and Candida tropicalis C 131 2000.
In a second step of our study, we focused 
our efforts on the introduction of modifications in 
the sequence α-MSH(6-9). Replacement of Arg8 by 
Lys in 2 and 4 gave peptides 5 and 6, respectively. 
This change produced a significant enhancement 
(p < 0.01) of antifungal activity, from 15% (peptide 
2) to 38% (peptide 5) and from 72% (peptide 4) to 
98% (peptide 6) of inhibition at 100 μ M aga inst 
C. neoformans. The same trend was observed for 
compounds 5 and 6 when tested against C. albi-
cans and C. tropicalis. It is interesting to empha-
size that peptide 6 was the most active peptide in 
this series, showing a significant antifungal activ-
ity against all the fungi tested, including C. albi-
cans. Next, we replace Tyr by Phe12 in peptide 5 
obtaining peptide 7. Although peptide 7 displayed 
a similar activity against C. neoformans to that 
of 5 and 6 at 200 µM, its inhibitory effect against 
this yeast at 100 µM, as well as its activity against 
C. albicans and C. tropicalis was markedly lower. 
Peptides 8-11 were obtained replacing Phe7 by Tyr 
in peptides 6, 7, 5 and 2, respectively. In general 
these peptides displayed a lower inhibitory effect 
with respect to their congeners, in particular pep-
tides 10 and 11, which displayed only a marginal 
effect.
In order to better understand the above 
experimental results, we performed an exhaus-
tive conformational and electronic study of all the 
peptides reported here using theoretical calcula-
tions. These results are presented in the next sec-
tion and might be useful to perform a structure-
activity relationship on this series.
3.2.2  Conformational Study
Linear peptides are highly flexible and 
therefore, to determine the biologically relevant 
conformations is not an easy task. It is necessary 
to perform an exhaustive conformational analy-
sis for these structures to obtain a good perspec-
tive about their conformational intricacies. Thus, 
a conformational study on all peptides reported 
here was carried out using EDMC calculations 
(Ripoll and Scheraga 1988, 1990). Theoretical cal-
culations were carried out as described in calcula-
tion methods section. These results are summa-
rized in table 3.2 and tables 3.1S-3.11S (shown 
in appendix A).
Calculations yielded a large set of con-
formational families for each peptide studied. The 
total number of conformations generated for each 
peptide varied between 94082 and 110569, and the 
number of those accepted was 5000 for all cas-
es. In the clustering procedure, a RMSD (Route 
Mean Square Deviation) of 0.75 Å and a ΔE of 
30 kcal mol-1 were used. The number of families 
after clustering varied between 221 and 366. The 
total number of families accepted with a relative 38 
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population higher of 0.20 % varied between 8 and 
20. Their populations summed up to ca 90% of all 
conformations in each case (see table 3.2).
Our results indicate that these peptides 
are highly flexible, showing equilibrium of sta-
tistical-coil (Vila et al. 2002) structures. All low-
energy conformers of octapeptides studied here 
were then compared to each other. The compari-
son involved the spatial arrangements, relative 
energy and populations. 
The preferred fully-folded form with 42 % 
of population (global minimum) obtained for pep-
tide  1 is comparable to the conformation reported 
by Caratenuto et al. from RMN spectroscopic data 
(Carotenuto et al. 2007). The torsional angles ob-
tained for the fragment Arg8-Trp9-Gly10-Lys11-Pro12 
are the following: φ8= -65 (-67 ± 5), ψ8= -41 (-41 ± 3); 
φ9= -89 (-76 ± 3), ψ9= -29 (-26 ± 2); φ10= 94 (-84 ± 5), 
ψ10= 39 (-1 ± 15); φ11= -63 (-67 ± 13), ψ11= -58 (-46 ± 6); 
φ12= -68, ψ12= -19 (-3 ± 45). The experimental data are 
given in brackets. As can be observed, there is a very 
good correlation between the theoretical and experi-
mental dihedral angles for Arg8, Trp9, Lys11 and Pro12. 
Nevertheless, the values obtained for Gly10 are quite 
shifted. Whereas from the theoretical calculations it 
Generateda  Acceptedb 
Pep. 
Elec.  Ran.  Ther.  Total  Elec.  Ran.  Ther.  Total 
# Fc # F0.20%
d % Pe 
1  7051  95871  237  103159  650  4158  192  5000  271  15  92.16 
2  6450  88021  181  94652  501  4356  143  5000  254  20  92.86 
3  7165  96921  258  104344  552  4246  202  5000  221  8  92.48 
4  7277  96253  275  103805  622  4169  209  5000  298  16  91.38 
5  6372  87496  214  94082  565  4266  169  5000  252  13  93.06 
6  6525  87475  208  94208  468  4378  154  5000  272  14  92.08 
7  7437  101014  267  108718  628  4164  208  5000  274  16  92.00 
8  7419  100395  317  108131  500  4261  239  5000  305  13  91.52 
9  7032  96579  258  103869  553  4284  163  5000  227  12  93.84 
10  7547  102709  313  110569  530  4218  252  5000  366  20  88.74 
11  6752  92559  227  99538  571  4247  182  5000  283  16  92.60 
a Number of conformations generated electrostatically, randomly and thermally during the conformational search. 
b Number of conformations accepted from those generated electrostatically, randomly and thermally during the conformational search. 
c #F: Total number of conformational families as result of the clustering run. 
d # F0.20%: Number of conformational families with populations above 0.20%  
e % P: Sum of the per cent relative population of # F0.20% 
Table 3.2: Selected conformational search and clustering results for peptides 1-11 optimized at the EDMC/SRFOPT/EC-
CEP/3 level of theory.
appears that this residue adopts a bend structure, the 
experimental results suggest a turn form. However, it 
must be pointed out that Gly is a very flexible residue 
as was previously highlighted by Carotenuto et al. and 
therefore this difference is not unexpected.
It was found that the active octapeptides 
2-9 possess low-energy conformers which were 
similar to each other. They showed mainly two 
preferred conformations considering the relative 
energy and population. These were a fully-folded 
conformation and a partially extended form (see 
figure 3.1). The fully-folded conformation dis-
played a turn along 7-10 residues, a bend at resi-
due 11 and the rest of the residues (6, 12 and 13) 
in a non-stable structure (figure 3.1a). The par-
tially extended conformation showed an extend-
ed form encompassing the first three residues, a 
turn along 9-12 residues and the last residue in a 
non stable structure (figure 3.1b). In addition, 
peptides 7, 8 and 9 displayed an α-helix confor-
mation with a relatively relevant population. In 
general, the relative populations obtained for the 
fully-folded and partially extended forms were 
in equilibrium, giving at least 50 % of the whole 
population. 39  
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Figure 3.1: Spatial view of the preferred forms obtained for peptide 6: (a) fully-folded conformation and (b) partially 
extended conformation. The backbones are shown as balls and sticks whereas the side chains are shown as wire representa-
tions. All hydrogens are omitted for clarity.
It is interesting to note that peptide 5, which 
was one of the most active peptides in this series, dis-
played the partially extended conformation as the high-
ly preferred form with a 65 % of the whole population. 
In contrast, peptides 1, 10 and 11, which were inactive 
or displayed only marginal activity, did not adopt the 
partially extended conformation among the preferred 
forms. These peptides displayed the fully-folded form 
as the highly preferred conformation, and a mixture 
between bend and coil conformations, as the second 
preferred form (see % of population in tables 3.1S, 
3.10S and 3.11S in appendix A). Thus, our results permit 
us speculate that the low antifungal activity obtained 
for peptides 1, 10 and 11 could be explained at least in 
part by this conformational difference. Interestingly 
enough, in the fully-folded conformations, a stabilizing 
π-stacking interaction between the aromatic residue at 
7 position (Phe7 or Tyr7) and the other aromatic residue 
located at 12 position (Phe12 or Tyr12) was observed.
Molecular recognition and the converse 
concept of specificity (Sarai 1989) are explained in 
mechanistic and reductionistic terms by a stereo-
electronic “complementarity” between the ligand 
and the receptor (North 1989). In this context, it 
is obvious that the knowledge of the stereoelec-
tronic attributes and properties of octapeptides 
and its analogues will contribute significantly 
to the elucidation of a possible pharmacophoric 
patron for these compounds acting as antifun-
gal compounds. Once the low-energy conforma-
tions for the octapeptides reported here were ob-
tained and, in an attempt to find the potentially 
reactive sites for the ligands, we evaluated the 
electronic aspects of the molecules under study 
using Molecular Electrostatic Potentials (MEP) 
(Politzer and Truhlar 1981).
3.2.3.  Molecular electrostatic potentials
MEP are of particular value because 
they allow the visualization and assessment of the 
capacity of a molecule to interact electrostatically 
with a putative binding site (Murray and Politzer 40 
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1998; Naray-Szabo and Ferenczy 1995; Politzer and 
Truhlar 1981). MEP can be interpreted in terms of 
a stereoelectronic pharmacophore condensing all 
available information on the electrostatic forces 
underlying affinity and specificity. Figure 3.2 
gives the MEP obtained for compounds 1  and 
3, showing the C-terminal portion of these pep-
tides. The different electronic behavior obtained 
for this moiety of peptide 1 with respect to 3 and 
the rest of the octapeptides reported here can be 
appreciated in this figure. Note that the electro-
static potentials near to the C-terminal portion of 
1 are markedly more negative than those obtained 
for peptide 3. Thus, there is not only a different 
conformational behavior between peptide 1 and 
the rest of peptides but also a clear different elec-
tronic distribution due to the replacement of an 
aromatic residue (Phe or Tyr) by Pro12. The differ-
ent conformational and electronic behavior ob-
served for 1 could explain the lack of antifungal 
effect observed for this peptide. Figure 3.3 gives 
the MEP obtained for peptides 5, 9 and 10 show-
ing, in this case, a spatial view of the stabilizing 
π-stacking interaction between the aromatic resi-
dues located at positions 7 and 12. The π-stacking 
interaction between Phe7 and Phe12 in peptide 5 
(figure 3.3a) displays both aromatic residues in 
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Figure 3.2: Electrostatic potential-encoded electron density surfaces of peptides 1 (a) and 3 (b).  The surfaces were gener-
ated with Gaussian 03 using RB3LYP/6-31G(d,p) single point calculations. The coloring represents electrostatic potential 
with red indicating the strongest attraction to a positive point charge and blue indicating the strongest repulsion. The 
electrostatic potential is the energy of interaction of the positive point charge with the nuclei and electrons of a molecule. It 
provides a representative measure of overall molecular charge distribution. The color-coded is shown on the left.
a parallel orientation and it is located far away in 
comparison to the similar interaction observed 
in peptides 9 and 10 (figure 3.3b and c, respec-
tively). It should be noted that the π-stacking in-
teractions involving Tyr residues (either at posi-
tions 7 or 12) adopted a perpendicular orientation 
between the aromatic residues and also displayed 
a nearby spatial position. These results suggest  
that π-stacking interactions involving Tyr resi-
dues appear to be stronger than those in which 
only Phe residues participate.  The preference for 
fully-folded structures observed for peptides 3, 
7-11 may be, in principle, related to the stronger 
stabilizing π-stacking interaction present in these 
structures. It appears that the replacement of Phe7 
or Phe12 by Tyr could be the responsible of such 
difference. It is interesting to note that the most 
active peptides (4, 5 and 6) possessing preferred 
partially extended forms, do not have Tyr in their 
respective sequence.
3.2.4.  Structure antifungal activity relationships
In a previous paper we demonstrated 
that the smallest fragment with measurable anti-
fungal activity was His6-Phe7-Arg8-Trp9-NH2 and 
some of its derivatives (Masman et al. 2006). It has 
been shown that the minimal sequence possess- 41  
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Figure 3.3: Electrostatic potential-encoded electron density surfaces of peptides 5 (a), 9 (b) and 10 (c). The color-coded is 
shown on the left.
ing α-MSH-like activity is the central tetrapeptide 
His-Phe-Arg-Trp (Hruby et al. 1987). This “core” 
sequence was suggested to be the “message” frag-
ment for α-MSH, the rest of the molecule being 
regarded as the “address” sequence (Otsyka and 
Inouye 1964).
Keeping in mind that peptides 2-9 can 
be considered active, whereas peptides 1, 10 and 
11 have reduced inhibitory effect, it is noteworthy 
that the partially extended conformations as pre-
ferred forms were only present in active analogues 
whereas fully-folded conformations were present 
both in active and inactive peptides. This suggests 
that the partially extended conformations could 
be operative in the recognition process between 
these peptides and their receptor. Figure 3.4 
shows a spatial view of the most populated and 
energetically preferred conformation of peptide 5. 
This conformation has been overlapped with the 
partially extended conformations of the rest of 
the active peptides 2-4 and 6-9. The conformers 
shown in figure 3.4 are very close to each oth-
er considering the values of the dihedral angles 
obtained for their backbones of the N-terminal 
portion (residues 6-9). From the analysis of 
figure 3.4, it is clear that there is not a complete 
conformational overlapping between these con-
formers. However, all the active peptide adopted 42 
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Figure 3.4: Stereoview of the overlapping of peptides 
2-9 partially extended conformers. The backbone “core” 
6-9 sequence is shown in sticks indicating each alpha car-
bon with spheres, the rest of the backbone structures are 
shown in wire representations. Peptide 2 is shown in red, 
3 (blue), 4 (white), 5 (pink), 6 (cyan), 7 (yellow), 8 (green) 
and 9 (purple). All hydrogens and side chains are omitted 
for clarity.
a very similar spatial ordering for the “core” 6-9 
sequence. A good fit among the four first amino 
acids was obtained, but there was not a good over-
lapping between the last four amino acids (resi-
dues 10-13). Thus, the backbone conformations of 
C-terminal tripeptide for the partially extended 
forms do not appear to be essential for the general 
spatial organization of these octapeptides. This 
situation might be well appreciated in figure 3.4. 
In contrast, our results indicate that in the fully-
folded forms of these peptides, the spatial order-
ing adopted by the C-terminal tripeptide (11-13 
sequence) in particular the aromatic amino acid 
Phe12 or Tyr12 could play a determinant role for the 
whole conformation of the octapeptide making a 
stabilizing π-stacking interaction. These results 
are in good agreement with our previous ones 
postulating a partially extended conformation as 
the biologically relevant form for His-Phe-Arg-
Trp-NH2 and derivatives. Interestingly, the acety-
lation of the same peptides led to inactive com-
pounds possessing a highly preferred fully-folded 
conformation (Masman et al. 2006).
Besides, these results agree fairly well 
with those previously reported by Sugg et al. 
postulating a partially extended conformation 
for the His-Phe-Arg-Trp “core” sequence as the 
biologically active α-MSH conformation (Sugg 
et al. 1986). Thus, it is worthwhile to compare the 
“biologically active conformation” proposed in 
this study for the backbone of the His-Phe-Arg-
Trp-NH2 portion, with that previously reported 
for the same sequence from proton NMR studies 
in aqueous solution. Sugg et al. reported that the 
observed topology was consistent with a non hy-
drogen-bonded β-like structure (φ = -139º and ψ = 
135º for L-amino acids) as the predominant con-
formation in solution (Sugg et al. 1986). This con-
formation is closely related to those obtained for 
the “core portion” (6-9 sequence) of the different 
conformers of the active peptides. In figure 3.5, 
we overlapped the conformation reported by Sugg 
et al. (in orange) with the partially extended con-
formations obtained for all the active peptides.
Grieco et al. suggested that the antimi-
crobial effects of α-MSH could be exerted through 
a unique mechanism different from that of other 
natural antimicrobial peptides (Grieco et al. 2003; 
Grieco et al. 2005). They suggested that the candi-
Figure 3.5: Stereoview of the overlapping of the backbone 
“core” 6-9 sequence conformation determined by Sugg 
and coworkers (Sugg et al. 1986) in orange sticks, and the 
partially extended backbone conformers of peptides 2-9 in 
wire representations. Peptide 2 is shown in red, 3 (blue), 4 
(white), 5 (pink), 6 (cyan), 7 (yellow), 8 (green) and 9 (pur-
ple). All hydrogens and side chains are omitted for clarity.
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dacidal effect of α-MSH is linked to the cAMP-in-
ducing activity. On the basis of our results, it ap-
pears that there is some parallelism between the 
α-MSH and antifungal effects; however, it should 
be noted that there are interesting differences as 
well. Previous structure-activity studies on the 
α-MSH(11-13) sequence disclosed the significance 
of Pro12 to the anti-inflammatory influence of the 
tripeptide. Indeed, substitution of Pro12 with its 
D-isomer abolished the anti-inflammatory ef-
fect (Hiltz et al. 1991). Subsequently, researches 
on C-terminally modified analogues of α-MSH 
confirmed the important role of Pro12 for binding 
and activity at the MC1 receptor (Peng et al. 1997). 
In contrast, our results indicate that the presence 
of Pro12 is not relevant for the antifungal activity. 
Replacement of Pro12 by Phe or Tyr gives a clear 
enhancement of inhibitory effect. A striking dif-
ference can be observed between the roles of Pro12 
of these peptides when acting as anti-inflamma-
tory or antifungal compounds.  On the other 
hand, the “core” 6-9 sequence (His-Phe-Arg-Trp) 
of melanocortins has long been considered es-
sential for melanocortin receptor recognition and 
activation (Holder and Haskell-Luevano 2004). 
Alanine replacement studies in B16 melanoma 
cells showed that when each amino acid in the 
6-9 sequence was replaced by alanine there was a 
substantial decrease in receptor recognition and 
activation by α-MSH (Sahm 1994). Our results 
indicate that the “core” 6-9 sequence, or a very 
similar structure, is also a structural requirement 
to produce the antifungal activity.
Carotenuto et al. hypothesized that the 
N-terminal portion (7-10) is responsible for re-
ceptor activation while the C-terminal moiety 
(10-13) works only enforcing the binding to the 
receptor through positive interactions with an 
auxiliary-binding site, for the candidacidal activ-
ity (Carotenuto et al. 2007). Our results are in a 
relatively good agreement with such hypothesis. 
It is clear that the fully-folded conformations, sta-
bilized by p-stacking interactions, do not show an 
adequate spatial ordering for the hypothetical re-
ceptor possessing two binding sites. On one hand, 
they cannot reach the adequate distances for both 
interactions and, on the other hand, the intra-
molecular interactions could affect the binding of 
the N-terminal portion proposed as the respon-
sible for the receptor activation. A similar expla-
nation could be applied for the inactive acetylated 
derivatives previously reported (Masman et al. 
2006). The fact that His-Phe-Arg-Trp-NH2 is the 
smallest fragment with significant antifungal ac-
tivity could be an additional support to consider 
the N-terminal portion as the responsible for re-
ceptor activation. However, caution is required 
for such speculations in particular because we 
are hypothesizing on a still unknown receptor. 
Although the actual existence of melanocortin 
receptors in yeasts has not been established, our 
results showing the effects of amino acid substi-
tutions on critical portions, suggest that the pres-
ence of such receptors or more probably a struc-
turally related receptor is highly plausible. 
 Conclusions
We designed and synthesized eleven 
α-MSH octapeptide analogues with different resi-
dues in the core and in the C-terminal sequences 
and tested their antifungal activity. Among com-
pounds tested, His-Phe-Lys-Trp-Gly-Arg-Phe-
Val-NH2 (6) displayed the best antifungal activity 
against C. neoformans, C. albicans and C. tropi-
calis. Other octapeptide analogues reported here 
displayed moderate but still significant antifungal 
effects against C. neoformans. 
A detailed conformational and elec-
tronic study supported by theoretical calcula-
tions helped us to identify a possible “biologically 
relevant conformation” and also understand the 
minimal structural requirements for the anti-
fungal actions of octapeptides reported here. Our 
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results are very encouraging since they show a 
great potential of His-Phe-Lys-Trp-Gly-Lys-Phe-
Val-NH2 and derivatives as a truly novel class of 
antifungal compounds particularly against the 
yeast C. neoformans. 
The general picture emerging from our 
results is that there is some parallelism between 
the recognition process for the α-MSH receptor 
and the hypothetical receptor involved in the 
antifungal response. However, in this regard it is 
interesting to note that there are also structural 
differences between the respective ligands, sug-
gesting some structural difference between the 
α-MSH receptor and the putative yeast’s receptor.
  Experimental section
3.4.1  Synthetic methods
Solid phase synthesis of the peptides 
was carried out manually on a p-methylbenzhy-
drylamine resin (1 g MBHA, 0.39 mmol/g) with 
standard methodology using Boc-strategy. Side 
chain protecting groups were as follows: Arg(Tos), 
His(Tos), Lys(2Cl-Z), Tyr(2Br-Z). All protected 
amino acids were coupled in CH2Cl2 (5 ml) us-
ing DCC (2.5 equiv.) and HOBt (2.5 equiv.) until 
completion (3 h) judged by Kaiser ninhydrin test 
(Kaiser et al. 1970). After coupling of the appro-
priate amino acid, Boc-deprotection was effected 
by using of TFA/CH2Cl2 (1:1, 5 ml)) for 5 min first 
then repeated for 25 min. Following neutraliza-
tion with 10% TEA/CH2Cl2 three times (5-5 ml of 
each), the synthetic cycle was repeated to assem-
ble the resin-bond protected peptide. The pep-
tides were cleaved from the resin with simulta-
neous side chain deprotection by acidolysis with 
anhydrous hydrogen fluoride (5 ml) containing 
2% anisole, 8% dimethyl sulfide and indole at 5°C 
for 45 min. The crude peptides were dissolved in 
aqueous acetic acid and lyophilized. Preparative 
and analytical HPLC of the crude and the puri-
fied peptides were performed on an LKB Bromma 
apparatus (for preparative HPLC, column: 
Lichrosorb RP C18, 7 μm, 250x16 mm; gradient 
elution: 30-100%, 70 min; mobile phase: 80% ace-
tonitrile, 0.1% TFA; flow rate: 4 ml/min, 220 nm, 
for analytical HPLC, column: Phenomenex Luna 
5C18(2), 250x4.6 mm; mobile phase: 80% aceto-
nitrile, o.1% TFA; flow rate: 1.2 ml/min, 220 nm). 
ESI-MS: Finnigan TSQ 7000 (Table 3.3).
3.4.2  Microorganisms and media
Candida  spp. and Cryptococcus sp. 
from the American Type Culture Collection 
(ATCC, Rockville, MD, USA) were used. The 
panel included Candida albicans 10231, Candida 
tropicalis C 131 and Cryptococcus neoformans 
ATCC 32264. Strains were grown on Sabouraud-
chloramphenicol agar slants for 24 h at 35 oC, 
maintained on slopes of Sabouraud-dextrose agar 
(SDA, Oxoid). Inocula of cell suspensions were 
obtained according to reported procedures and 
adjusted to 1-5 x103 cells with colony forming units 
(CFU) /mL (Pfaller 2002a).
3.4.3  Antifungal evaluation
The test was performed in 96 wells-
microplates. Peptide test wells (PTW) were pre-
pared with stock solutions of each peptide in 
DMSO (maximum concentration ≤2%), diluted 
with RPMI-1640 to final concentrations 200 and 
100 µM. Inoculum suspension (100 µl) was added 
to each well (final volume in the well = 200 µL). 
A growth control well (GCW) (containing me-
dium, inoculum, the same amount of DMSO 
used in PTW, but compound-free) and a sterility 
control well (SCW) (sample, medium and st  er- ster-
ile water instead of inoculum) were included for 
each strain tested. Microtiter trays were incubated 
in a moist, dark chamber at 35 oC, 24 or 48 h for 
Candida spp. or Cryptococcus sp., respectively. 
Microplates were read in a VERSA Max micro-
plate reader (Molecular Devices, Sunnyvale, CA, 
USA). Amphotericin B (Sigma Chemical Co, St 
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Louis, MO, USA)  was used as positive control 
(100 % inhibition). Tests were performed by du-
plicate. Reduction of growth for each peptide con-
centration was calculated as follows: % of inhibi-
tion: 100- (OD405 PTW- OD405 SCW) / OD405 GCW 
- OD405 SCW.
3.4.4  Statistical analysis
Data were statistical analyzed by both, 
one-way analysis of variance and Student’s test. A 
p< 0.05 was considered significant.
3.4.5  Computational methods
3.4.5.1  Edmc calculations
The conformational space of each pep-
tide was explored using the method previously 
employed by Liwo et al. (Liwo et al. 1996b) that in-
cluded the Electrostatically Driven Monte Carlo 
(EDMC) method (Ripoll and Scheraga 1988, 1990). 
The conformational energy was evaluated using 
the ECEPP/3 force field (Némethy et al. 1992). This 
force field employs rigid valence geometry. The 
hydration energy was evaluated using a hydra-
tion-shell model with a solvent sphere radius of 
1.4 Å and atomic hydration parameters that have 
been optimized using nonpeptide data (SRFOPT) 
(Vila et al. 1991; Williams et al. 1992). In this mod-
el in addition to a sum of electrostatic, non-bond-
ing, hydrogen-bond and torsional energy terms, 
the total conformational energy includes terms 
accounting for loop closing and peptide solvation. 
The conformation with minimized energy was 
subsequently perturbed by changing its torsional 
φ and ψ angles using the Monte Carlo method 
(Li and Scheraga 1987). Piela’s algorithm (Piela 
and Scheraga 1987), which was also applied at this 
stage, greatly improves the acceptance coefficient. 
In this algorithm φ and ψ angles are changed in a 
manner which allows the corresponding peptide 
group to find the most proper orientation in the 
electrostatic field of the rest of the peptide chain. 
The energy of the new conformation is mini-
mized, compared to the previous one and can be 
accepted or discarded on the basis of energy and/
or geometry. If the new energy-minimized con-
formation is similar in shape and in energy to the 
starting conformation, it is discarded. Otherwise, 
the energy of the new conformation is compared 
with the energy of the parent conformation. If the 
new energy is lower, the new conformation is ac-
cepted unconditionally, otherwise the Metropolis 
criterion (Metropolis et al. 1953) is applied in or-
der to accept or reject the new conformation. If 
the new conformation is accepted, it replaces the 
starting one; otherwise another perturbation of 
the parent conformation is tried. A temperature 
jump may be included if the perturbation is not 
successful for an arbitrarily chosen number of it-
erations. The process is iterated, until a sufficient 
number of conformations have been accepted. 
Sidor et al. give a more detailed description of this 
procedure (Sidor et al. 1999).
In order to do an extensive exploration of the 
conformational space, we have been carried out 10 dif-
ferent runs, each of them with a different random num-
ber, for each peptide studied. Since the EDMC proce-
dure uses random numbers, there is a need to initialize 
the random number generator by providing an integer. 
Therefore, we collected a total of 5000 accepted con-
formation for each peptide studied. Each EDMC run 
was terminated after 500 energy-minimized conforma-
tions had been accepted. The parameters controlling 
the runs were the following: a temperature of 298.15 K 
had been used for the simulations. A temperature jump 
of 50000 K had been used;  the maximum number of 
allowed repetitions of the same minimum was 50; the 
maximum number of electrostatically-predicted con-
formations per iteration was 400;  the maximum num-
ber of random-generated conformations per iteration 
was 100; the fraction of random/electrostically-pre-
dicted conformations was 0.30; the maximum number 
of steps at one increased temperature was 20; and the 
maximum number of rejected conformations until a 
temperature jump is executed was 100. Only trans pep-
tide bonds (ω ≈ 180°) had been considered.
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tions was then clustered into families using the 
program ANALYZE (Meadows et al. 1994b; Post 
et al. 1990; Scheraga et al. 1983), which applies the 
minimal-tree clustering algorithm for separa-
tion, using backbone atoms, energy threshold of 
30 kcal mol-1 and R.M.S.D. of 0.75 Å as separation 
criteria. This procedure allows for substantial 
reduction of the number of conformations and 
eliminates repetitions.
3.4.5.2  Molecular electrostatic potentials and 
molecular interaction calculations
Quantum mechanics calculations 
were carried out using the Gaussian 03 program 
(Frisch et al. 2003). We use low-energy confor-
mations of peptide 1-11 obtained from EDMC 
calculations. Subsequently, single point DFT 
(RB3LYP/6-31G(d,p)) calculations were carried 
out. The electronic study was carried out using 
molecular electrostatic potentials (MEP) (Politzer 
and Truhlar 1981). These MEP were calculated us-
ing RB3LYP/6-31G(d,p) wave functions and MEP 
graphical presentations were created using the 
MOLEKEL program (Flükiger et al. 2000).
Molecular graphics images were pro-
duced using the UCSF Chimera package from 
the Resource for Biocomputing, Visualization, 
and Informatics at the University of California, 
San Francisco (supported by NIH P41 RR-01081) 
(Pettersen et al. 2004b). ■
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“I pack my suit in a bag. I’m all dressed up for Prague. 
I’m all dressed up with you, all dressed up for him too...
Prepare myself for a war, before I even open up my 
door, before I even look out, I’m pissing all of my bullets 
about...”
(D. Rice)Penetratin & derivatives acting as antifungal agents
Marcelo F. Masman, Ana M. Rodríguez, Marcela Raimondi, Susana A. Zacchino, Paul G. M. 
Luiten, Csaba Somlai, Tamas Kortvelyesi, Botond Penke & Ricardo D. Enriz
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Abstract
The synthesis, in vitro evaluation, and conformational study of RQIKIWFQNRRMKWKK-NH2 (pen-
etratin) and related derivatives acting as antifungal agents are reported. Penetratin and some of its de-
rivatives displayed antifungal activity against the human opportunistic pathogenic standardized ATCC 
strains Candida albicans and Cryptococcus neoformans as well as clinical isolates of C. neoformans. 
Among the compounds tested, penetratin, along with the nonapeptide RKWRRKWKK-NH2 and the 
tetrapeptide RQKK-NH2 exhibited significant antifungal activities against the Cryptococcus sp. A com-
prehensive conformational analysis on the peptides reported here using three different approaches, Mo-
lecular Mechanics, Simulated Annealing and Molecular Dynamics simulations, was carried out. The 
experimental and theoretical results allow us to identify a topographical template which may provide a 
guide for the design of new compounds with antifungal characteristics against C. neoformans.
European Journal of Medicinal Chemistry (2009) 44:212-228. 51  
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 Introduction
Fungal infections are a persistent 
major health problem which especially affects 
and threatens immunocompromised patients 
(Georgopapadakou and Tkacz 1995; McNeil et 
al. 2001; Pfaller and Diekema 2007; Walsh et al. 
2004). Invasive fungal infections as well as der-
matomycoses produced by fungal organisms with 
even low virulence can be life-threatening (Nagiec 
et al. 1997) for individuals with increased vulner-
ability such as neonates, cancer patients receiv-
ing chemoteraphy, organ transplant patients, and 
burns patients, apart from those with acquired 
immunodeficiency syndrome (AIDS). Other 
risk factors include corticosteroid and antibiotic 
treatments, diabetes, lesions of epidermis and 
dermis, malnutrition, neutropenia and surgery 
(Georgopapadakou and Tkacz 1995). Many fungal 
infections are caused by opportunistic pathogens 
that may be endogenous or acquired from the en-
vironment (Candida, Cryptococcus, Aspergillus 
infections). Patients with significant immunosup-
presion frequently develop Candida esophaguitis. 
Cryptococcosis, caused by the encapsulated yeast 
Cryptococcus neoformans, has been the cause of 
fungal mortality among HIV-infected patients. 
This organism has a predilection for the central 
nervous system and leads to severe, life-threaten-
ing meningitis. In addition, an increasing num-
ber of normal individuals, including children 
in third-world nations (Ablordeppey et al. 1999; 
Freixa et al. 1998) that suffer deficient sanitation 
and education, are prone to fungal infections, 
specially those involving the skin and mucosal 
surfaces.
Although it appears that many drugs 
are available for the treatment of systemic and 
superficial mycoses, there are in fact only a lim-
ited number of effective antifungal drugs (Walsh 
et al. 2004). Many of the antifungal compounds 
currently available have undesirable effects or are 
very toxic (amphotericin B); are fungistatic and 
not fungicidal (azoles), or lead to the development 
of resistance, as with 5-fluorocytosine (White et 
al. 1998). Amphotericin B, developed in the 1950’s, 
still remains a widely used antifungal drug, most 
recently gaining renewed applications through 
lipid based formulations. According to Polak  ide-
al drugs to cure fungal infections have not been 
discovered yet (Polak 1999). In the meantime, re-
sistance to currently available antifungal agents 
continues to grow (Bartroli et al. 1998a). Although 
combination therapy has emerged as a good alter-
native to bypass these disadvantages (Bartroli et 
al. 1998a, b; Polak 1999), there is an urgent need 
for a next generation of safer and more potent 
antifungal agents (Bartroli et al. 1998b; Walsh et 
al. 2004). These explorations have resulted in the 
identification of novel molecules, which could 
prove promising for further future development. 
Among them, some natural peptides were recent-
ly described as antifungal compounds, inhibiting 
a broad spectrum of fungi (Bulet and Stöcklin 
2005; Hancock et al. 1995; Hancock and Lehrer 
1998; Lee et al. 2003; Masman et al. 2006). It has 
also been reported that a group of cationic anti-
microbial peptides are major players in the innate 
immune response (Boman et al. 1993; Ganz and 
Lehrer 1995; Zasloff 1992). These peptides are very 
ancient elements of the immune response of all 
species of animal and plant life, and the induction 
pathways for these compounds in vertebrates, 
insects and plants (Boman et al. 1993; Ganz and 
Lehrer 1995; Hoffmann et al. 1999; Zasloff 1992) 
are highly conserved. Furthermore, it is becom-
ing increasingly clear that cationic antimicrobial 
peptides play many potential roles in inflamma-
tory responses, which represent an orchestration 
of the mechanisms of innate immunity.
Small cationic peptides are abundant 
in nature and have been described as “nature´s 
antibiotics” or “cationic antimicrobial peptides” 
(Hancock 1997; Hancock and Patrzykat 2002). 
These peptides are 12-50 amino acids long with a 
net positive charge of +2 or +9, which is due to 
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an excess of basic arginine and lysine residues, 
and approximately 50% hydrophobic amino acids 
(Hancock 1997). These molecules are also folded 
in three dimensions so that they have both a hy-
drophobic face comprising non-polar amino acid 
side-chains, and a hydrophilic face of polar and 
positively charged residues: these molecules are 
amphipatic. Despite these two similarities these 
compounds vary considerably in length, amino 
acid sequence, and secondary structure. The dif-
ferent spatial orderings include small β-sheets 
stabilized by disulphide bridges, amphipathic 
α-helices and, less commonly, extended and loop 
structures.
Cell-penetrating peptides (CPPs) are de-
fined as peptides with a maximum of 30 amino 
acids, which are able to enter cells in a seemingly 
energy-independent manner, thus being able to 
translocate across membranes in a non-endocy-
totic fashion (Langel 2002). In 1991 Joliot et al. 
reported that the 60 amino acid homeodomain 
of the Antennapedia protein of Drosophila was 
able to translocate over cell membranes (Joliot et 
al. 1991). In order to understand the driving force 
for the internalization, the homeodomain was 
modified by site-directed mutagenesis leading to 
the discovery that its third helix was necessary 
and also sufficient for membrane translocation, 
which resulted in the development of a 16 amino 
acid-long CPP called penetratin (1) (Derossi et al. 
1994). Thus, peptide 1, a synthetic 16-amino acid 
peptide from the third helix of Antennapedia 
homeodomain (Derossi et al. 1996; Derossi et al. 
1994; Fischer et al. 2000) is a cationic amphipatic 
peptide which might penetrate cell membranes 
via a proposed “inverted micelle” pathway. 
However, the mechanism of membrane translo-
cation is not well known. The question is whether 
the peptide is internalized via endocytosis which 
is energy-dependent or via direct transport. 
While the latter mechanism is scarcely known 
at present, it is believed that the process is non-
receptor-mediated (Derossi et al. 1996; Drin et al. 
2001). In addition, we have previously provided 
evidence on the energy-dependent and lipid raft-
mediated endocytic uptake of penetratin (Letoha 
et al. 2005). Peptide 1 has been proposed as a uni-
versal intracellular delivery vehicle (Dupont et 
al. 2002). Since 1 possesses 16 amino acids and a 
charge of +8, it might be included in the general 
classification of “cationic antimicrobial peptide”. 
To the best of our knowledge this is the first study 
reporting the antifungal activity of 1 and struc-
turally related derivatives.
The aim of the present investigation 
is exploring the antifungal potential of 1 and 
its derivatives against Candida albicans and 
Cryptococcus neoformans. To better character-
ize the structure-antifungal activity relationship 
of peptide 1 and related compounds under study 
the present analysis explored influences of amino 
acid substitutions and deletions on its antifungal 
activity. In addition, an extensive conformational 
analysis of 1 and its derivatives was carried out 
using three different approaches: molecular me-
chanics, simulated annealing (SA) and molecular 
dynamics (MD) simulations. The ability of each 
method to obtain the different conformations is 
tested and compared. Conformational and elec-
tronic studies were carried out in order to identify 
a topographical and/or a sub-structural template, 
which may be the starting structure for the design 
of new antifungal compounds.
  Results and discussion
4.2.1  Antifungal activity
To evaluate the antifungal potential, 
concentrations of peptides up to 200 μM were 
incorporated in the growth media according to 
previously reported procedures (Masman et al. 
2006; Sortino et al. 2007; Zacchino et al. 2003). 
Compounds producing no inhibition of fun-
gal growth at 200 μM were considered inactive. 
table 4.1 gives the antifungal activity obtained  53  
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for peptide 1 against C. albicans and C. neoform-
ans. Peptide 1 displayed a significant antifungal 
activity against both fungi being C. neoformans 
the more sensitive sp. It is interesting to note 
that 1 displayed a significant degree of inhibition 
against C. neoformans even at low concentrations 
(90 % of inhibition was observed at 12.5 μM and 
100% at 25 μM). The inhibitory effect observed 
against C. albicans was slightly lower than that 
obtained for C. neoformans at 12.5 μM but similar 
at 25-200 μM.
In order to gain insight into the spec-
trum of activity, peptide 1 was tested against a 
panel of clinical isolates of C. neoformans. The 
minimum inhibitory concentration (MIC) values 
of 1 were determined against this new panel by 
using three endpoints: MIC100, MIC80 and MIC50 
(the minimum concentration of compounds that 
inhibit 100, 80 and 50 % of growth, respectively). 
The application of a less stringent end point such 
as MIC80 and MIC50 has been shown to consis-
tently represent the in vitro activity of compounds 
and many times provide a better correlation with 
other measurements of antifungal activity such  
as the minimum fungicide concentration (MFC) 
(Ernst et al. 2002; Klepser et al. 1998). In addition 
to MIC determinations, the evaluation of MFC of 
1 against this panel was accomplished by subcul-
turing a sample of media from MIC tubes show-
ing no growth, onto drug-free agar plates. So, 
peptide 1 was tested against ten clinical isolates 
of C. neoformans, all provided by the Malbrán 
Institute (Buenos Aires). These results are shown 
in table 4.2 and the activity was similar to, or 
lower than, those obtained against the standard 
strain (ATCC 32264).
Peptide 2 possesses the same amino ac-
ids of peptide 1 but located in a completely differ-
ent sequence. In fact, the sequence of this peptide 
was randomly generated. This peptide showed no 
antifungal activity against both fungi tested at 
12.5 μM but inhibit 96% and 60 % of the growth of 
C. neoformans and of C. albicans at 200 μM, re-

C
a
n
d
i
d
a
 
a
l
b
i
c
a
n
s
 
C
r
y
p
t
o
c
o
c
c
u
s
 
n
e
o
f
o
r
m
a
n
s
 
P
e
p
t
i
d
e
 
S
e
q
u
e
n
c
e
 
%
 
i
n
h
i
b
.
 
2
0
0
 
P
M
 
%
 
i
n
h
i
b
.
 
1
0
0
 
P
M
 
%
 
i
n
h
i
b
.
 
5
0
 
P
M
 
%
 
i
n
h
i
b
.
 
2
5
 
P
M
 
%
 
i
n
h
i
b
.
 
1
2
,
5
 
P
M
 
%
 
i
n
h
i
b
.
 
2
0
0
 
P
M
 
%
 
i
n
h
i
b
.
 
1
0
0
 
P
M
 
%
 
i
n
h
i
b
.
 
5
0
 
P
M
 
%
 
i
n
h
i
b
.
 
2
5
 
P
M
 
%
 
i
n
h
i
b
.
 
1
2
,
5
 
P
M
 
1
 
R
Q
I
K
I
W
F
Q
N
R
R
M
K
W
K
K
-
N
H
2
 
1
0
0
 
 
±
 
0
.
2
 
1
0
0
 
±
 
0
.
6
 
9
5
 
±
 
1
.
2
 
9
1
 
±
 
1
.
6
 
4
 
±
 
0
.
1
 
1
0
0
 
±
 
0
.
1
 
1
0
0
 
±
 
0
 
1
0
0
 
±
 
0
 
1
0
0
 
±
 
0
.
2
 
9
0
 
±
 
2
.
3
 
2
 
W
K
Q
K
N
I
K
W
R
F
R
Q
K
M
I
R
-
N
H
2
 
6
0
 
±
 
4
.
2
 
5
2
 
±
 
3
.
0
 
0
 
0
 
0
 
9
6
 
±
 
2
.
7
 
9
2
 
±
 
5
.
7
 
3
6
 
±
 
3
.
4
 
2
8
 
±
 
2
.
9
 
0
 
3
 
R
K
W
R
R
K
W
K
K
-
N
H
2
 
1
0
0
 
±
 
0
.
0
8
 
7
6
 
±
 
0
.
9
7
 
5
8
 
±
 
0
.
7
1
 
4
0
 
±
 
1
.
7
5
 
1
5
 
±
 
1
.
0
 
9
9
 
±
 
1
.
6
8
 
6
8
 
±
 
2
1
.
2
2
 
1
4
 
±
 
1
.
3
2
 
1
6
 
±
 
1
.
7
8
 
0
 
4
 
R
K
F
R
R
K
F
K
K
-
N
H
2
 
6
1
 
±
 
1
.
1
6
 
4
4
 
±
 
7
.
0
0
 
3
3
 
±
 
7
.
4
2
 
2
3
 
±
 
3
.
7
9
 
0
 
7
3
 
±
 
1
.
5
1
 
1
1
 
±
 
3
.
9
2
 
1
3
 
±
 
2
.
3
2
 
9
 
±
 
3
.
8
0
 
0
 
5
 
R
K
R
R
K
W
K
K
-
N
H
2
 
2
9
 
±
 
1
.
0
5
 
1
3
 
±
 
0
.
5
5
 
0
 
0
 
0
 
1
0
0
 
±
 
0
.
3
6
 
3
3
 
±
 
4
.
7
9
 
1
1
 
±
 
4
.
3
5
 
6
 
±
 
2
.
1
4
 
0
 
6
 
R
K
R
R
K
K
K
-
N
H
2
 
4
3
 
±
 
4
.
9
6
 
1
2
 
±
 
0
.
4
 
0
 
0
 
0
 
6
0
 
±
 
2
.
9
4
 
1
4
 
±
 
2
.
0
9
 
1
9
 
±
 
6
.
7
3
 
1
0
 
±
 
2
.
8
9
 
0
 
7
 
K
W
K
K
-
N
H
2
 
9
 
±
 
2
.
3
 
2
 
±
 
1
.
0
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
0
 
8
 
R
Q
K
K
-
N
H
2
 
6
 
±
 
1
.
2
 
0
 
0
 
0
 
0
 
1
0
0
 
±
 
1
.
2
 
1
0
0
 
±
 
4
.
0
 
9
2
 
±
 
3
.
6
 
6
2
 
±
 
7
.
4
 
3
2
 
±
 
2
.
3
 
A
m
p
h
o
t
e
r
i
c
i
n
 
B
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
K
e
t
o
c
o
n
a
z
o
l
e
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 
1
0
0
 

Table 4.1: Antifungal activity (% inhibition) of peptides 
against Candida albicans ATCC 10231 and Cryptococcus 
neoformans ATCC 3226454 
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spectively. It is clear that the antifungal activity of 
1 and 2 are markedly different; whereas 1 showed 
a significant antifungal activity against both C. 
albicans and C. neoformans; peptide 2 was prac-
tically inactive. On the basis of these results it 
can be concluded that the sequence as well as the 
different spatial orderings of the cationic, polar 
and hydrophobic residues are important determi-
nants for the antifungal activity. In contrast, the 
positive charge (+8) of 1 appears to be a necessary 
requirement but not by itself sufficient to produce 
the antifungal response. 
To study the structure-antifungal activ-
ity relationship on these peptides, the effects of 
structural changes in the sequence of peptide 1 
were considered. Our principal goal was to syn-
thesize shorter derivatives of 1 trying to maintain 
the antifungal activity as much as possible. In a 
first step we synthesized compound 3, a nonapep-
tide possessing the last four amino acids of 1. In 
this peptide we maintain the same numbers of 
cationic amino acids (Arg and Lys) deleting Gln2, 
Ile3, Ile5, Phe7, Gln8, Asn9 and Asn12. Peptide 3 dis-
played a lower antifungal activity with respect to 
1. The antifungal activity against C. neoformans 
and C. albicans was moderately effective but still 
significant. We decided to perform changes on 
peptide 3 and then we synthesized peptides 4-6. 
In peptide 4 we replaced the two Trp residues of 
peptide 3 (Trp3 and Trp7) by Phe. This structural 
change yielded a reduction of antifungal activity 
(compare the % of inhibition of 3 and 4 in table 
4.1) which is not an unexpected result; a role for 
Trp as translocation determinant of peptides has 
been proposed (Schiffer et al. 1992) and mutation 
of both tryptophans in peptide 1 was found to 
abolish internalization (Derossi et al. 1994). In ad-
dition, it has previously been reported that tryp-
tophans are poorly replaceable by phenylalanine 
in 1 and derivatives when tested for their pene-
trating properties (Letoha et al. 2003). Our results 
lend support to previously reported findings, but 
in addition demonstrate the antifungal activity of 
these peptides. Octapeptide 5 was obtained delet-
ing Trp3 from peptide 3; in turn heptapeptide 6 
was obtained deleting Trp3 and Trp7 from peptide 
3. Whereas octapeptide 5 displayed only a mar-
ginal antifungal activity, peptide 6 was practically 
ineffective in comparison to their congeners. 
In order to further understand the 
above experimental results, we performed a con-
formational study of the peptides reported here 
using different approaches.
4.2.2  Conformational study of peptide 1 and derivatives
A large number of studies have been per-
formed in order to shed light on the structural as-
pects and mechanism of action for translocation of 1. 
However, compared to these mechanistic properties, 
the conformational intricacies of this compound have 
received relatively little attention. It is however obvious 
that a better understanding of the conformational be-
havior of peptide 1 is of paramount importance. Linear 
peptides are highly flexible and therefore to determine 
the biologically relevant conformations is a matter of 
high complexity, which requires an exhaustive confor-
mational analysis of these structures. Consequently, 
we carried out calculations using three different ap-
proaches: electrostatically driven Monte Carlo (EDMC) 
calculations implemented in the ECCEPAK (Ripoll and 
Scheraga 1988, 1990) package, SA calculations using the 
Tinker Molecular Modelling package (Ponder 2004) 
and MD simulations from the GROMACS program 
(Lindahl et al. 2001; Van Der Spoel et al. 2005).
Table 4.2: Minimum inhibitory concentrations (MIC100, 
MIC80 and MIC50) and minimum fungicidal concentra-
tion (MFC) of penetratin (1) against clinical isolates of C. 
neoformans.
Voucher 
specimen 
MIC100
  MIC80  MIC50  MFC 
Amph. B 
MIC100 
Itz. 
MIC100 
IM 983040  31.2  31.2  31.2  31.2  0.13  <0.015 
IM 972724  62.5  62.5  31.2  62.5  0.06  0.25 
IM 042074  62.5  62.5  31.2  62.5  0.25  <0.015 
IM 983036  62.5  62.5  31.2  62.5  0.13  <0.015 
IM 00319  62.5  62.5  31.2  62.5  0.25  <0.015 
IM 972751  62.5  31.2  31.2  62.5  0.25  <0.015 
IM 031631  62.5  31.2  16  62.5  0.13  0.25 
IM 031706  125  31.2  16  125  0.25  0.50 
IM 961951  125  31.2  16  125  0.06  <0.015 
IM 052470  125  31.2  31.2  125  0.50  <0.015 
MIC100, MIC80 and MIC50: concentration of a compound that caused 100, 80 or 50% reduction of the 
growth control, respectively. Within Voucher specimen: IM =Malbran Institute (Buenos Aires, 
Argentina).Amph. B = Amphotericin B; Itz. = Itraconazole  55  
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4.2.2.1  EDMC results
EDMC results are summarized in table 
4.3 and figure 4.1 and more details are given in 
tables 4.1S-4.8S in appendix A as supporting in-
formation. Calculations yielded a large set of con-
formational families for each peptide studied. The 
total number of conformations generated for each 
peptide varied between 47391 and 129922, and the 
number of those accepted was 5000 for all the 
cases. In the clustering procedure, a RMSD (root 
mean square deviation) of 0.75 Å and a cutoff of 
30 kcal mol-1 were used. The number of families 
after clustering varied between 137 and 1001. The 
total number of families accepted with a relative 
population higher of 0.20 % varied between 11 and 
86. Their populations sum up to ca 80% of all con-
formations in each case (see table 4.3)
All low-energy conformers of the pep-
tides studied here were then compared to each  
other. The comparison involved the spatial ar-
rangements, relative energy and populations.
A total of 639 different families were 
found for peptide 1. However, 82.92 % of total 
population of this peptide corresponded to only 
eleven families (table 4.3). It is interesting to note 
that the energetically preferred family comprises 
70.48 % of the entire population. Thus, this fam-
ily which adopts an α-helix structure is the most 
representative form of this molecule. This confor-
mation is characterized by stabilizing hydrogen 
bonds between the carbonylic oxygen (residue 
i) and the NH group (residue i+4). The first and 
the last residues do not present a stable structure. 
A spatial view of this conformation is shown in 
figure 4.1a. The second most populated family 
(7.46%) corresponds to a structure possessing the 
first four residues without a stable structure; resi-
dues 5 to 7 in a turn structure and residues 10 to 
15 with a typical α-helix structure. The residues 
8 and 9 present a bend structure connecting the 
turn moiety with the α-helix portion. The last res-
idue does not display a stable form (figure 4.1b). 
However, this family has an energy gap of 22.61 
kcal mol-1 with respect to the global minimum.
For peptide 2 a total of 703 different 
families were obtained, from which nineteen 
comprise 81.92 % of the total population. The most 
populated family (61.06%) presents an α-helix 
conformation from residues 3 to 15. This confor-
mation has an energy gap of 1.27 kcal mol-1 with 
respect to the global minimum, which has 6.04% 
of population. The lowest energy conformation 
possesses the following structure: from residues 
2 to 5 in a turn structure; residue 6 in a bend form 
and from residue 7 to 15 in a typical α-helix struc-
P
e
p
  Generateda Acceptedb 
#Fc  #F0.20%
d  %Pe 
Elec  Rand  Ther  Total  Elec  Rand  Ther  Total 
1  8973  119535  575  129083  1431  3245  324  5000  639  11  82.92 
2  9200  120229  493  129922  1349  3373  278  5000  703  19  81.92 
3  8050  107710  304  116064  1372  3412  216  5000  270  6  88.94 
4  7490  102380  245  110115  1121  3697  182  5000  288  11  88.72 
5  7905  106150  294  114349  1176  3606  218  5000  242  11  89.76 
6  7191  98483  213  105887  1192  3635  173  5000  137  6  91.02 
7  3007  44352  32  47391  508  4466  26  5000  505  74  82.82 
8  3939  54133  54  58126  579  4379  42  5000  481  45  83.34 
a Number of conformations generated electrostatically, randomly and thermally during the conformational search. 
b Number of conformations accepted from those generated electrostatically, randomly and thermally during the conformational search. 
c #F: Total number of conformational families as result of the clustering run. 
d # F0.20%: Number of conformational families with populations above 0.20%  
e % P: Sum of the per cent relative population of # F0.20% 

Table 4.3: Selected conformational search and clustering results for peptides 1-8 optimized at the EDMC/SRFOPT/EC-
CEP/3 level of theory.56 
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ture. Residues 1 and 16 do not show any stable 
structure. In general the conformational behavior 
of 1 and 2 is comparable. However, in peptide 1 the 
most populated family (a typical α- helix struc-
ture) is also the energetically preferred one. In 
contrast, for peptide 2, the fully α- helix structure 
is not the most preferred form. 
Compounds  3-6 display a closely re-
lated conformational behavior preferring a he-
lical structure for the most populated families. 
Peptides 3-6 are somewhat more rigid with re-
spect to 1. This fact might be appreciated compar-
ing the total number of conformational families 
obtained for each compound (table 4.3). 
To better characterize the peptide spa-
tial orientations, we plotted Edmundson wheel 
representations of peptides 1-6 (figure 4.2). The 
representation obtained for peptide 1 displays two 
clearly differentiated faces: the “charged face” (de-
noted in dash blue line in figure 4.2) and a more 
extended “non-charged face” (denoted in full 
green line). The first face identifies residues R11, 
K4, K5 and R1 as those accounting for the mutual 
coulombic binding. The first three residues are lo-
cated on the same side of the helical peptide and 
hence we designated it as the “charged face”. These 
positively charged residues are able to produce 
salt bridges with the hydrophilic part of the lipids.
The non-charged face is more extensive 
and is formed by six hydrophobic (M12, I5, W6, I3, 
W14 and F7) and two polar residues (N9 and Q2). 
However, it should be noted that 1 displays a ho- ho-
mogeneously distributed remainder of the posi-  remainder of the posi- posi-
tively charged residues. Thus, residue K13, K16 and 
R10 are strategically intercalated along the “non-
charged face”. This is a striking difference with 
respect to peptide 2 which displays two “charged 
faces” where all the cationic residues are concen-
trated. The Edmundson wheel representations 
obtained for peptides 3 and 4 are very similar 
displaying a very extensive charged face and a 
markedly reduced non-charged face. Peptide 5 
in turn gives only a minimal non-charged zone 
corresponding to the W6 residue and the rest is 
“charged face”. Obviously, peptide 6 displays a 
completely charged face because only cationic 
residues form it. Previously Lensink et al. report-
ed that a homogeneous distribution of positively 
charged residues along the axis of the helical pep-
tide, and especially K4, R11, and K15, contribute to 
the association of peptide 1 with lipids (Lensink 
et al. 2005). Our EDMC results showed some re-
sembling features with those reported by Lensink 
et al, regarding the conformational preferences of 
peptide 1. In addition a very good correlation be-
tween the antifungal activities and the potential 
penetrating properties of these peptides is par-
ticularly striking.
4.2.2.2  SA simulation
In order to exhaustively describe the con-
formational behavior of these peptides, a SA set of 
simulations was carried out using two different force 
fields in an implicit solvent model (water). The ini-
tial structure of peptides 1-6 was fully extended. The 
secondary structures of the lowest energy conform-
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Figure 4.1: Spatial view of the preferred forms obtained 
for peptide 1: (a) the global minimum (α-helix structure) 
and (b) the second most populated conformation. 57  
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Table 4.4: Secondary structures of the best conformation of peptides 1-8 obtained from simulated annealing calculations 
by using AMBER99 and OPLS-AA force fields (FF).
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Figure 4.2: Edmundson wheel representations of pep-
tides 1-6. The number in the center of the wheel corre-
sponds to the peptide number. The “charged” (CF) and 
“non-charged” (NCF) faces are shown in blue dash lines 
and full green lines, respectively. Positively charged amino 
acids are denoted with blue dots, the polar ones with or-
ange, and the hydrophobic ones with yellow.
Pep.a  FF 
Secundary Structureb 
Residue Number 
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16 
1 
AMBER99  _  _  S  S  S  S  G  G  G  T  T  _  T  T  T  _ 
OPLS-AA  _  _  _  _  _  _  S  S  S  _  S  S  S  _  _  _ 
2 
AMBER99  _  _  S  S  _  S  _  T  T  T  _  S  S  T  T  _ 
OPLS-AA  _  _  S  S  S  H  H  H  H  S  _  _  S  _  _  _ 
3 
AMBER99  _  _  G  G  G  T  T  T  _               
OPLS-AA  _  _  _  S  S  S  _  _  _               
4 
AMBER99  _  _  T  T  T  T  T  _  _               
OPLS-AA  _  _  _  S  S  S  S  _  _               
5 
AMBER99  _  _  _  H  H  H  H  _                 
OPLS-AA  _  _  _  S  S  _  _  _                 
6 
AMBER99  _  _  G  G  G  _  _                   
OPLS-AA  _  _  S  S  S  S  _                   
7 
AMBER99  _  T  T  _                         
OPLS-AA  _  _  _  _                         
8 
AMBER99  _  T  T  _                         
OPLS-AA  _  _  _  _                         
a Peptide codes used in TABLE 4.1 
b The secondary structure code obtained from DSSP program. H: 4-helix (α-helix), S: bend, G: 3-helix (310-helix); T: H-
bonded turns, and _: loops or irregular elements.  
ers calculated by DSSP program (Kabsch and Sander 
1983) are summarized in table 4.4 The best structure 
of peptide 1 contains bends (I3-W6), 310-helix (F7-N9) 
and β-turn (R10-R11, K13-K15) and bends (F7-N9, R11-K13) 
in Amber99 and OPLS-AA force field calculations, re-
spectively. Hierarchical clustering shows bending and 
helical backbone structures for peptide 1 for the most 
representative clusters. OPLS-AA calculations, as in 
peptides 2-6, predict H-bonds in other positions than 
AMBER99. Four H-bonds were formed between O(i) 
and H-N(j), two H-bonds between O(i) and H-N(i +3), 
one H-bonds between O(i) and H-N(i+2), and O(i) and 
H-N(i +4) (AMBER99 results). The results of OPLS-AA 
calculations predict eight H-bonds formed between 
O(i) and H-N(j), in peptide 1 four H-bonds between 
O(i) and H-N(i +2) and two H-bonds between O(i) and 
H-N(i +4), one between O(i) and H-N(i +3). In peptide 
2, bend (Q3-K4, I6, Q12-K13) and β-turn (W8-F10, M14-I15) 
alternate. Almost all of the bend structures remained 
(Q3-N5, F10, K13) and an α-helix formed (I6-R9) which in-
cludes H-bonds. Peptides 3-6 contain α-helix, 310-helix 
and β-turn in the central residues in AMBER99 results. 
OPLS-AA predicts bend structures almost at the same 
residues.58 
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Due to the different results obtained for 
these two force fields, no striking conclusions can be 
made. Thus, less can be said regarding this approach. 
Although, a consecutive arrangement of bend struc-
tures was often observed for peptide 1 and 2. Such ar-
rangement might confer helical-like features to these 
peptides. Nevertheless, this fact is not reliable enough 
to assure that a helical structure is the preferred one. 
This is a remarkable difference with the EDMC results 
which showed high preference for helical conforma-
tions.
4.2.2.3  MD simulations
To give a deeper look into the conforma-
tional preferences of these peptides and also take 
into account not only the involvement of time but 
also the influences of an explicit solvent model, 
we applied here the MD approach.
In the trajectory analysis of peptides 
1-6, the total and potential energies, radius of gy-
ration (Rg) and the RMSD of the backbone (N–
Cα–C(carbonyl)) atoms related to the structure at 
the end of equilibration (100 ps) were calculated.( 
figure 4.1S-4.4S, in appendix A). The root mean 
square fluctuation (RMSF) of the backbone atoms 
(figure 4.5S, in appendix A) and the hydro-
philic and hydrophobic solvent accessible surface 
area (SASA) were also calculated. The secondary 
Figure 4.3: Change in the secondary structure during 
molecular dynamics simulation for pep. 1.
structures of peptides were analyzed by sampling 
trajectories every 10 ps with the DSSP program 
(Kabsch and Sander 1983).
In all peptides simulated here, the initial 
310-helix was destroyed in the first 50–100 ps. The RMSD 
and the RMSF of the backbone during the simulation 
characterize this change in their secondary structure. 
The relatively small change in the RMSD of the pep-
tides in the trajectory is evidence for the stabilization of 
the backbone structure. RMSD for simulations 1–6 are 
shown in figure 4.4S in appendix A. RMSD increased 
to 0.2–0.8 nm in all cases and remained almost con-
stant in simulations 3–6. The fluctuation in RMSD is 
attributed to slight changes in structure. In simulations 
1 and 2 the conformations fluctuated between helical 
and turn/bend structures (figures 4.3 and 4.4).
The N- and C-terminal residues in all simu-
lations appear to have a large flexibility as indicated by 
the change of RMSF values during the simulations. The 
change at central residues is moderate in simulations 1 
and 2 (about 0.25 nm). The simulations 3–5 have shown 
a 0.15–0.20 nm change at residues 2–4 and 7. Also, the 
simulations 3 and 5 in the region which seems to be 
the most sensitive in the conformational change have a 
~0.35 nm change at residues 5 and 4, respectively.
The conformational changes in simu-
lation  1 are shown in figure 4.3. The initial 
Figure 4.4: Change in the secondary structure during 
molecular dynamics simulation for pep. 2.
 59  
chapter 4
conformation returned and remained stable in 
simulation  1, suggesting that the starting heli-
cal structure was destroyed to form a mixture 
of α-helix, β-turn and bend in the structure at 
residues 2–15. Such a conformational behavior 
was observed until the end of the simulation. The 
residues 4-6 have shown the highest preference 
for α-helix conformation. The initial and final 
residues appear to have a random coil structure 
because of the flexibility of these residues. For 
the same peptide in water Czajlik et al. (Czajlik 
et al. 2002) found a significant amount of helix-
like conformation, even in a membrane-mimetic 
solvent system (TFEd2/water = 9 : 1), by 1H-NMR. 
Thus, our MD simulation is in good agreement 
with these experimental results. In simulation 2 
(figure 4.4), the initial conformation of 310-helix 
was destroyed and α-helix, β-turn/bend and ran-
dom meander structures at the N- and C-terminal 
region fluctuated during the whole simulation. 
The residues 5-10 have shown the highest prefer-
ence of 310-helix conformation. Here, in peptide 
2, the β-turn and bend conformations were main-
ly formed at residues 2–4 and 11-15. Also in this 
simulation the initial and final residues appear to 
have random coil structure because of the flex-
ibility of these residues.
In simulations 3-6, all derivatives adopt a 
helix-like conformation. However, while peptide 4 
displays both α-helical and 310-helical features, the 
structure of peptide 3 is predominantly a 310-helix (not 
shown).
In summary our MD simulations indicate 
that peptides 1-6 showed a propensity to adopt helix-
like conformations. However, whereas peptide 1 dis-
plays a marked preference for an α-helix structure, pep-
tide 2 shows a mixture of beta turn, bend and 310-helix, 
being the preferred form the 310-helix features.
4.2.3  Comparison of theoretical results obtained 
from different approaches
The energetically preferred cluster ob-
tained with EDMC calculations for peptide 1 
(70.48% of the total population) contains an 
α-helix structure, the second most populated clus-
ter (7.46% of the total population) displays α-helix 
and β-turn structures. On the other hand, the en-
ergetically most stable form obtained in SA with 
minimization showed bend, 310-helix and β-turn 
structures using AMBER99 force field, and only 
bend and coil features using OPLS-AA force fields 
(see table 4.4). The energetically preferred form 
of peptide 2 showed bend and β-turn structures 
for AMBER99 force field, and bend and α-helix 
structures for OPLS-AA force field. Peptides 
3-6 showed structures with helical or consecu-
tive turn secondary structures (AMBER99 force 
field) and bend with coil features (OPLS-AA force 
field). These peptides have shown a higher flexibil-
ity than peptides 1-2 due to their smaller size. In 
summary, the AMBER99 force field has shown a 
slight preference for helical structures. Thus, this 
force field has a better correlation with ECCEP/3 
force field than OPLS-AA force field. The OPLS-
AA results differ significantly showing some dif-
ferences in φ and ψ angles values and H-bond po-
sitions. Despite this fact, all force fields used here 
predict a helix-like structure for peptides 1-6. The 
N- and C-terminal residues have shown a high 
flexibility, since no regular stable structure could 
be observed.
These results support the use of the MD 
simulations for these peptides. It is clear, how-
ever that in order to obtain a relatively complete 
picture about the conformational intricacies of 
peptide 1 and derivatives at least 100 ns of simu-
lation appears to be necessary. Such simulations 
can provide useful information about the confor-
mational preferences and molecular flexibility of 
1 and derivatives, which might be useful to get a 
more profound understanding of the biological 
response of these peptides.
Comparing the results obtained for the con-
formational analysis using the different approaches, we 
can conclude that, in general, these methods predict a 
helix-like structure for peptide 1 and derivatives. These 60 
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results are also in agreement with the experimental re-
sults obtained from NMR (Czajlik et al. 2002).
4.2.4  molecular electrostatic potentials
Knowledge of the stereoelectronic at-
tributes and properties of peptide 1 and deriva-
tives will contribute significantly to the elucida-
tion of the molecular mechanism involved in 
the antifungal activity. Molecular electrostatic 
fields, and molecular electrostatic potentials 
(MEPs), which are their visualisation, offer an 
informative description of the capacity of pep-
tides to generate stereoelectrostatic forces. Thus, 
the electronic study of peptides was performed 
using MEPs (Politzer and Truhlar 1981). MEPs 
have been shown to provide reliable informa-
tion, both on the interaction sites of molecules 
with point charges and on the comparative reac-
tivities of those sites (Carrupt et al. 1991; Murray 
and Politzer 1998; Naray-Szabo and Ferenczy 
1995; Politzer and Truhlar 1981). More positive 
potentials reflect nucleus predominance, while 
less positive values represent rearrangements of 
electronic charges and lone pairs of electrons. 
The fundamental application of this study is the 
analysis of non-covalent interactions (Naray-
Szabo and Ferenczy 1995), mainly by investigating 
the electronic distribution in the molecule. Thus, 
this methodology was used to evaluate the elec-
tronic distribution around molecular surface for 
peptides reported here. The MEPs of peptide 1 is 
shown in figure 4.5 and the MEPs of peptides 3 
and 6 are plotted in figure 4.6. We evaluated the 
MEPs of all peptides tested but we show here only 
the MEPs obtained for the three peptides which 
displayed a significant antifungal activity.
To better appreciate the electronic be-
haviour of 1, and considering that two different 
faces were denoted in figure 4.2, we present the 
MEPs of 1, showing the two faces of this pep-
tide (figure 4.5). figure 4.5a gives the “charged 
face” (CF) characterised by the presence of four 
cationic residues (R1, K4, R11 and K15). Although 
it is possible to visualise residue K16 near to this 
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Figure 4.5: Electrostatic potential-encoded electron den-
sity surfaces of peptide 1: (a) “charged face”, (b) and (c) two 
different views of the “non-charged face”. The surfaces 
were generated with Gaussian 03 using RHF/6-31G single 
point calculations. The coloring represents electrostatic 
potential with red indicating the strongest attraction to 
a positive point charge and blue indicating the strongest 
repulsion. The electrostatic potential is the energy of inter-
action of the positive point charge with the nuclei and elec-
trons of a molecule. It provides a representative measure 
of overall molecular charge distribution. The color-code is 
shown at the left.
face, in fact this residue is somewhat shifted 
in the direction of the non-charged face. It has 
been previously reported that peptide-lipid as-
sociation occurs through formation of salt 
bridges between the positively charged residues 
K4, R11 and K15 and the lipid phosphate groups 
(Lensink et al. 2005). In addition, tryptophan 
fluorescence studies previously showed the im-
portance of peptide with positively charged resi-
dues for the initial binding to negatively charged 
vesicles, since double R/K→A mutations involv-
ing the residues K4/R10/R11/K13/K15 significantly 
decreased the binding affinity (Christiaens et 
al. 2004; Christiaens et al. 2002a, b). The MEPs 
of 1 suggests that the above mentioned residues  61  
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(R1, K4, R11 and K15) could be responsible for the 
initial binding. The previously reported π stack-
ing interaction between F7 and R11 residues might 
be also appreciated on this face (Lensink et al. 
2005). Although the main positive potentials (V(r) 
ranging from 0.60 to 0.43 el.au-3) are concentrat-
ed on this face, it should be noted that there is a 
relatively homogeneous distribution of positively 
charged residues along the entire structure. Thus, 
residues R10, K16 and K13 are strategically located 
in an alternated fashion within the non-charged 
face. Since the non-charged moiety is too large, 
two different views of the MEPs were plotted in 
order to better visualise this face (figures 4.5b 
and 4.5c). figure 4.5b displays four hydrophobic 
residues I3, W6, F7 and W14. It appears that a kind 
of π-stacking cluster through W6/R10/W14 occurs 
in this portion of 1. Lensink et al. reported that 
these residues could protect the peptide from the 
water phase (Lensink et al. 2005). A clear hydro-
phobic interaction between I3 and W6 might be 
also appreciated in this figure. figure 4.5c dis-
plays a more polar face in comparison to figure 
4.5b, since it possesses the three polar residues of 1 
(Q2, Q8 and N9). Interestingly, I5 is located in an in-
tercalated position with respect to polar residues 
and therefore there are no interactions between 
them. These results suggest that these polar resi-
dues could be highly solvated. Mutation of either 
tryptophan decreases internalization, whereas 
double substitution completely inhibits peptide 
internalization (Derossi et al. 1994; Fischer et al. 
2000; Letoha et al. 2005; Lindberg et al. 2003). 
These results indicate that peptide 1 is not suffi-
ciently hydrophobic to insert deeply into phos-
pholipid model membranes (Brattwall et al. 2003; 
Drin et al. 2001). Therefore charge neutralisation 
is required for a deeper insertion of the peptide 
into the hydrophobic core of the membrane. The 
extended non-charged face alternating cationic 
residues among the hydrophobic and polar ones 
observed in the MEPs of 1 appears to be opera-
tional in this sense.
Figure 4.6a gives the MEPs obtained 
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Figure 4.6: Electrostatic potential-encoded electron den-
sity surfaces of peptides 3 (a) and 6 (b). The color-code is 
shown at the left.
for peptide 3. This surface shows a more extended 
positively charged face with respect to 1. In this 
portion are located five cationic residues R4, K8, 
R1, R5 and K9. The MEPs obtained for peptide 6 is 
shown in figure 4.6b. A very extensive deep blue 
zone with potential values in the order of 0.60 
el.au-3 clearly dominates this surface. Previously 
reported MD simulations indicated that the aro-
matic residues do not contribute to the initial 
binding, but rather to the subsequent insertion of 
peptide 1 between the bilayer head groups, where 
they shield the peptide from the aqueous phase 
(Lensink et al. 2005). The importance of hydro-
phobic residues seems to be crucial for the anti-
fungal activity as well. Comparing the MEPs ob-
tained for peptides 1, 3 and 6 it is evident that they 
correlate very well with their antifungal activities: 
the most active peptide of this series, intermedi-
ate activity and completely inactive molecule, re-
spectively. These results lend additional support 
for the key role of the hydrophobic residues in 
these peptides acting as antifungal compounds.
4.2.5  Small size antifungal peptides
The consideration, that a peptide-based 62 
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antifungal agent should be as short as possible in 
order to reduce costs, prompted us to synthesize 
even shorter derivatives of 1. Thus, with the aim 
to predict the potential antifungal effect of small-
size peptides, we performed a molecular model-
ing study in a series of tetrapeptides. Several dif-
ferent tetrapeptides were modeled; however we 
report here only the results obtained for two of 
them (KWKK-NH2 (7) and RQKK-NH2 (8)), be-
ing representative of the entire series.
Tetrapeptides 7 and 8 displayed a com-
pletely different conformational and electronic 
behavior. EDMC, SA and MD results obtained 
for these peptides are summarized in tables 4.3, 
4.4 and tables 4.7S-4.8S and figures 4.1S-4.5S 
in appendix A, respectively. EDMC results ob-
tained for tetrapeptides 7 and 8 predict a higher 
molecular flexibility in comparison to the lon-
ger peptides. Also, considering the length of the 
backbone of these peptides they cannot achieve 
a stable structure. Although both tetrapeptides 
display a statistical-coil (Vila et al. 2002) struc-
ture, their conformational preferences are mark-
edly different. Whereas peptide 7 displays a 
quasi-π-helix form (ψ1= -62.9, φ2= -88.1, ψ2= 81.8, 
φ3= -86.4, ψ3= 72.3 and φ4= -82.7), peptide 8 pre-
fers a quasi-α-helix structure (ψ1= -18.7, φ2= -73.9, 
ψ2= -25.5, φ3= -82.3, ψ3= -27.6 and φ4=-78.4). This is 
a striking difference obtained for these tetrapep-
tides. SA calculations indicate that these peptides 
are more flexible than peptides 1-6 (table 4.4). 
The small size of these peptides could explain 
the irregular structures obtained for peptides 7-8 
(OPLS-AA force field), whereas turn structures 
were preferred for the central residues of these 
peptides (AMBER99). MD calculations indicate 
that peptides 7 and 8 show a statistical coil struc-
ture during the whole simulation time because of 
their high flexibility. However, from MD a clear 
difference obtained for these tetrapeptides is that 
peptide 8 displays a tendency to adopt a turn con-
formation, whereas peptide 7 has the tendency to 
achieve extended conformations. The spatial or-
dering adopted by peptide 8 is closely related to 
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Figure 4.7: Electrostatic potential-encoded electron den-
sity surfaces obtained for peptides 1 (a), 3 (b) and 8 (c) in a 
front view of the N-terminal portion (left hand). Also this 
figure sows at the right hand: (a) a frontal spatial view of 1, 
(b) an overlapped stereoview of peptide 1 (white) with pep-
tide 3 (yellow), and (c) an overlapped stereoview of peptide 
1 (white) with peptide 8 (green).
those obtained for the first four residues of pep-
tide 1 (see figure 4.7c right hand).
figure 4.7 gives the MEPs obtained for 
compounds 1, 3 and 8 in a front view. The similar 
MEPs values obtained for peptides 1 and 8 can be 
appreciated in this figure. In contrast a more posi-
tively charged MEP was obtained for compound 3 
as it was previously discussed.
On the basis of the stereoelectronic 
similarity obtained for peptides 1 and 8, it is rea-
sonable to think that tetrapeptide 8 could present 
some antifungal activity, but not peptide 7. Thus, 
to confirm our hypothesis, we decide to test the 
antifungal effects of tetrapeptides 7 and 8.  As 
expected, peptide 7 did not show any antifungal 
activity with the concentrations reported here. In 
contrast, peptide 8 displayed a moderate but sig-
nificant antifungal effect against C. neoformans 
(table 4.1). It must be pointed out that peptide 8  63  
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displays antifungal activity only against C. neo-
formans; in contrast this compound was not ac-
tive against C. albicans. This is a striking differ-
ence with respect to 1. It is clear however, that the 
antifungal potency found for 8 against C. neofor-
mans is very interesting particularly considering 
its small size.
Inspection of figure 4.7 led us to ap-
preciate that although peptides 1, 3 and 8 are of 
different size, they display some stereoelectronic 
similarities primarily near the N-terminal por-
tion, implicating a likely overlap on these moi-
eties. Cellular uptake experiments previously 
demonstrated the crucial role of arginines in cell-
penetrating peptides (Thoren et al. 2003). Also, 
MD simulations indicated that arginine residues 
could be responsible for the initial electrostatic 
binding forming bidentate hydrogen bonds with 
lipid phospate groups. It should be noted that the 
first residue of peptides 1, 3 and 8 is arginine. In 
fact there are various ways in which 8 may pro-
duce its antifungal activity, on which we can 
only to speculate. In that respect the similar ste-
reoelectronic behaviors observed between 8 and 
the N-terminal portions of 1 and 3 is particularly 
noteworthy.
In the present paper, we report the 
design, synthesis and antifungal effects of 
peptide  1 and derivatives, a new series of an-
tifungal peptides. Among the peptides test-
ed, RQIKIWFQNRRMKWKK-NH2 (1), 
RKWRRKWKK-NH2 (3) and RQKK-NH2 (8) dis-
played the most powerful inhibitory effect against 
C. neoformans. A detailed conformational and 
electronic study supported by theoretical calcula-
tions helped us to identify a possible “biologically 
relevant conformation” for these peptides. A par-
ticular combination of cationic and hydrophobic 
residues adopting a definite spatial ordering ap-
pears to be the key parameter for the transition 
from hydrophilic to hydrophobic phase, which  
could be a necessary step to produce the anti-
fungal activity. We believe that our results could 
contribute to an understanding of the minimal 
structural requirements for the antifungal poten-
tial of peptides reported here and to the design 
of novel structurally related agents. These results 
are very encouraging in that they show a great po-
tential for peptides 1 and 8 as a truly novel class 
of antifungal compounds particularly against the 
yeast C. neoformans. Thus, the antifungal act  iv- the antifungal activ-
ity reported in this chapter for peptides 1 and 8 
opens promising ways for the development of 
a new antifungal agent for treatment of crypto-
coccosis. Since C. neoformans remains an im-
portant life-threatening complication for immu-
nocompromised hosts, particularly for patients 
who have undergone transplantation of solid 
organs and therefore, new compounds effective-
ly acting against this fungus are highly needed 
(Kontoyiannis et al. 2003; Singh 2003).
Peptide 1 has been used as a nonviral, 
nontoxic and highly efficient vector for deliver-
ing bioactive substances, that by themselves are 
membrane-impermeable, to the cytoplasm or nu-
cleus of cells (Derossi et al. 1994; Joliot et al. 1991). 
The antifungal activity found for 1 is very inter-
esting by itself but it is also important consider-
ing its potential use as a carrier for other known 
antifungal drugs. Thus, this system may improve 
the pharmaceutical properties of the drugs by, for 
example, improving solubility and bioavailability, 
or by minimizing toxicity and overcoming drug 
resistance.64 
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Compounds 
Retention 
factor 
(min) 
Gradient 
elution (%) 
RQIKIWFQNRRMKWKK-NH2 (1) 4.280  30-50 (10 min) 
WKQKNIKWRFRQKMIR-NH2 (2) 11.200  5-80 (25 min) 
RKWRRKWKK-NH2 (3)  13.200  5-35 (15 min) 
RKFRRKFKK-NH2 (4)  9.387  5-30 (10 min) 
RKRRKWKK-NH2 (5)  9.339  5-35 (15 min) 
RKRRKKK-NH2 (6)  4.576  5-35 (15 min) 
KWKK-NH2 (7)  9.012  5-35 (15 min) 
RQKK-NH2 (8)  3.553  5-20 (15 min) 
Table 4.5: HPLC data of the synthesized peptides. 4.4
  Experimental section
4.4.1  Synthetic methods
Solid phase synthesis of 1, 
RQIKIWFQNRRMKWKK-NH2, was carried out 
manually on a p-methylbenzhydrylamine resin 
(MBHA, 0.39 mmol/g) with standard method-
ology using Boc-strategy. Side chain protecting 
groups were as follows: Tos for Arg and 2-chloro-
Z for Lys. All protected amino acids were coupled 
in CH2Cl2 or CH2Cl2/DMF solvent mixture in 
a ratio of 1:1 (for Gln and Asn) using DCC (2.5 
equiv.) and HOBt (2.5 equiv.). Amino acid incor-
poration was monitored by Kaiser ninhydrin test 
(Kaiser et al. 1970). After coupling of the amino 
acid, Boc-deprotection was effected by using 
TFA/CH2Cl2 (1:1) for 5 min first then repeated for 
25 min. The completed peptide resin was treated 
with liquid HF/dimethyl sulfide/anisole/indole 
(86:6:4:2) at 5°C for 1 h. HF was removed and the 
resulted free peptide was solubilized in 10% aque-
ous acetic acid and lyophilized. The crude peptide 
was purified by semipreparative RP HPLC on a 
Lichrosorb C-18 column (16 x 250 mm, 7 μm) with 
a linear gradient of acetonitrile 30-100%, 0.1% 
TFA in 70 min, 4 ml/min flow. The appropriate 
fractions were pooled and lyophilized. The puri-
fied peptide was characterized by HPLC and mass 
spectometry using a Finnigan TSQ 7000 tandem 
quadrupole electrospray mass spectrometer. M+H 
calc.: 2244.3, found: 2244.5. Analytical HPLC con-
ditions: column: Luna C-18, 5 μm, 4.6 x 250 mm, 
gradient: 30-50% AcN, 0.1% TFA in 10 min, 1.2 ml/
min flow, 220 nm. Rt: 4.280 min. Same synthesis 
procedures and analytical HPLC conditions were 
applied for the peptide analogues (2-8) as shows 
table 4.5.
4.4.2  Antifungal evaluation
4.4.2.1  Microorganisms and media
For the antifungal evaluation, standard-
ized strains from the American Type Culture 
Collection (ATCC), Rockville, MD, USA, were 
used. Candida albicans ATCC 10231, Cryptococcus 
neoformans ATCC 32264. Active compounds 
were tested against clinical isolates from the 
Malbrán Institute [(M), Av. Velez Sarsfield 563. 
Buenos Aires)]. The isolates included 10 strains 
of Cryptococcus neoformans which voucher speci-
mens are presented in table 4.2. Strains were 
grown on Sabouraud-chloramphenicol agar 
slants for 48 h at 30 oC, maintained on slopes of 
Sabouraud-dextrose agar (SDA, Oxoid) and sub-
cultured every 15 days to prevent pleomorphic 
transformations. Inocula of cells were obtained 
according to reported procedures and adjusted to 
1-5 x103 cells with colony forming units (CFU) /
mL (Pfaller 2002a).
4.4.2.2  Antifungal susceptibility testing. 
MIC determinations
MIC of each extract or compound was de-
termined by using broth microdilution techniques ac-
cording to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI), formerly National 
Committee for Clinical and Laboratory Standards for 
yeasts (M27-A2) (Pfaller 2002a). MIC values were de- MIC values were de-
termined in RPMI-1640 (Sigma, St Louis, Mo, USA) 
buffered to pH 7.0 with MOPS. Microtiter trays were 
incubated at 35 oC in a moist, dark chamber, and MICs 
were visually recorded at 48 h. For the assay, st  ock   so- For the assay, stock so-
lutions of pure compounds were two-fold diluted with 
RPMI from 256 - 0.98 µg/mL (final volume = 100 µl) 
and a final DMSO concentration ≤ 1%. A volume of 
100 µl of inoculum suspension was added to each well 
with the exception of the sterility control where ster- 65  
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ile water was added to the well instead. Ketoconazole, 
Amphotericin B and Itraconazole (all from Sigma 
Chemical Co, St Louis, MO, USA) were used as positive 
controls. Endpoints were defined as the lowest concen-
tration of drug resulting in total inhibition (MIC100) of 
visual growth compared to the growth in the control 
wells containing no antifungal. MIC80 and MIC50 were 
defined as the lowest concentration of a compound that 
caused 80 % or 50 % reduction of the growth control re-
spectively (culture media with the microorganism but 
without the addition of any compound) and was deter-
mined spectrophotometrically with the aid of a VERSA 
Max microplate reader (Molecular Devices, USA). The 
MFC of peptide 1 against each isolate was also deter-
mined as follows: after determining the MIC, an ali-
quot of 5 µL sample was withdrawn from each clear well 
of the microtiter tray and plated onto a 150-mm RPMI-
1640 agar plate buffered with MOPS (Remel, Lenexa, 
Kans.). Inoculated plates were incubated at 30°C, and 
MFC were recorded after 48 h. The MFC was defined 
as the lowest concentration of each compound that re-
sulted in total inhibition of visible growth.
4.4.2.3  Determination of percentage of inhibition
The test was performed in 96 wells-
microplates. Peptide test wells (PTW) were pre-
pared with stock solutions of each peptide in 
DMSO (maximum concentration ≤ 2%), diluted 
with RPMI-1640 to final concentrations 200 -12.5 
µM. Inoculum suspension (100 µl) was added to 
each well (final volume in the well = 200 µL). A 
growth control well (GCW) (containing medium, 
inoculum, the same amount of DMSO used in 
PTW, but compound-free) and a sterility control 
well (SCW) (sample, medium and st   erile wa- sterile wa-
ter instead of inoculum) were included for each 
strain tested. Microtiter trays were incubated 
in a moist, dark chamber at 35 oC, 24 or 48 h for 
Candida spp. or Cryptococcus sp., respectively. 
Microplates were read in a VERSA Max micro-
plate reader (Molecular Devices, Sunnyvale, CA, 
USA). Amphotericin B was used as positive con-
trol (100 % inhibition). Tests were performed by 
duplicate. Reduction of growth for each peptide 
concentration was calculated as follows: % of in-
hibition: 100- (OD405 PTW- OD405 SCW) / OD405 
GCW - OD405 SCW.
4.4.2.4  Statistical analysis
Data were statistical analyzed by one-
way analysis of variance. A p< 0.05 was consid-
ered significant.
  Computational methods
4.5.1  EDMC calculations
The conformational space of each peptide 
was explored using the method previously employed by 
Liwo et al. (Liwo et al. 1996b) that included the electro-
statically driven Monte Carlo (EDMC) method (Ripoll 
and Scheraga 1988, 1990). Conformational energy was 
evaluated using the ECEPP/3 force field (Némethy et al. 
1992). This force field employs rigid valence geometry. 
Hydration energy was evaluated using a hydration-
shell model with a solvent sphere radius of 1.4 Å and 
atomic hydration parameters that have been optimized 
using nonpeptide data (SRFOPT) (Vila et al. 1991; 
Williams et al. 1992). In this model, in addition to a sum 
of electrostatic, non-bonding, hydrogen-bond and tor-
sional energy terms, the total conformational energy 
includes terms accounting for loop closing and peptide 
solvation. The conformation with minimized energy 
was subsequently perturbed by changing its torsional 
φ and ψ angles using the Monte Carlo method (Li and 
Scheraga 1987). Piela’s algorithm (Piela and Scheraga 
1987) which was also applied at this stage, greatly im-
proves the acceptance coefficient. In this algorithm φ 
and ψ angles are changed in a manner which allows the 
corresponding peptide group to find the most proper 
orientation in the electrostatic field of the rest of the 
peptide chain. The energy of the new conformation is 
minimized, compared to the previous one and may 
be accepted or discarded on the basis of energy and/
or geometry. If the new energy-minimized conforma-
tion is similar in shape and in energy to the starting 
conformation, it is discarded. Otherwise, the energy 
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of the new conformation is compared to the energy of 
the parent conformation. If the new energy is lower, the 
new conformation is accepted unconditionally, other-
wise the Metropolis criterion (Metropolis et al. 1953) is 
applied in order to accept or reject the new conforma-
tion. If the new conformation is accepted, it replaces 
the starting one; otherwise another perturbation of the 
parent conformation is tried. A temperature jump may 
be included if the perturbation is not successful for an 
arbitrarily chosen number of iterations. The process 
is iterated, until a sufficient number of conformations 
have been accepted. Sidor et al. give a more detailed de-
scription of this procedure (Sidor et al. 1999).
In order to explore the conformational space 
extensively, we carried out 10 different runs, each of 
them with a different random number, for each pep-
tide studied. Since the EDMC procedure uses random 
numbers, there is a need to initialize the random num-
ber generator by providing an integer. Therefore, we 
collected a total of 5000 accepted conformations for 
each peptide studied. Each EDMC run was terminated 
after 500 energy-minimized conformations had been 
accepted. The parameters controlling the runs were 
the following: a temperature of 298.15 K was used for 
the simulations. A temperature jump of 50,000 K was 
used; the maximum number of allowed repetitions of 
the same minimum was 50. The maximum number of 
electrostatically predicted conformations per iteration 
was 400; the maximum number of random-generated 
conformations per iteration was 100; the fraction of 
random/electrostically predicted conformations was 
0.30. The maximum number of steps at one increased 
temperature was 20; and the maximum number of re-
jected conformations until a temperature jump is ex-
ecuted was 100. Only trans peptide bonds (ω ≈ 180°) 
were considered.
The ensemble of obtained conforma-
tions was then clustered into families using the 
program ANALYZE (Meadows et al. 1994b; Post 
et al. 1990; Scheraga et al. 1983), which applies the 
minimal-tree clustering algorithm for separation, 
using all heavy atoms, energy threshold of 30 kcal 
mol-1, and RMSD of 0.75 Å as separation criteria 
for all peptides here studied. Molecules contain-
ing seven, eight and sixteen amino acids residues 
were clustered using the same method but, instead 
of using all heavy atoms it used only the backbone 
atoms (Cα, N and C(carbonyl)). This procedure 
allows for substantial reduction of the number of 
conformations and eliminates repetitions.
4.5.2  SA calculations
To find the best structures of peptides 
studied, 5000 structures were generated by simulated 
annealing (SA) implemented in Tinker Version 4.2 
(Kundrot et al. 1991). Peptides were generated by the 
software and minimized with a charge and van der 
Waals cutoff of 1.8 nm and 1.4 nm, respectively, with 
OPLS-AA and AMBER99 force fields. A taper of 0.8 
was applied to smooth the cutoff to zero in the calcu-
lations. The solvation was simulated by GB/SA (gener-
alized Born/surface area model). The tolerance of the 
minimization was 0.001 kcal mol-1 Å-1. The following 
protocol was used in the simulated annealing: 5000 
times were repeated 2000 steps equilibration in 1000K 
and 2000 steps cooling to 50K exponentially with 1 fs 
step-size. After cooling the structures were minimized 
with the previous method. The minimized structure 
was applied for the next step. The secondary structures 
of the peptides were analyzed by DSSP (Kabsch and 
Sander 1983). The algorithm measures the geometry 
and the hydrogen bonding in peptides. The second-
ary structures are assigned by the following way: turns 
within 3, 4 and 5 residues, respectively, are assigned on 
the basis of hydrogen bonds between i to i + 1 (three res-
idue turn), i to i + 1 or i + 2 (four residue turn), i to i + 1 
or i + 2 or i + 3 (five residue turn). A β-bridge is assigned 
when two non-overlapping stretches of 3 residues each, 
i - 1, i, i + 1 and j - 1, j, j + 1 form H-bonding parallel or 
antiparallel pattern. Two or more consecutive β-bridge 
structures are assigned as β-sheet structures. A bend 
is defined as a five residue turn without H-bonds with 
a curvature of at least 70o between the first 3 residues 
(i - 2, i - 1 and i) and the last 3 residues (i, i + 1 and i + 2). 
The position of the bend is marked at i. Two consecu-
tive turns at position i - 1 and i form a helix. 310-helix is 
marked a positions i, i + 1 and i + 2. α-helix and π-helix  67  
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at i, i + 1, i + 3 and i, i + 1, i + 2, i + 3, i + 4, respectively. 
Residues without recognized secondary structures are 
assigned as irregular or loop (random coil) structure. 
For clustering 5000 structures a perl script in MMTSB 
(Feig et al. 2001) was used.
4.5.3  MD simulations
Molecular dynamics (MD) simulations were 
performed using the GROMACS 3.2.1 package of pro-
grams (Lindahl et al. 2001; Van Der Spoel et al. 2005), 
with the OPLS-AA force field (Jorgensen et al. 1996; 
Kaminski et al. 2001; McDonald and Jorgensen 1998; 
Price et al. 2001; Rizzo and Jorgensen 1999; Watkins 
and Jorgensen 2001). The calculations were carried out 
using a standard 310-helix (φ = -49.00°,ψ = -26.00°) as a 
starting structure. The peptides 1-8 were embedded in a 
box containing the SPC water model (Berendsen et al. 
1981a) that extended to at least 10 Å between the solutes 
and the edge of the box. The total number of water mol-
ecules was between 1389 and 2791. Then Cl- ions were 
added to the systems by replacing water molecules in 
random positions, thus making the whole system neu-
tral. For details see table 4.9S in appendix A. Prior to 
dynamics simulation, internal constraints were relaxed 
by energy minimization. Following the minimization, 
a MD equilibration run was performed under posi-
tion restraints for 20 ps. An unrestrained run was then 
initiated. During the MD runs, the LINCS algorithm 
(Hess et al. 1997) was used to constrain the lengths of 
hydrogen containing bonds; the waters were restrained 
using the SETTLE algorithm (Miyamoto and Kollman 
1992). The time step for the simulations was 0.002 ps. 
The simulations were run under NPT conditions, using 
Berendsen’s coupling algorithm (Berendsen et al. 1984) 
for keeping the temperature and pressure constant (P 
= 1 bar, τP = 0.5 ps; T = 310 K, τT = 0.1 ps). The com-
pressibility was 4.8x10-5 bar-1. Van der Waals forces 
were treated using a 12 Å cutoff. Long-range electro-
static forces were treated using the particle mesh Ewald 
method (PME) (Darden et al. 1993b). The coordinates 
were saved every 10 ps. The total simulation time was 
100 ns for every peptide. The analysis of the simulations 
was performed using the analysis tools provided in the 
Gromacs package. 
4.5.4  Molecular electrostatic potentials
Quantum mechanics calculations were car-
ried out using the Gaussian 03 program (Frisch et 
al. 2003). We use the most populated conformations 
of peptides 1-8 obtained from EDMC calculations. 
Subsequently, single point ab initio (RHF/6-31G(d)) 
calculations were carried out. The electronic study 
was carried out using molecular electrostatic poten-
tials (MEPs) (Politzer and Truhlar 1981). These MEPs 
were calculated using RHF/6-31G(d) wave functions 
and MEPs graphical presentations were created us-
ing the MOLEKEL program (Flükiger et al. 2000). ■ 
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Chapter 5
Abstract
Amyloid oligomers are considered to play causal roles in the pathogenesis of amyloid-related degenera-
tive diseases including Alzheimer’s disease. Using MD simulations techniques, we explored the con-
tributions of the different structural elements of trimeric and pentameric full-length Aβ42 aggregates 
in solution to their stability and conformational dynamics. We found that our models are stable at the 
temperature of 310 K, and converge toward an interdigitated side-chain packing for intermolecular con-
tacts within the two β-sheet regions of the aggregates: β1 (residues 18-26) and β2 (residues 31-42). MD 
simulations reveal that the β-strand twist is a characteristic element of Aβ aggregates, permitting a com-
pact, interdigitated packing of side chains from neighboring β-sheets. The β2 portion formed a tightly 
organised β-helix, whereas the β1 portion did not show such a firm structural organization although it 
maintained its β-sheet conformation. Our simulations indicate that the hydrophobic core comprising 
the β2 portion of the aggregate is a crucial stabilizing element in the Aβ aggregation process. Based on 
these structure-stability findings the β2 portion emerges as an optimal target for further anti-amyloid 
drug-design.
Journal of Physical Chemistry B (2009) 113:11710-11719. 71  
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 Introduction
Proteins can adopt an amazing array of 
sequence-dependent structures that enable them 
to perform the myriad of chemical functions criti-
cal to life. However, over the past decade, it has 
become clear that many different proteins can also 
form misfolded structures leading to insoluble ag-
gregates. With respect to human brain function-
ing protein misfolding can have dramatic conse-
quences and can result in devastating diseases of 
the brain. There are several known degenerative 
diseases whose pathogenic mechanism is based 
on the pathological aggregation of polypeptides. 
These types of neurodegenerative diseases in-
clude Alzheimer’s disease (AD), Parkinson’s dis-
ease, Huntington’s disease, prion diseases like 
Creutzfeldt-Jacob disease, and type II diabetes 
(Lynn and Meredith 2000; Rochet and Lansbury 
2000; Selkoe 2003). It is a common feature to all 
of the above mentioned diseases that the native 
structure of the specific peptides has been changed 
and that during a fast aggregation process, they 
provide fibrillary products which are toxic to 
nerve cells or nervous tissue and resistant against 
enzymatic breakdown. The most extensively stud-
ied amyloid-associated disease is AD, which is 
characterized pathologically by abnormally high 
numbers of amyloid- or senile plaques in the cere-
bral cortex and amyloid deposits in the walls of ce-
rebral blood vessels, and by neurofibrillary tangles 
in dead and dying neurons (Holtzman and Mobley 
1991). Amyloid plaques are brain lesions that are 
composed of amyloid polymers and degenerating 
neurites accompanied by activated microglia, the 
inflammatory cells of the brain. The major com-
ponent of amyloid plaques is a small peptide of 39 
to 43 amino acids in length called β-amyloid (Aβ), 
which is a proteolytic splicing product of the large 
amyloid precursor protein (APP). Compelling 
evidence now indicates that factors which increase 
the production of amyloidogenic variants of Aβ, 
or which facilitate deposition or inhibit elimina-
tion of amyloid deposits, are major risk factors for 
AD (Selkoe 1999).
Currently, more than 20 different forms 
of Aβ are known (Westermark 1997), some of 
which are rare and some of which play central 
roles in the pathogenesis of diseases affecting 
millions of patients worldwide. The investiga-
tion of amyloid, as a major example of pathology 
due to protein misfolding, has become a widely 
studied enterprise (Kisilevsky 2000; Lesne et al. 
2006; Sato et al. 2006; Sciarretta et al. 2006b; Soto 
et al. 2007; Westermark 2005; Zheng et al. 2007). 
Consequently, the 3D structure of the amyloid 
polymers and fibrils is a focus of interest both for 
a molecular understanding of amyloidogenesis 
and for the development of innovative therapeu-
tic and diagnostic approaches. Solid-state NMR 
studies have contributed substantially to the un-
derstanding of amyloid fibrils (Ritter et al. 2005; 
Tycko 2004). However, only a few 3D structures of 
amyloid fibrils have yet been determined (Luhrs 
et al. 2005; Nelson et al. 2005), owing in part to 
the fibrils’ noncrystalline, insoluble, and me-
soscopically heterogeneous nature. This makes 
these structures difficult to access by established 
structural techniques such as X-ray crystallog-
raphy or solution-state NMR (Thompson 2003). 
Since the 1970’s, amyloid has been defined by 
its main β-sheet fibrillary structure (Eanes and 
Glenner 1968; Glenner 1980a, b), and by proper-
ties associated with this. The unifying structure 
is an assembled protein fibril in which the sheets 
are parallel to the fibril direction and where the 
strands run perpendicular to the fibril. This prin-
cipal organization is believed to be common to 
all amyloid fibrils, irrespective of the biochemical 
nature (Westermark 2005).
The amyloid beta 1-42 peptide (Aβ42) 
fragment is the dominant Aβ species in the amy-
loid plaques of AD patients, and compared with 
Aβ40  it displays a dramatically increased pro-
pensity to form amyloid fibrils in vitro (Burdick 
et al. 1992; Jarrett et al. 1993a, b; Riek et al. 2001). 
Furthermore, a comparison of the kinetic data 
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of Aβ40 and Aβ42 shows that Aβ40 adopts more 
varied conformational structures compared to 
Aβ42, as seen by the fluctuations of the Tyr sig-
nal displayed by Aβ40 (Vestergaard et al. 2005). A 
comparative experimental-theoretical conforma-
tional study has been carried out by Sgourakis et 
al. (Sgourakis et al. 2007), which sheds light on 
the differential conformational behavior of the 
monomers in aqueous solution of Aβ40 and Aβ42. 
The presence of metal ions, in particular cop-
per, zinc, and iron, has been reported to enhance 
Aβ aggregation (Atwood et al. 1999; Atwood et 
al. 2004; Huang et al. 2004). Several important 
structural characteristics of Aβ42 fibrils have been 
determined (Luhrs et al. 2005; Nelson et al. 2005; 
Ritter et al. 2005; Thompson 2003; Tycko 2004), 
establishing that Aβ42 fibrils form a cross-β struc-
ture (Kirschner et al. 1986) that contains parallel, 
in-register β-sheets (Balbach et al. 2002). Most re-
cently it was found that memory deficits in mid-
dle-age transgenic AD model mice are caused by 
the extracellular accumulation of a dodecameric 
Aβ42 soluble assembly (Lesne et al. 2006). While 
the major toxic species in AD are probably Aβ-
oligomers, thus being a principal target of AD 
drug development, it remains unclear why Aβ-
oligomers should be neurotoxic. Plausible mecha-
nisms of toxicity include links to oxidative stress, 
metal binding, free radical formation (Chauhan 
and Chauhan 2006) or ion channel formation 
(Quist et al. 2005), and therefore it may be pos-
sible to interact with these processes by applying 
reducing agents, metal chelators (Bush 2002) or 
ion channel inhibitiors. In general terms an ide-
al approach would be to interfere with the early 
phases of molecular pathways that lead to the 
disease. Consequently, one attractive therapeutic 
strategy for the treatment of AD is to inhibit Aβ 
peptide aggregation since this appears to be one 
of the first steps in the pathogenic process of amy-
loidosis that is not associated with some natural 
biological function (Lansbury 1997). Breaking 
these amyloid aggregates down by non-peptide or 
peptide inhibitors seems to be a promising way to 
combat AD (Doig 2007). To that aim, it is crucial 
to understand the conformational and dynamic 
behavior of the structure of the Aβ42 aggregates 
in order to rationally design a putative AD drug. 
Moreover, the conformational analysis and the 
investigation of the structure of Aβ42 aggregates 
might lead to a more profound understanding of 
the primary pathogenesis of AD and comprehend 
the development at the molecular level of this 
dramatic disease. 
Most computational investigations of 
the structure and dynamics of Aβ-peptides have 
focused on monomers (Baumketner et al. 2006; 
Buchete et al. 2005; Gordon and Meredith 2003; 
Lazo et al. 2005; Massi et al. 2001; Petkova et al. 
2005; Petkova et al. 2006; Sato et al. 2006; Scheibel 
et al. 2003; Sciarretta et al. 2006a; Sgourakis et 
al. 2007; Wei and Shea 2006), dimers (Huet and 
Derreumaux 2006; Tarus et al. 2005; Urbanc et 
al. 2004), and other low-order oligomers (Buchete 
and Hummer 2007; Gnanakaran et al. 2006; 
Hwang et al. 2004; Klimov and Thirumalai 2003; 
Ma and Nussinov 2006; Rohrig et al. 2006; Zheng 
et al. 2007). The idea of considering a full-length 
molecular model of the Aβ aggregates is worthy 
of consideration, since the majority of the stud-
ies mentioned above have employed models us-
ing a truncated-sequence molecular model and/
or insoluble fibril state. In our present investiga-
tion, profiting from the structural information 
available from recent solid-state nuclear magnetic 
resonance (ssNMR) experiments (Balbach et al. 
2002; Luhrs et al. 2005; Paravastu et al. 2006; 
Petkova et al. 2002; Petkova et al. 2005; Petkova 
et al. 2006) on the parallel cross-β structure of Aβ 
protofilaments, we perform all-atom/explicit sol-
vent simulations of amyloid aggregates contain-
ing three and five peptide units. Every unit with 
“hairpin” shaped Aβ1–42 peptides was located in 
a plane roughly perpendicular to the fibril axis 
as it was observed by using ssNMR (Luhrs et al. 
2005). Among the different structural topologies 
possible depending on experimental growth con-
ditions (Paravastu et al. 2006; Petkova et al. 2005;  73  
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Petkova et al. 2006), we focus on Aβ1–42 fibrils 
grown under the conditions defined as in refer-
ence 16. The objectives of our study are twofold: 1) 
to explore the contributions of the different struc-
tural elements to stability of full-length aggregat-
ed Aβ42 in solution, and 2) to investigate the most 
promising, potential structural target for further 
drug-design based on the structure-stability in-
formation of our model. Our reasonably long-
time simulations (100 ns) of both tri- and pen-
tameric aggregates at 310 K, in which fibrils are 
experimentally stable (below ~330 K), permit us 
to draw conclusions on structurally relevant ag-
gregate characteristics such as the secondary-to-
quaternary structural elements (e.g., β-strands, 
intra- and intermolecular contacts), internal salt-
bridges, and the interior hydration. In the present 
study we analyze the evolution of these elements 
at 310 K, focusing in particular on the structure 
and dynamics behavior in solution of the full-
length Aβ42 aggregates.
 Methods
5.2.1  System setup
The human amyloid beta 1-42 peptide 
(Aβ42)  (figure 5.1) was taken as a model sys-
tem. The calculations were carried out using the 
structure of the Aβ42  fibrils (PDB entry 2BEG) 
determined by Lührs and coworkers (Luhrs et al. 
2005) that was downloaded from the Protein Data 
Bank (Berman et al. 2002). Due to the fact that 
residues 1-17 are disordered and lacking a unique 
and stable conformation we only had experimen-
tal structural information from residues 18-42 
(Luhrs et al. 2005). Therefore, in order to have the 
completed molecule of Aβ42, the sequence for the 
residues 1-17 was completed using an arbitrary to-
tally extended orientation (φ≈ 180° and ψ≈ 180°). 
Both trimeric and pentameric aggregates were in-
vestigated. The trimeric system was obtained by 
deletion of the edging chains of the experimental 
structure determined by Lührs and coworkers 
(Luhrs et al. 2005), which is a pentameric aggre-
gate. Protons were added using the program pd-
b2gmx, in the GROMACS suite of programs, for 
optimization of the hydrogen bond network.
The peptide aggregates were embed-
ded in a rectangular box containing SPC waters 
(Berendsen et al.), leaving at least 10 Å between 
the solutes and the edge of the box. The total 
number of water molecules varied between 15630 
and 25919. Na+ ions were added to the systems by 
replacing water molecules in random positions, 
thus making the whole system neutral (table 
5.1). In order to equilibrate our systems we carried 
out an extensive simulating annealing (SA) pro-
tocol with repeating heating/cooling cycles cov-
ering a broad temperature range (from 310 up to 
500 K), in which fibrils are experimentally stable 
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Figure 5.1: Amino acid sequence of human amyloid beta 1-42 peptide (Aβ42) and schematic 
representation of a molecule of Aβ42 in a hairpin shape. The residues 1-17 comprise the disordered region. 
The residues 18-42 comprise the β-sheet region.74 
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(below ~330 K) or fully dissociated (above ~373 
K) (Meersman and Dobson 2006; Sasahara et al. 
2005). During the whole minimization position 
restraint was applied for the alpha carbons (Cα) 
of residues 18-42. As a result of the SA runs, the 
DR residues showed a large range of conforma-
tional sampling. Multiple simulations were per-
formed for each system, starting from different 
initial random velocity distributions, generating 
five independent strands of simulations (labelled 
A-E, see table 5.1). Details of the equilibration 
procedure can be found in the Supp. Information of 
chapter 5 in appendix A. For each strand between 
20-100 ns production runs were obtained and ana-
lyzed. The coordinates were saved every 2 ps.
5.2.2  Simulation parameters
All simulated annealing (SA) simula-
tions and molecular dynamics (MD) simulations 
were performed using the GROMACS 3.3.2 pack-
age of programs (Van Der Spoel et al. 2005), with 
the OPLS-AA force field (Kaminski et al. 2001). 
The simulations were run under NPT conditions, 
using Berendsen’s coupling algorithm (Berendsen 
et al. 1984) for keeping the temperature and pres-
sure constant (P = 1 bar, τP = 0.5 ps; T = 310 K or 
500 K, τT = 0.1 ps). The LINCS algorithm (Hess 
et al. 1997) was used to constrain the lengths of 
hydrogen containing bonds; the waters were re-
strained using the SETTLE algorithm (Miyamoto 
and Kollman 1992). A force constant of 1000 kJ 
mol-1 nm-1 was used for position restraints dur-
ing the SA. For the subsequent unrestrained MD 
simulations, the same parameters were used as 
for the restrained MD, except that the tempera-
ture was maintained at 310 K and no positional 
restraints were applied. The time step for the 
simulations was 0.002 ps and the compressibility 
4.8x10-5 bar-1. Van der Waals forces were treated 
using a 1.2 nm cutoff. Long-range electrostatic 
forces were treated using the particle mesh Ewald 
method (PME) (Darden et al. 1993a). 
5.2.3 Analysis
The analysis of the simulations was per-
formed using the analysis tools provided in the 
Gromacs package. The root mean square deviation 
(RMSD) of backbone atoms, the total and potential 
energies were calculated. The root mean square fluc-
tuation (RMSF) of the backbone atoms and the hy-
drophilic, hydrophobic and total Solvent Accessible 
Surface Area (SASA) were also determined. The total 
number of hydrogen bonds in the peptide group were 
quantified by counting acceptor and donor atom 
pairs that are not further apart than 0.35 nm (Beke 
et al. 2006). Secondary structure analysis used DSSP 
(Kabsch and Sander 1983). All molecular graphical 
presentations were created by VMD (Humphrey 
et al. 1996) and/or UCSF Chimera (Pettersen et al. 
2004a) packages. The standard deviation of every 
given value is shown in between brackets. 
MD  # EA  # Na+ # H2O  # Atoms  Time 
A3  3  9  17284  53742  20 
B3  3  9  17284  53742  20 
C3  3  9  17302  53796  20 
D3  3  9  15630  48780  20 
E3  3  9  17284  53742  100 
A5  5  15  25919  80907  20 
B5  5  15  21200  66750  20 
C5  5  15  20832  65646  20 
D5  5  15  20832  65646  20 
E5  5  15  20009  63177  100 
Table 5.1: Selected parameters used in simulations A-E.   
Molecular Dynamics simulation code (MD), number of 
Aβ42 chains per system (#βA), number of Na+ ions added 
for neutrality (#Na+), number of water molecules per sim-
ulation (#H2O), total number of atoms per system (#At-
oms) and total simulation time (Time, in ns) are shown. 75  
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Results and discussion
To more clearly present the results ob-
tained with our simulations, we have divided our 
system into two regions. The first region encom-
passes the residues 1 to 17, which is very likely to 
be a region with a large degree of flexibility. We 
will refer to this region as the “disordered region” 
(DR). The second region comprises the residues 
18 to 42, which is the β-sheet region (βR). The βR 
presents a β-strand-turn-β-strand motif (hook-
like or hairpin shape) that contains two inter-
molecular, parallel, in-register β-sheets that are 
formed by residues 18-26 (β1) and 31-42 (β2) con-
nected by a turn formed by residues 27-30(Luhrs 
et al. 2005) (figure 5.1). figure 5.2 shows the 
superposition of five structures collected every 2 
ns of SA of the pentameric system, which form 
the starting structures of the five independent 
simulations performed (denoted strands A-E). In 
figure 5.2, a high degree of mobility of the DR is 
clearly visible. A similar result was observed for 
the trimeric system. Using the final structures ob-
tained by the SA protocol as starting structures 
for the MD simulations, we initially generated 20 
ns trajectories for each of the strands. Although 
the potential energies of the systems quickly 
equilibrate over a period of 100 ps (see figure 5.3S 
in appendix A), it became clear that 20 ns is too 
short to reach equilibrium in the overall struc-
tural properties of the aggregates, e.g.: β-helix 
formation.
Therefore we extended two of the simu-
lations, for both the trimeric and the pentameric 
system, to 100 ns. The first 20 ns of these simula-
tions is considered equilibration time. The results 
described and discussed in the remaining part 
of this paper are mainly based on the extended 
simulations, corresponding to string E, never-
theless, strings A-D have shown similar results. 
Figure 5.3 shows snapshots of the trimeric and 
pentameric aggregates at 0 and 100 ns of simula-
tion. Top and lateral views are shown. 
The average values of the properties (e.g. 
RMSD and angles) are calculated only consider-
ing the last 80 ns of the simulations. figure 5.4 
displays the evolution of RMSDs and RMSFs for 
simulations E. As a general feature it can be ob-
served that the trimeric system compared to the 
pentameric form displays a higher flexibility. 
figures 5.4A and 5.4C shows the evolution of 
the RMSD for the DR and the βR ( and its subdi-
visions; β1, Turn and β2) for simulations E3 and 
E5. The portions β1 and Turn showed the higher 
Figure 5.2: Overlapped stereoviews of 5 configurations 
collected every 2 ns of simulation from the SA of the pen-
tameric aggregate. (A) Top view indicating the Cα’s posi-
tion restraint zone. (B) Lateral view.
Figure 5.3: Snapshots at 0 and 100 ns of simulation of the 
trimeric and pentameric aggregates. Top and lateral views 
are shown.76 
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fluctuations of RMSD. This flexibility can also 
be appreciated in figures 5.4B and 5.4D which 
show the RMSF values per residue per chain. It 
was observed in all simulations (strings A-E) and 
as a general feature, that the trimeric aggregate is 
structurally more flexible than the pentamer. 
This fact may be attributed to the higher 
degree of packing that a pentameric aggregate has 
in comparison with the trimeric one. Especially 
in the case of the trimeric aggregate, generally 
large fluctuations in RMSD occurred for the β1 
and Turn portions with an average value of 0.43 
(0.06) and 0.44 nm (0.08), respectively. On the 
other hand, it is interesting to note that the β2 
portion reached an average RMSD value of 0.34 
nm (0.02) after ~12 ns of simulation (figure 
5.4A). This can be correlated with the formation 
of a β-helix structure in this portion of the ag-
gregate. Nevertheless, in the case of pentameric 
aggregates generally no large RMSD fluctuations 
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Figure 5.4: Cα Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation as a function of time and (RMSF) 
plotted against the number of residues for; (A and B) trimeric aggregate and (C and D) pentameric aggregate.
were observed. For pentamers the largest RMSD 
value was observed for the β1 portion with 0.41 nm 
(0.03), while the turn portion revealed the small-
est RMSD value of 0.24 nm (0.03). The β2 por-
tion showed an average RMSD value of 0.30 nm 
(0.03) (figure 5.4C) which was smoothly reached 
after 20 ns of simulation, and which can be at-
tributed to the formation of a β-helix structure in 
this portion of the aggregate. A good correlation 
with what was observed for RMSD profiles can be 
appreciated in figures 5.4B and 5.4D that show 
the RMSF values for each portion of the trimeric 
and pentameric aggregate respectively. The high-
est RMSF values were observed for amino acid 
residues located in the DR, β1 and turn portions 
for the trimeric aggregate, while for the pentam-
eric aggregate this was mainly seen in DR and β1 
portions (figures 5.4B and 5.4D). Interestingly, 
in the vicinity of each Gly residue (residues 9, 25, 
29, 33, 37 and 38) RMSF values increased due to  77  
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the natural lack of side chains of this amino acid 
residue. It is worth noting that the lowest RMDF 
values, in all simulations for both trimeric and 
pentameric aggregates, were observed for those 
amino acid residues located in the β2 portion.
figure 5.5A and 5.5B, illustrate the tem-
poral development of the secondary structure 
content for the trimeric and pentameric aggre-
gates, along the 100 ns trajectory. In table 5.2 the 
secondary structure content for the DR and βR is 
summarized. For all simulations, both β1 and β2 
portions are stable at room temperature for the 
duration of the simulations. Even peptides located 
at the ends of the aggregate present stable β-strand 
regions, with the occasional loss of β-sheet con-
tent in the β1 portion. A small content of α-helix 
and 310-helix structures is infrequently observed 
for the DR. These kinds of helices are notably pres-
ent with peptides at the edge of the aggregate. As a 
general phenomenon, the loss of structure is more 
pronounced in the trimeric aggregates, indicating 
 
$
%
Figure 5.5: Change in the secondary structure during 
molecular dynamics simulation for both trimeric (A) and 
pentameric (B) model systems.
that, at least at the finite lengths studied here, they 
are more structurally flexible than the pentamers. 
The loss of structure, especially of the β-strand 
motifs, of peptides from the aggregate ends seems 
to start at the β1 and in the turn portions, while 
the core of the aggregate comprised of the β2 por-
tion remains largely intact. On the other hand, 
transient helical conformations in the N-terminal 
residues (figure 5.5) were also reported in previ-
ous fibril formation experiments and simulations 
(Baumketner et al. 2006; Kirkitadze et al. 2001; 
Massi et al. 2002; Tarus et al. 2005).
figure 5.6 shows the average inter-
chain distances of the mass center of the Cα’s at 
the various regions of our systems. A large fluc-
tuation can be appreciated for the turn portion 
in simulation E3, which suggests a great mobility 
in this portion of the aggregate. The DR showed 
an average value of 0.77 nm (0.04), which is also 
slowly reached (after ~40 ns) by the β1 portion 
with an average of 0.72 nm (0.09) indicating that 
these two parts of the molecule behave similarly 
with respect to inter-chain mobility. 
It is interesting to note the great influ-
ence that the DR has over the β1 portion. The β2 
portion showed the lowest fluctuation as com-
pared to the other portions, and also the lowest 
average value of 0.42 nm (0.03) suggesting a low 
System 
Secondary 
Structure 
DR 
ER 
E1  Turn  E2 
Trimeric 
Extended
a  15.1(3.1)  24.4(7.0)  0.0  63.1(7.7) 
Helical
b  4.5(2.9)  0.0  0.0  0.0 
Bend
c  28.3(4.7)  7.4(4.0)  0.8(3.3)  0.5(1.0) 
Coil
e  52.4(4.5)  68.2(6.4)  99.2(3.4)  36.4(7.8) 
Pentameric 
Extended
a  5.2(1.3)  29.3(5.3)  6.5(5.8)  63.7(4.4) 
Helical
b  4.4(3.1)  0.00  0.00  0.00 
Bend
c  36.1(3.6)  0.6(1.1)  0.7(2.3)  0.00 
Coil
e  54.2(2.1)  70.1(5.5)  92.7(6.1)  36.3(4.4) 
a Extended = E-Strand + E-Bridge 
b Helical = α-Helix + 310-Helix (3-Helix) + π-Helix (5-Helix) 
c Bend = Turns Type I-IV + Bend 
e Coil = Unstructured  
The standard deviation is given in between brackets  

Table 5.2: Summarized average percentage of the sec-
ondary structural composition of the different regions 
and portions of the Aβ aggregates in solution. The aver-
age values here shown are calculated over the last 80 ns 
of simulation.78 
aβ42 oligomers in solution
inter-chain mobility and a great compactness in 
this portion (figure 5.6A). A very similar pat-
tern was observed for the pentameric aggregate of 
the β2 portion with respect to mobility and com-
pactness. In this case an average value of 0.45 nm 
(0.01) was rapidly and smoothly reached (figure 
5.6B). On the other hand, the DR region showed 
a general trend towards a larger inter-chain dis-
tance (1.21 nm (0.02) for simulation E5), while 
the β1 portion did not follow a same pattern as 
the DR which we found for the trimeric aggre-
gate. Therefore, the β1 portion in the pentameric 
configuration appears to be more compact (0.66 
nm (0.04)) than the β1 portion of the trimeric 
aggregate. Interestingly, the turn portion in the 
pentamers showed a smaller fluctuation than 
the same portion in the trimers, suggesting that 
this as well as the β1 portion, has a lower inter-
chain mobility and a higher compactness (0.53 nm 
(0.02)) in the pentameric aggregate. Very similar 
inter-chain distances in the center of mass were 
seen for the Ccarbonyl’s and Cβ’s of each portion 
in our system (see figure 5.4S in appendix A). 
These results, especially the behavior of the β2 
portion, are in good agreement with the experi-
mental findings of Balbach et al. (Balbach et al. 
2002) for a parallel β-sheet organization, who re-
ported the nearest-neighbor intermolecular dis-
tances of 4.8±0.5 Å for carbon sites. At this point 
we emphasize the high stability observed for the 
β2 portion, which suggests a possible mechanism 
for fibril elongation as was previously reported 
(Buchete and Hummer 2007). Hypothetically, in a 
first step, the initial monomer addition at the end 
of a growing aggregate would be driven by strong 
hydrophobic interactions stabilizing the β2 por-
tion. In a second stage, the less stable β1 portion 
would form, finally followed by the more flex-
ible turn with its relatively hydrophilic residues 
adopting the fibril conformation. On the other 
hand, it was also observed for Aβ42 monomers in 
solution that the sequence I31IGLMVGGVVIA42 
(namely, the β2 portion) may be responsible for 
the higher propensity of this peptide to form am-
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Figure 5.6: Average inter-chain distances of the mass 
center of the Cα’s versus time of the different regions and 
portions of the trimeric (A) and pentameric (B) system.
yloids (Sgourakis et al. 2007).
Consistent with ssNMR data on amyloid 
fibrils (Petkova et al. 2002; Petkova et al. 2005; 
Petkova et al. 2006), all our starting fibril confor-
mations have Asp23/Lys28 salt bridge contacts in 
the loop region. Other studies also showed that 
charged residues are important for the dynamics 
of protein aggregation and the stability of β-sheet 
structures (Dima and Thirumalai 2004; Ma and 
Nussinov 2006; Massi et al. 2002; Thirumalai 
et al. 2003). Consistent with previous results 
(Buchete and Hummer 2007; Buchete et al. 2005), 
our trajectories of both trimeric and pentameric 
aggregates reveal that the Asp23/Lys28 bridges are 
maintained at 310 K. figure 5.7 shows the dis-
tance between the center of mass of the carboxyl 
group of Asp23 and the center of mass of the NH3
+ 
group of Lys28, as well as a simplified image of the 
starting configuration and the configuration after 
100 ns of simulation for the pentameric case. 79  
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Figure 5.7: A simplified image of the starting configuration (A) and the final configuration (B) after 100 ns of the interac-
tion Asp23/Lys28 for the pentameric system is shown. The distance between the center of mass of the carboxyl group of Asp23 
and the center of mass of the NH3
+ group of Lys28 versus time for the interactions Asp23
n/Lys28
n (C; intra-chain salt-bridge) 
and Asp23
n/Lys28
n-1 (D; inter-chain salt-bridge), where n stands for the peptide chain number, is also shown.
It can be appreciated that the positive 
and negative charges alternate along the fibril 
axis as in a one-dimensional ionic crystal. We ob-
served that both trimeric and pentameric aggre-
gates form intra-chain salt bridges (Aspn
23/Lysn28) 
and inter-chain salt bridges (Aspn
23/Lysn-1
28), 
where n stands for the chain number. Moreover, 
the majority of the salt bridges were maintained 
during the whole simulation time reaching an av-
erage distance between the center of mass of the 
carboxyl group of Asp23 and the center of mass 
of the NH3
+ group of Lys28 of 0.32 nm (0.03) for 
simulation E5, and of 0.38 nm (0.19) for simula-
tion E3. Also, as illustrated in figure 5.6 it can be 
concluded that for those salt bridges where Asp2
23 
took part in, an average distance of 0.58 nm (0.15) 
was reached after approximately 32 ns, which was 
kept until the end of the simulation. On the other 
hand, salt bridges involving Asp5
23 were broken 
(~43 ns, Asp523/Lys528, figure 5.7C) or displayed 
large fluctuations (~50 ns, Asp5
23/Lys4
28,  figure 
5.7D) since after a certain amount of simulation 
time this negatively charged amino acid resi-
due was totally solvated by molecules of water. 
Figure 5.5S, in appendix A, shows the distance 
between the center of mass of the carboxyl group 
of Asp23 and the center of mass of the NH3
+ group 
of Lys28 for the trimeric system. In this case, the 
intra-chain salt bridges and the inter-chain salt 
bridges were formed and broken over the entire 
simulation time.  In case of trimeric aggregates 
large fluctuations occurred, salt bridges being 
formed and broken over the entire simulation 
time, which may explain, at least in part, the high-80 
aβ42 oligomers in solution
er flexibility of the trimeric system compared to 
the pentameric conformation (figure 5.5S in ap-
pendix A). Also, as reported before for Aβ40 fibrils 
(Buchete and Hummer 2007; Buchete et al. 2005), 
we find narrow water channels solvating the Asp23/ 
Lys28 salt bridges within the aggregates. Indirect 
experimental evidence for interior hydration of 
Aβ fibrils comes from differential scanning calo-
rimetry (Sasahara et al. 2005), although ssNMR 
data do not indicate large structural differences 
between lyophilized and wet fibrils (Paravastu 
et al. 2006; Petkova et al. 2006). Visual inspec-
tion reveals the formation of narrow water chan-
nels solvating the interior Asp23/Lys28 salt bridges 
into the aggregates. Recent simulations of fibrils 
with up to 32 Aβ16–22 peptides in antiparallel 
β-strands have also shown similar water channels 
hydrating the Lys16/Glu22 side chains (Rohrig et al. 
2006). In several instances we noted an exchange 
in the salt bridge partners from the initial Asp23/
Lys28 pair to Glu22/Lys28 as the end peptides begin 
to dissociate from the aggregates (figure 5.6S). 
figure 5.6S in appendix A displays the distance 
between the center of mass of the carboxyl group 
of Glu22 and the center of mass of the NH3
+ group 
of Lys28 for the intra-chain salt bridges (Glun
22/
Lysn
28) and the inter-chain salt bridges (Glun
22/
Lysn-1
28) for the pentameric case. The presence of 
Glu22/Lys28 salt bridges has been suggested for 
small Aβ peptide aggregates, Aβ monomers in so-
lution (Baumketner et al. 2006; Borreguero et al. 
2005; Cruz et al. 2005; Lazo et al. 2005), and Aβ40 
fibrils (Buchete and Hummer 2007). The Glu22/
Lys28 ion pair might play an important role in 
the aggregate elongation (Buchete and Hummer 
2007). Overall, based on our own and other previ-
ous studies the main driving force for fibril elon-
gation appears to be the formation of C-terminal 
β-sheets (our β2 portion). This hypothesis seems 
to be supported by recent experiments showing 
that perturbing the hydrogen bonds in the β1 and 
β2 portions through selective N-methylation af-
fects both fibril growth and structure (Sciarretta 
et al. 2006a). Disrupting the backbone hydrogen 
bonds of the β1 portion resulted in relatively slow 
growth of fibrils with a blurred boundary, while 
derangement of the β2 hydrogen bonds, had less 
effects on fibril growth and yielded fibrils with a 
sharply defined surface. These experimental re-
sults are consistent with our simulation findings.
figure 5.8 displays the formation of a 
β-helix structure occurring especially on the β2 
portion of the pentamers. In order to quantify the 
twist of this β-helix motif, two dihedral angles 
were defined, namely γ and δ. Using as a pivot 
the amino acid residue Val36, which encompasses 
the β2 portion of our model, the definition of the 
γ angle involves the Cα’s of residues Ilen
31, Valn
36, 
Valn-1
36 and Ilen-1
31, while the definition of the δ 
angle involves residues Alan
42, Valn
36, Valn-1
36 and 
Alan-1
42. figures 5.8A and 5.8B show a spatial view 
of the β2 portion at 0 ns and 100 ns of simula-
tion time respectively. Top views (figures 8A1 
and 8B1) and lateral views (figures 8A2 and 8B2) 
are also shown. figures 8C and 8D illustrate the 
temporal development of the γ and δ angles, re-
spectively.
The  β-helix is a plausible structural 
motif for amyloid fibrils, since it is primar-
ily a β-sheet structure with the proper cross-β 
orientation(Esposito et al. 2006; Ferguson et al. 
2006; Zheng et al. 2006a; Zheng et al. 2006b) 
and known to occur in bona fide proteins. As de-
scribed above, in our model of Aβ42 aggregates in 
solution the formation of a β-helix structure oc-
curred especially on the β2 portion (figure 5.8). 
The model used by us is an elaboration of the 
classical cross-β molecular structure, which per-
mits the incorporation of the favorable twisted 
β-sheet structures. This kind of helical struc-
tures enables the hydrogen bonding between the 
β-strands to be extended over the total length of 
the amyloid fibrils, thereby accounting for their 
characteristic rigidity and stability(Tycko 2004). 
Increased fibril twisting could be caused by the 
loss of directional hydrogen bonding, and a gain 
in packing interactions(Chothia and Janin 1982).  81  
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Figure 5.8: Simplified images of the starting configuration (A1, top view and A2 lateral view) and the final configuration 
(B1, top view and B2 lateral view) after 100 ns of the β2 portion for the pentameric system is shown. The γ (C) and δ (D) 
dihedral angles versus time are also shown. The definition of the γ dihedral angle involves the Cα’s of residues Ilen31, Valn36, 
Valn-1
36 and Ilen-1
31, while the definition of the δ dihedral angle involves residues Alan
42, Valn
36, Valn-1
36 and Alan-1
42, where n 
stands for the number of the peptide chain.
A schematic definition of those angles is shown 
in figure 5.8A. In general, after approximately 20 
ns of simulation an average value of -8.95° (0.97) 
and -9.40° (1.93) was reached for γ and δ, respec-
tively. In figure 5.8C a great fluctuation for the δ 
angle can be observed. This may be caused by the 
fact that the definition of this angle involves the 
Cα of the terminal residues Ala42, which are in 
direct contact with the solvent and therefore lead-
ing to a greater mobility. Since twisted β-sheets 
optimize the hydrogen bonds, side-chain stack-
ing, and electrostatic interactions, it is commonly 
accepted that twisted sheets are more stable than 
flat ones. This result is in good agreement with 
those reported by Periole et al. that shows the for-
mation of a cross-β by the peptide GNNQQNY 
with a twist ranging from 0 to 12 degrees per pep-
tide around its axis when fully solvated (Periole 
et al. 2009).
Although our model is a full-length 
model for Aβ42 aggregate in solution, it is of in-
terest to compare our results to other proposed 
truncated and/or full-length models for Aβ40 
structures. The so called Tycko’s model(Petkova et 
al. 2006), and the LECB model(Ma and Nussinov 
2002) are similar to our model, specifically, re-
garding the hairpin shape of the aggregates. There 82 
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is a slight difference between our model, and the 
Tycko’s model. Our model forms a hydrophobic 
core with Leu34 facing the interior of the aggre-
gate in the β2 portion, whereas in Tycko’s model 
the Leu34 faces outside. In our model it was ob-
served that the residues Leu34 and Val36 of the 
portion β2 formed an inner hydrophobic core in 
the aggregates. Regarding this matter, our model 
is more similar to the LECB model than Tycko’s. 
The internal Asp23/Lys28 salt bridge interaction 
is supported by experimental and theoretical 
data(Luhrs et al. 2005; Ma and Nussinov 2002, 
2006; Petkova et al. 2002; Petkova et al. 2006). 
This interaction has been observed in our model, 
as well as in the above mentioned models. We 
note that the position of the turn in our model 
differs with the position of the same moiety in the 
LECB model. The turn portion encompasses the 
residues Asn27-Ala30 in our model, while the same 
portion encompasses the residues Val24-Asn27 in 
the LECB model. As a result of this organization 
the Asp23/Lys28 salt bridge shows a slight differ-
ence between the LECB model and our model. 
In the LECB model the Asp23 residue is located in 
one of the β-strands of the peptide, and the Lys28 
residue is located in the other β-strand segment, 
therefore, the Asp23/Lys28 interaction occurs in 
between the two β-strand portion of this model. 
In our model, the Asp23 is located in the β1 por-
tion, while the Lys28 is located in the turn portion. 
A closely related structural model for Aβ40 fibrils 
has been proposed by Wetzel et al.(Shivaprasad 
and Wetzel 2004; Williams et al. 2004). In agree-
ment with our model, the Wetzel’s model places 
the side chains of Phe19, Ile32, Leu34, and Val36 in 
the interior of a single molecular layer. In contrast 
to our model, side chains of Asp23 and Lys28 are on 
the exterior of a single molecular layer. A highly 
similar molecular organization has been de-
scribed for another peptide with amyloidogenic 
properties. The molecular structural organization 
of the CA150.WW2 protofilament(Ferguson et al. 
2006) is stabilized by interdigitated hydrophobic 
regions, as well as, by the presence of a intra-chain 
salt bridge between the Glu7 and Arg24 in a par-
allel β-sheet arrangement. This structural model 
has similarities to those reported for aggre-
gates of the Aβ1–40(Petkova et al. 2002), Aβ1–42 
peptides(Luhrs et al. 2005) and the structure re-
ported for the peptide Sup35(Zheng et al. 2006b). 
Beyond the stabilization effect due to the long-
range interactions (e.g.: salt bridges formation) 
depending on sequence composition, length, and 
environmental conditions, the interdigitating hy-
drophobic side chains interactions of the aggre-
gates seems to be a commonly recurring feature 
of these aggregates.
In summary, the contributions of the 
different structural elements of the full-length 
Aβ42 aggregates in solution to their stability and 
conformational dynamics were explored. Using 
multiple 20–100 ns long MD simulations of fi-
bril systems of ~60,000 atoms, we studied aggre-
gate models that differ in the quantity of peptide 
chains, notably pentameric and trimeric aggre-
gates. We found that our models are stable at the 
temperature of 310 K, and converge towards an 
interdigitated side-chain packing for intermo-
lecular contacts within the two parallel β-sheet 
regions of the aggregates, β1 (residues 18-26) and 
β2 (residues 31-42). In spite of the fact that those 
chains at the edge of the aggregates showed a 
higher mobility than those chains near to the ag-
gregate core, the β-sheet region kept its arrange-
ment (β1-turn-β2 / hairpin shape) during the en-
tire simulation time. The β1 portion showed to be 
more flexible than the β2 portion, which may well 
be induced by the proximity of the disordered re-
gion to the β1 portion. This provides good argu-
ments to study the full-length Aβ models, since 
the dynamic behavior of a determinate portion of 
the aggregate can affect the behavior of its sur-
roundings. The Asp23/Lys28 salt bridges maintain a 
stable and relatively rigid interdigitated structure. 
However, during the initial stages of fibril disso-
ciation the Asp23/Lys28 contacts in Aβ peptides at 
the aggregates ends can break to form the com-
peting Glu22/Lys28 interaction. Thus, it suggests  83  
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5.4
 Conclusions
that the loss of Glu22/Lys28 contacts could be an 
important indicator for the transition of the Aβ 
peptides from their solution structures towards 
the aggregated conformations (Baumketner et 
al. 2006; Buchete and Hummer 2007). Our whole 
molecule simulations reveal that the β-strand 
twist is a characteristic element of Aβ aggregates, 
permitting a compact, interdigitated packing of 
side chains from neighboring β-sheets. The β2 
portion formed a very well organised β-helix, 
whereas the β1 portion did not reach such a high 
level of organization although it maintained its 
β-sheet conformation. 
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This study demonstrates the impor-
tance of studying the full-length Aβ aggregates 
in solution in order to have a more general view 
of how each part of the aggregate influences the 
conformational behavior of the whole system. 
Moreover, these simulations suggest that the hy-
drophobic core comprising the β2 portion of the 
aggregate is a crucial stabilizing element in the 
process of aggregation and possibly in the elon-
gation of Aβ aggregates. For that reason the β2 
portion appears to be a promising target for fur-
ther drug-design based on the structure-stability 
information, such as new potential “amyloid in-
hibitors” capable to interact specifically with this 
portion of the aggregates. ■“Still here”
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Abstract
Misfolding, oligomerization and aggregation of the amyloid-beta (Aβ) peptide is widely recognized as 
a central event in the pathogenesis of Alzheimer’s disease (AD). Recent studies have identified soluble 
Aβ oligomers as the main pathogenic agents and provided evidence that such oligomeric Aβ aggregates 
are neurotoxic, disrupt synaptic plasticity and inhibit long-term potentiation (LTP). A promising thera-
peutic strategy in the battle against AD is the application of short synthetic peptides which are designed 
to bind to specific Aβ-regions thereby neutralizing or interfering with the devastating properties of 
oligomeric Aβ species. In the present study we investigated the neuroprotective properties of the amy-
loid sequence derived pentapeptide Leu-Pro-Tyr-Phe-Asp-NH2 (LPYFDa) in vitro as well as its memory 
preserving capacity against Aβ42-induced learning deficits in vivo. In vitro we could show that neurons in 
culture treated with LPYFDa are protected against Aβ42-induced cell death. Moreover, in vivo LPYFDa 
prevented memory impairment tested in a contextual fear conditioning paradigm in mice after bilateral 
intrahippocampal Aβ42 injections. We thus showed for the first time that an anti-amyloid peptide like 
LPYFDa can preserve memory by reverting Aβ42 oligomer induced learning deficits.
Journal of Alzheimer’s Disease (2010), 19:991-1005. 87  
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 Introduction
Progressive neurodegeneration and 
cognitive decline are typical features of Alzheimer’s 
disease (AD), the most common form of dementia 
(Haass and Selkoe 2007). Besides the formation of 
neurofibrillary tangles, it is widely acknowledged 
that the aggregation of amyloid β (Aβ) initiates a 
complex series of events that ultimately results in 
neuronal cell death particularly in forebrain regions, 
which is paralleled by the cognitive and behavioral 
decline that is characteristic for pathogenesis of 
AD. Aβ is generated by sequential proteolytic cleav-
age from the amyloid-β precursor protein (APP) 
by beta-, and gamma-secretases (amyloidogenic 
processing). Alternatively APP can be cleaved by 
α-secretase within the Aβ sequence which prevents 
the generation of Aβ peptide. Once released, Aβ due 
to its physico-chemical properties has the strong 
tendency to misfold, oligomerize and to aggregate 
into fibrils and plaques (Wisniewski et al. 1997).
Although amyloid plaques represent 
a major hallmark of AD, they correlate poorly 
with the progression of the disease (Forman et 
al. 2007). Interestingly, more recent studies have 
identified soluble Aβ–oligomer assemblies as 
the main pathogenic agents which, in contrast to 
plaques, do correlate well with the mental decline 
observed in AD patients (Haass and Selkoe 2007; 
Lue et al. 1999; McLean et al. 1999; Naslund et al. 
2000; Wang et al. 1999). Furthermore, soluble Aβ 
oligomers have been shown to be neuro- and syn-
aptotoxic, and to inhibit long-term potentiation 
(LTP) (Chang et al. 2006; Chapman et al. 1999a; 
Shankar et al. 2008; Walsh and Selkoe 2007; 
Wasling et al. 2009). Acute application of oligo-
meric Aβ leads to internalization of glutamatergic 
AMPA and NMDA receptors and finally to syn-
aptic downscaling (Hsieh et al. 2006; Shankar et 
al. 2007a). However, it should be appreciated that 
next to its pathological properties, Aβ notably in 
very low physiological concentrations, may have 
important roles in synaptic plasticity and nor-
mal brain functioning (Pearson and Peers 2006; 
Puzzo et al. 2008; Wasling et al. 2009). The en-
dogenous level of Aβ in the brain is regulated by 
synaptic activity in vivo, suggesting a dynamic 
feedback loop involving APP metabolism and Aβ 
that may modulate synaptic activity (Haass and 
Selkoe 2007). Recently, Garcia-Osta and cowork-
ers showed that depletion of endogenous Aβ by 
a single intrahippocampal (i.h.) administration 
of anti- Aβ -antibody leads to disrupted memory 
retention in rats (Garcia-Osta and Alberini 2009). 
During the pathogenesis of AD the equilibrium 
of Aβ generation and Aβ clearance is disturbed, 
which eventually leads to elevated Aβ levels, in-
creased Aβ aggregation and impaired memory 
function (Wasling et al. 2009).
Multiple therapeutic strategies have 
been developed since the second half of the previ-
ous century (Harkany et al. 2000). Unfortunately, 
most of the currently available therapies target 
only the symptoms since acting on presumed 
downstream neurotoxic pathogenic mechanisms 
without tackling the cause and thus hardly able to 
affect the progression of the disease. Experimental 
data from animal studies using immunotherapy 
in order to remove Aβ from the brain were highly 
promising (Schenk et al. 1999). However, clinical 
trials with active immunization against Aβ were 
halted due to severe brain inflammation and pre-
mature death of several patients (Hock et al. 2003; 
Orgogozo et al. 2003b).
Consequently, as a therapeutic strategy 
compounds were developed that could inhibit or 
delay the development of Aβ aggregation, fibril-
lization, and/or plaque formation and were thus 
potentially capable of protecting neurons from 
Aβ toxicity. As part of this approach small pep-
tides derived from the Aβ sequence were designed 
such as the pentapeptide Leu-Pro-Tyr-Phe-Asp-
NH2 (LPYFDa) which seemed to offer a promis-
ing starting point to develop potential drugs that 
can somehow revert the devastating impact of Aβ 
6.188 
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aggregates. The advantage of such compounds, 
in comparison to other putative therapeutic ap-
proaches for AD such as vaccination, is that they 
specifically target the abnormal conformation of 
Aβ without interfering with any possible physi-
ological function of the soluble, monomeric Aβ 
peptide.
There have been numerous attempts to 
develop treatments developed to interfere with 
various key steps in the amyloidogenic process. 
Promising putative treatments may be those de-
signed to inhibit steps that precede  Aβ peptide 
aggregation, by blocking production of the toxic 
soluble Aβ oligomers in the first place, or by revers-
ing, somehow, the toxic effect of these oligomers.
In the present study we established an in 
vivo model in the mouse for Aβ induced memory 
impairment through a single bilateral injection 
of oligomeric Aβ42 into the hippocampus and 
explored in this model whether LPYFDa can be 
beneficial against the Aβ-induced cognitive defi-
cits. Furthermore, we investigated the neuropro-
tective properties of Aβ-derived synthetic penta-
peptide Leu-Pro-Tyr-Phe-Asp-NH2 (LPYFDa) 
(Datki et al. 2004; Juhasz et al. 2009; Szegedi et 
al. 2005) against the neurotoxic effects of soluble 
Aβ42 oligomers in cultured mouse primary corti-
cal neurons (PCN). Finally, we employed molecu-
lar modeling and docking experiments to reveal 
part of the putative mechanism of action of these 
peptides.
  Material and methods
6.2.1 Compounds
The beta-sheet breaker LPYFDa was 
synthesized in our laboratories by a solid-phase 
procedure involving the use of Merriﬁeld resin 
and Boc chemistry. Purity control and struc-
ture verification were carried out by amino acid 
analysis and mass spectrometry as previously 
described (Zarandi et al. 2007). The control pep-
tide (scrP), which is a scrambled version of the 
LPYFD peptide (Pro-Asp-Tyr-Leu-Phe-NH2), 
and Aβ1−42 (Aβ42) were purchased from EZBiolab 
Inc. (Carmel, USA). Anti-Aβ antibody (6E10) was 
obtained from Covance (Emeryville, USA). Other 
compounds used in this study were purchased 
from Invitrogen (Carlsbad, USA) or Sigma-
Aldrich Corporation (St. Louis, USA).
6.2.2  Preparation of aβ-oligomers
Oligomeric Aβ42 was prepared as was 
described by Dahlgren and colleagues (Dahlgren 
et al. 2002). In short, the synthetic Aβ42 peptide 
was initially dissolved in 1,1,1,3,3,3-hexafluoro-2-
propanol (HFIP) to a concentration of 1 mM. The 
peptide solution was divided into aliquots and 
the HFIP removed by evaporation under vacu-
um (SpeedVac; Savant Instruments, Hyderabad, 
India). The dry peptide films were stored at -20°C 
until further processing. Before use, the dry film 
Aβ42 was dissolved in anhydrous DMSO to 5 mM 
followed by bath sonication (Decon, Hove Sussex, 
UK) for 10 min, subsequently diluted in neuro-
basal medium to a final concentration of 100 μM 
(stock solution) and incubated at 4°C for 24 h to 
enable Aβ42 oligomerization. The aggregation 
state and the secondary structure of the oligo-
meric Aβ42 preparation was examined by sodium 
dodecyl sulfate (SDS) - PAGE Western blotting 
and Circular Dichroism (CD) spectrometry (fig-
ure 6.1).
6.2.3  Gel electrophoresis and western blot analysis
Gel electrophoresis and Western blot 
analysis were adopted from Stine et al., 2003 
(Stine et al. 2003). Briefly, unheated samples in 
SDS sample buffer were applied to 10-20% tris-tri-
cine gradient gels (Bio-Rad, Munich, Germany), 
electrophoresed using tricine running buffer and 
subsequently transferred to 0.45-µm polyvinyli-
dene difluoride membranes (Millipore, Bilerca,  89  
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USA). Membranes were blocked with 1% I-Block 
(Tropix, Bedford, USA) in Trisbuffered saline con-
taining 0.0625% Tween-20. Blots were incubated 
with primary antibody 6E10 over night (1:2000; 
mouse monoclonal against Aβ residues 1–16; 
Covance Emeryville, USA). Immunoreactivity 
was detected using enhanced chemilumines-
cence (Pierce Biotechnology, Rockford, USA) 
and imaged on an Kodak X-Ray film (Eastman 
Kodak Company, Rochester, USA) (figure 6.1A). 
Molecular weight values were estimated using 
the PageRuler (Fermentas International, Ontario, 
Canada) pre-stained molecular weight marker.
6.2.4  CD spectrometry
CD measurements were performed at 
25 °C on a CD Spectrometer Model 62DS (AVIV 
Associates Inc., Lakewood, USA) using a quartz 
cell of 0.1-cm pathlength. All spectra were aver-
ages of four scans; the resolution was 1 nm. The 
oligomerized Aβ was diluted in PBS to a concen-
tration of 25 µM. The samples were sonicated for 
10 min immediately after dissolution. CD spectra 
were expressed as mean residue ellipticity [Q]MR 
in units of deg cm2 dmol−1, (figure 6.1B). The per-
centages of secondary structures were analyzed 
using the K2D2 program (Perez-Iratxeta and 
Andrade-Navarro 2008).
6.2.5  Primary cortical neuron culture
Primary cortical neurons were pre-
pared from embryonic brains (E14) of C57Bl/6J 
mice. The cortices were carefully dissected, me-
ninges were removed and the neurons separated 
by trituration. Cells were plated on poly-D-lysine 
pre-coated plates at a density of 1.2 x 105 cells/
well (96 well plates). Neurobasal medium supple-
mented with 2% (v/v) B27-supplement, 0.5 mM 
Figure 6.1: (A) Oligomeric preparation of Aβ42 was examined by Western blot using the anti-Aβ antibody 6E10 (1:2000). 
Bands correspond to monomeric up to tetrameric forms of Aβ42. (B) CD spectrum of (×) Aβ42 in PBS after 24 hours incuba-
tion at 4 °C.(—) fitted line data using K2D2 program. (C) Schematic outline of the experimental procedure in vitro. PCN 
from C57BL6 mouse embryos (E14) were cultured for 6 days and then treated for 24 h with different concentrations of 
oligomerized Aβ42, beta-sheet breaker peptides or combinations of both. On day 7 medium was completely exchanged and 
24 h later the cell viability was assessed by an MTT reduction assay. (D) Schematic outline of the experimental setup in 
vivo. C57BL/6J mice were cannulated 7 days prior i.h. injection with oligomerized Aβ42 and/or beta-sheet breaker peptides. 
One hour after the injection the animals were trained in a contextual fear conditioning paradigm. 24 h after the training 
session memory performance was assessed. Cannula position was evaluated by methylene blue injection after the behav-
ioural test. (E) Representative coronal brain sections of a bilateral dorsal hippocampal (i.h.) injection with methylene blue 
counterstained with nuclear fast red.90 
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glutamine and 1% (v/v) penicillin/ streptomycin 
was used as a culture medium. After 48 h neurons 
were treated with 10 μM cytosine arabinoside for 
another 48 h to inhibit non-neuronal cell growth. 
Subsequently, the medium was completely ex-
changed and after 6 days of in vitro culture, the 
neurons were used for experiments.
6.2.5.1  Treatment of cells
Possible toxicity of LPYFDa, its control 
peptide scrP and Aβ42 oligomers was determined 
by incubating neuronal cultures for 24 h with dif-
ferent concentrations of the peptide solutions. The 
neuroprotective effect of LPYFDa was assessed by 
incubating neurons (cultured in 96 well plates) for 
24 h with 20 mM oligomeric Aβ in the presence or 
absence of different concentrations of LPYFDa or 
control peptide. After the treatment, the medium 
was completely exchanged, and 24 h later, the cell 
viability was determined by an MTT-assay (fig-
ure 6.1C). All treatments were performed in trip-
licates and the experiments were repeated at least 
two times.
6.2.5.2  determination of cell viability by MTT-assay
Neuronal viability was determined by 
the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl-)2,5-diphenyltetrazolium bromide] assay as 
described previously (Mosmann 1983). 1.25 mg/
ml MTT solution was added to each well of a 96 
well plate. After 2 h of incubation, cells were lysed 
in acidic propan-2-ol solution (37% HCl/ pro-
pan-2-ol: 1/166). The absorbance of each well was 
measured with an automated ELISA plate reader 
(Bio-Rad, Munich, Germany) at 595 nm with a 
reference filter at 630 nm.
6.2.6 Animals
Behavioral experiments were performed 
with 9–12 weeks old male C57Bl/6J mice (Harlan, 
Horst, The Netherlands). Individually housed 
mice were maintained on a 12 h light/dark cycle 
(lights on at 7.00 a.m.) with food (Hopefarms, 
standard rodent pellets) and water ad libitum. A 
layer of sawdust served as bedding. The animals 
were allowed to adapt to the housing conditions 
for 1–2 weeks before the experiments started. The 
procedures concerning animal care and treat-
ment were in accordance with the regulations 
of the Ethical Committee for the use of experi-
mental animals of the University of Groningen 
(DEC4668C).
6.2.6.1  Animal surgery
Double guide cannulae type C235 (Plastics 
One, Roanoke, USA) were implanted in the brain us-
ing a Kopf stereotactic instrument during Hypnorm/
Midazolam (10 ml/kg, i.p.) anesthesia under asep-
tic conditions as previously described (Nijholt et al. 
2008) with anteroposterior (AP) coordinates zeroed at 
Bregma directed toward both dorsal hippocampi (i.h.), 
AP -1.5 mm, lateral 1 mm, depth 2 mm (Franklin and 
Paxinos 1997). Each double guide cannula with insert-
ed dummy cannula and dust cap was fixed to the skull 
with dental cement (3M ESPE AG, Seefeld, Germany). 
Administration of 1 mg/ml finadyne (2.5 mg/kg s.c.) be-
fore the surgery served as analgesic. The animals were 
allowed to recover for 6–7 days before the behavioral 
measurements started.
6.2.6.2  Intrahippocampal injections
Bilateral i.h. injections were performed un-
der short isofluran anesthesia using a Hamilton micro-
syringe fitted to a syringe pump unit (TSE systems, Bad 
Homburg, Germany) at a constant rate of 0.3 µl/min 
(final volume: 0.3 µl per side). The amount of injected 
Aβ42 was of 15, 30 or 60 pmol and LPYFDa as well as 
the control peptide scrP in an amount of 150 pmol into 
the dorsal hippocampus. PBS (pH 7.5) served as vehicle. 
One hour after the injection the animals were subjected 
to a training session in a fear conditioning paradigm 
(figure 6.1D). The number of animals per group varied 
from 5 to 9.
6.2.6.3  Fear conditioning
Fear conditioning was performed in a plexi-
glas cage (44 x 22 x 44 cm) with constant illumination 
(12 V, 10W halogen lamp, 100–500 lux). The training  91  
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(conditioning) consisted of a single trial. Before each 
individual mouse entered the box, the box was cleaned 
with 70% ethanol. The mouse was exposed to the con-
ditioning context for 180 s followed by a scrambled 
footshock (0.7 mA, 2 s, constant current) delivered 
through a stainless steel grid floor. The mouse was re-
moved from the fear conditioning box 30 s after shock 
termination to avoid an aversive association with the 
handling procedure. Memory tests were performed 
24 h after fear conditioning. Contextual memory was 
tested in the fear conditioning box for 180 s without 
footshock presentation. Freezing, defined as the lack  
of movement except for respiration and heart beat, was 
assessed as the behavioral parameter of the defensive 
reaction of mice by a time-sampling procedure every 
10 s throughout memory tests. In addition, mean ac-
tivity of the animal during the training and retention 
test was measured with the Ethovision system (Noldus, 
Wageningen, The Netherlands).
6.2.7 Histology
Immediately after the behavioral test  
mice were injected i.h. with methylene blue so-
lution during sodium-pentobarbital anesthesia 
(0.1 ml/ 10g, i.p.). Brains were removed and seri-
ally sectioned at 50 µm. Sections were stained on 
glass for 5 min in 0.1% nuclear fast red solution. 
To identify the location of the injection, sections 
were analyzed using light microscopy. Only data 
from animals in which the proper intrahippo-
campal site of injection was confirmed, were eval-
uated (figure 6.1E).
6.2.8  Molecular modeling
6.2.8.1  Stochastic conformational search. 
Edmc calculations
The conformational space was explored 
using the method previously employed by Liwo et 
al. (Liwo et al. 1996a) which includes the electro-
statically driven Monte Carlo (EDMC) method 
(Ripoll and Scheraga 1988, 1990) implemented 
in the ECEPPAK package. Conformational en-
ergy was evaluated using the ECEPP/3 force field 
(Némethy et al. 1992). Hydration energy was eval-
uated using a hydration-shell model with a sol-
vent sphere radius of 1.4 Å and atomic hydration 
parameters that have been optimized using non-
peptide data (SRFOPT) (Vila et al. 1991; Williams 
et al. 1992). In order to explore the conformational 
space extensively, we carried out 10 different runs, 
each of them with a different random number. 
Therefore, we collected a total of 5000 accepted 
conformations. Each EDMC run was terminated 
after 500 energy-minimized conformations had 
been accepted. The parameters controlling the 
runs were the following: a temperature of 298.15 
K was used for the simulations. A temperature 
jump of 1,000 K was used; the maximum num-
ber of allowed repetitions of the same minimum 
was 50. The maximum number of electrostati-
cally predicted conformations per iteration was 
400; the maximum number of random-generated 
conformations per iteration was 100; the fraction 
of random/electrostatically predicted conforma-
tions was 0.30. The maximum number of steps at 
one increased temperature was 20; and the maxi-
mum number of rejected conformations until a 
temperature jump is executed was 100. Only trans 
peptide bonds (ω ≈ 180°) were considered. All ac-
cepted conformations were then clustered into 
families using the program ANALYZE (Meadows 
et al. 1994a; Pohorille and Pratt 1990) by applying 
the minimal-tree clustering algorithm for separa-
tion, using all heavy atoms, energy threshold of 
30 kcal mol-1, and RMSD of 0.75 Å as separation 
criteria. This clustering step allows a substantial 
reduction of the number of conformations and 
the elimination of repetitions. A more detailed 
description of the procedure used here is given 
in section 4.4 Computational methods   of    
(Masman et al. 2009b).
6.2.8.2  Docking studies
Two models for Aβ were used as tar-
get systems; the monomeric Aβ42 elucidated by 
Crescenzi et al (monomeric model) (Crescenzi 
et al. 2002), PDB code 1IYT, and the pentam-92 
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eric aggregate Aβ42 developed by Masman et al 
(pentameric model) (Masman et al. 2009a). The 
structures were prepared for docking study as fol-
lows: for the Aβ42 molecules, water molecules were 
removed from the PDB file and hydrogen atoms 
were added; Gasteiger charges, atomic solvation 
parameters and fragmental volumes were merged 
to the target system. For both LPYFDa and scrP, 
the structure of the most populated family (results 
from the EDMC calculations) was taken as initial 
conformation. Gasteiger charges were assigned 
and non-polar hydrogen atoms were merged. All 
torsions were allowed to rotate during docking. 
The docking energy grid was produced with the 
auxiliary program AutoGrid. The grid dimen-
sions were 60x60x60 for the monomeric model, 
and 90x60x60 for the pentameric model, points 
along the x-, y- and z-axes, with points separated 
by 0.375Å. The grids were chosen to be sufficiently 
large to cover significant portions of the putative 
binding sites. The center of the pentapeptide was 
positioned at the grid center. All graphic manip-
ulations and visualizations were performed by 
means of the AutoDock Tools (Sanner 1999) and 
the Chimera (Pettersen et al. 2004a) programs, 
and ligand docking with AUTODOCK 4 (Morris 
et al. 2009). The Lamarckian genetic algorithm 
was utilized and the energy evaluations were set 
at 2.5x106. A total of 250 accepted conformations 
were collected. Other parameters were set to de-
fault values.
6.2.9  Statistical analysis
Behavioral data were analyzed by 
analysis of variance (ANOVA) followed by the 
Bonferroni post-hoc test to determine statistical 
significance. For statistical analysis of the MTT 
assays, an unpaired Student’s t test with unequal 
variance was used. A p-value < 0.05 was con-
sidered to be statistically significant. Data are 
presented as mean value ± standard error of the 
mean (SEM).
 Results
6.3.1  Characterization of the oligomeric aβ42
The state of aggregation of the oligomeric 
Aβ42 preparation was determined by Western 
blot analysis. The results confirmed that the Aβ42 
preparation consisted of a mixture of small mo-
lecular weight Aβ42 oligomers from monomeric 
to tetrameric Aβ42 (figure 6.1A). In addition we 
used CD spectrometry to characterize the sec-
ondary structure of Aβ42 in solution. We could 
show that our oligomeric Aβ42 preparation con-
sists of 43.02% β-sheets, 5.40% α-helix and 51.58% 
random-coil conformation (figure 6.1B), which 
shows a good correlation to the conformation be-
havior of Aβ42 aggregates observed by Masman et 
al (Masman et al. 2009a).
6.3.2  Molecular modeling and stochastic con-
formational search. Edmc calculations
To have a better view at the molecular 
lever, it is crucial to assess the conformational be-
havior of the pentapeptides in solution. Therefore, 
LPYFDa and scrP were selected for energy calcu-
lations to determine the biologically relevant con-
formations. The results of the theoretical calcula-
tions are summarized in table 6.1.
Calculations yielded a large set of 
conformational families for each peptide stud-
ied. The total number of conformations gener-
ated was 62515 and 65056, for LPYFDa and scrP 
respectively, whereof 5000 conformations for 
each pentapeptide were accepted. In the cluster-
ing procedure, an R.M.S.D (Root Mean Square 
Deviation) of 0.75 Å and a ΔE of 30 kcal mol-1 were 
used. The number of families after clustering was 
220 and 323, for LPYFDa and scrP, resp. The to-
tal number of families accepted with a relative 
population higher than 0.50% was 10 and 25, for 
LPYFDa and scrP, resp. that sum up to ca 90% of 
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LPYFDa  Electrostatic Random Thermal Total 
Generateda 4233 58242 40 62515
Acceptedb 535 4431 34 5000
Family  NF c  %PF d  Etot   ΔE 
1  2502 50.04 -70.79 0.00
2  768 15.36 -70.76 0.03
3  370 7.40 -69.43 1.36
4  262 5.24 -70.12 0.66
5  261 5.22 -69.31 1.47
6  247 4.94 -70.25 0.54
7  62 1.24 -69.37 1.42
8  47 0.94 -70.13 0.66
9  35 0.70 -69.75 1.03
10  30 0.60 -68.45 2.34
scrP  Electrostatic Random Thermal Total 
Generateda 4288 60708 60 65056
Acceptedb 362 4595 43 5000
Family  NF c  %PF d  Etot  ΔE 
1  1146 22.92 -49.71 1.18
2  635 12.70 -50.16 0.73
3  478 9.56 -49.95 0.93
4  329 6.58 -50.88 0.00
5  272 5.44 -49.66 1.22
6  250 5.00 -49.94 0.94
7  190 3.80 -50.19 0.69
8  116 2.32 -49.71 1.17
9  114 2.28 -50.57 0.31
10  101 2.02 -49.44 1.44
11  97 1.94 -49.63 1.26
12  88 1.76 -50.23 0.65
13  60 1.20 -50.25 0.64
14  53 1.06 -49.47 1.41
15  51 1.02 -49.81 1.07
16  48 0.96 -49.39 1.50
17  45 0.90 -48.58 2.30
18  39 0.78 -48.78 2.10
19  39 0.78 -48.22 2.66
20  38 0.76 -48.97 1.91
21  37 0.74 -49.23 1.65
22  32 0.64 -49.74 1.14
23  30 0.60 -48.90 1.98
24  27 0.54 -49.03 1.86
25  26 0.52 -49.07 1.81
a Number of conformations generated electrostatically, randomly and thermally 
during the conformational search. 
b Number of conformations accepted from those generated electrostatically, 
randomly and thermally during the conformational search. 
c NF represents the total number of conformational families as result of the 
ustering run.  cl
d 
c
%PF represents the percent relative population based on a total of 5000 accepted 
onformations. 

Table 6.1: Conformational search and clustering results 
for LPYFDa and scrP optimized at the EDMC/SRFOPT/
ECCEP/3 level of theory. Total (Etot, kcal mol-1) and relative 
(ΔE, kcal mol-1) energies are also shown. All conforma-
tional families shown here have relative population (%PF) 
higher than 0.5%.
Figure 6.2: Stereoview of selected conformations for 
LPYFDa and scrP optimized at EDMC/SRFOPT/EC-
CEP/3 level of theory. (A) overlapping of the two most  
populated and energetically preferred families of LPYF-
Da, family 1 (ΔE = 0.00 cal.mol-1, white) and family 2 
(ΔE = 0.03 kcal mol-1, pink). (B) Family 4 with a relative 
energy (ΔE) of 0.00 kcal mol-1 and (C) Family 1 with an 
ΔE = 1.18 kcal mol-1 of ScrP. All hydrogen atoms have been 
deleted for more clarity.
all conformations. All low-energy conformers of 
pentapeptides studied here were then compared 
to each other. The comparison involved the spa-
tial arrangements, relative energy and popula-
tions. The LPYFDa evaluation showed that the 
most populated family (50.04%) is also the en-
ergetically preferred one, while its second most 
populated family (15.36%) has a relative energy of 
0.03 kcal mol-1 above the global minimum. This 
small energetic difference is due to a slight re-
orientation of the side-chain of the residue Phe 
(see figure 6.2A), while the rest of the structure 
showed approximately the same orientation. On 
the other hand, the most populated family of scrP 
(22.92%) showed a relative energy of 1.18 kcal mol-1 
above the global minimum and a relative popu-
lation of 6.38%. It was observed that LPYFDa is 
confrontationally, generally more restricted than 
scrP, with a preference to form folded structures, 
while scrP tended to form semi-extended or fully-
extended conformations. Spatial views of selected 
conformations, for LPYFDa and scrP are shown 
in figure 6.2.94 
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6.3.3  Docking studies
6.3.3.1  Monomeric model
Two potential binding sites were found 
by using a single blind docking run (results not 
shown) on the monomeric Aβ42 molecule (PDB 
code 1IYT), which comprises two α-helix moi-
eties (residues 8-25 and 29-39) connected by a 
loop (residues 26-28). Site I encompasses the resi-
dues 21-26 containing Glu22 and Asp23, which were 
previously identified as residues for aggregation 
of the oligomers (Buchete and Hummer 2007; 
Masman et al. 2009a). Site II includes residues 
6-12 located in the portion of the molecule that 
loses all structural organization after oligomer 
formation, thus forming the so-called disordered 
region. In table 6.2 the two most populated fam-
ilies of the complexes of LPYFDa and scrP with 
the monomeric Aβ42 are summarized. LPYFDa 
showed lower binding energies, while site II was 
in general energetically preferred over site I but 
families on site II poorly populated. In general it 
can be concluded that LPYFDa binds stronger to 
the monomeric Aβ42 than scrP.
6.3.3.2  Pentameric model
As previously reported by Masman et 
al. (Masman et al. 2009a), the Aβ42 aggregates 
contain two β-sheet moieties (β1, residues 18-26 
and β2, residues 31-42) organized into a parallel 
interchain orientation, which were proposed as 
intermolecular binding sites for the pentameric 
conformation. Moreover, a third possible site for 
interactions with ligand molecules was postulat-
ed, which involves the β1 and β2 portions of the 
chain located at the edge of the aggregate. This 
site is orientated into axis of the oligomers, in the 
same direction where the oligomers grows by ag-
gregation. Table 6.2 shows the two most popu-
lated families of the complexes of LPYFDa and 
ScrP with the pentameric Aβ42.
For all the sites proposed, LPYFDa 
showed lower binding energies than scrP. 
Interestingly, both pentapeptide LPYFDa and 
scrP, revealed an energetic preference for site β1. 
LPYFDa was designed on the basis of Soto’s pen-
tapeptide LPFFD, which derives from the amino 
acid sequence Leu17-Val-Phe-Phe-Ala21 of Aβ42, 
being the β1 portion of the aggregate. Figure 6.3 
shows the atomic details of the interactions of the 
best complex (family β1 1, in table 6.2) found be-
tween LPYFDa and the pentameric Aβ42. It can 
be appreciated that the N-terminal of LPYFDa 
formed a double salt bridge with the Glu22’s of the 
second and third chain of the aggregate. Also, a 
second salt bridge links the Lys16 to the Asp resi-
due of LPYFDa. All salt bridges, indicated with a 
block-arrow that points to the positive member of 
the interaction, revealed an interacting distance 
of approximately 3.5 Å. All the ligand-target con-
tacts are depicted as wireframe spheres. An im-
portant hydrophobic pocket was formed between 
the residues Phe20 and Val18 of the aggregate, and 
the residues Leu, Pro and Phe of the pentapeptide 
LPYFDa. This hydrophobic pocket is indicated 
with a dashed line.
Table 6.2: The two most populated families of LPYFDa 
and scrP found by docking simulations on the monomeric 
and pentameric Aβ42 peptide and the corresponding bind-
ing energies (EB, kcal mol-1) of the complexes. The bind-
ing constant (KB, M) and the relative populations (%P) are 
also shown.
     LPYFDa scrP 
     EB  KB
a  %P  EB  KB
a  %P 
M
o
n
o
m
e
r
i
c
 
A
E
4
2
 
Site 
I 
1  -4.42  5.78x10
-4  13.60  -3.67  2.05x10
-3  4.80 
2  -4.35  6.49x10
-4  8.00  -3.18  4.66x10
-3  4.00 
Site 
II 
1  -4.95  2.35x10
-4  6.40  -4.10  9.89x10
-4  3.20 
2  -4.66  3.85x10
-4  3.20  -3.96  1.24x10
-3  2.00 
          
P
e
n
t
a
m
e
r
i
c
 
A
E
4
2
 
TOP 
1  -5.67  6.99x10
-5  5.60  -4.50  5.03x10
-4  5.20 
2  -5.04  2.02x10
-4  3.60  -4.73  3.39x10
-4  3.60 
E1 
1  -8.19  9.88x10
-7  8.80  -6.17  3.00x10
-5  5.20 
2  -7.05  6.75x10
-6  6.80  -5.01  2.11x10
-4  4.40 
E2 
1  -4.75  3.32x10
-4  6.00  -4.68  3.69x10
-4  2.80 
2  -4.77  3.20x10
-4  3.20  -4.92  2.48x10
-4  2.40 
a KB is calculated in with the equation KB=exp((ΔG*1000.)/(Rcal*TK), where ΔG 
is the docking energy, Rcal is 1.98719 and TK is 298.15  95  
chapter 6
Figure 6.3: A steric view of binding between the pentameric Aβ42 model and LPYFDa. Salt bridges are signalized with 
block-arrows. All the ligand-target contacts are depicted as wireframe spheres.
6.3.4  Leu-pro-tyr-phe-asp-nh2 is neuroprotec-
tive against oligomeric aβ42 in vitro
Part of our study was to assess the neuro-
protective potential of the beta-sheet breaker LPYFDa 
against Aβ-induced toxicity. Therefore, we first deter-
mined the toxic effect of the Aβ42 oligomer preparation 
in vitro on cultured primary cortical neurons (PCN). 
Neuronal cultures were exposed to increasing concen-
trations of oligomerized Aβ42 for 24 h, followed by an 
MTT-reduction assay to assess cell viability. The results 
showed a clear Aβ-induced, dose dependent decrease 
in cell survival reaching significance at concentrations 
higher than 10 µM (figure 6.4A). For the subsequent 
experiments we used oligomeric Aβ42 at a concentra-
tion of 25 µM as a toxic stimulus.
Second, we investigated if LPYFDa or the 
control peptide scrP exhibited any toxicity to PCN and 
whether the beta-sheet breaker peptides were capable 
to overcome the toxic effect of oligomeric Aβ42. For this 
purpose PCN were exposed to different concentrations 
of LPYFDa or scrP alone, Aβ42 alone (25 µM) or beta-
sheet breaker peptides and Aβ42 together for 24 h. The 
results showed that LPYFDa and scrP alone were not 
toxic to PCN at any tested concentration (figure 6.4B). 
Furthermore, the control peptide scrP was not able to 
protect the neurons from Aβ-induced toxicity (fig-
ure 6.4C). In contrast, we could demonstrate a dose 
dependent neuroprotective effect of LPYFDa against  
Aβ-induced toxicity, reaching significance at 4 µM 
LPYFDa and higher (figure 6.4D).
6.3.5  A single intrahippocampal injection of 
oligomeric aβ42 induces cognitive defi-
cits in contextual fear conditioning
One hour prior to the training session in 96 
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Figure 6.4: Cell viability of PCN as determined by an MTT-assay. Neurons treated with increasing concentrations of (A) 
Aβ42 or (B) pentapeptides LPYFDa and scrP incubated for 24 h. Neuroprotection by (C) scrP or (D) LPYFDa was deter-
mined by co incubating increasing concentrations of the pentapeptides with 25 μM Aβ42 for 24 h. Bars indicate the mean 
cell viability in % relative to untreated controls ± SEM. (* = significant at p < 0.05).
a contextual fear conditioning paradigm C57BL/6J 
mice received a single injection of oligomeric Aβ42 
(15, 30 or 60 pmol) or vehicle. Injections did not 
affect locomotion or the shock reaction during 
training (data not shown). The vehicle injected 
animals displayed an average relative freezing 
behavior of 58.9± 2.9% which did not differ from 
untreated control animals (61.1± 2.4 %). The mice 
injected with Aβ42 showed a dose dependent de-
crease in freezing behavior (figure 6.5A). 15 
pmol Aβ42 caused an average relative freezing of 
50.0±4.2 % which was not significantly different 
from the vehicle-injected animals. However, the 
mice injected with 30 pmol and 60 pmol of Aβ42 
had significantly reduced freezing scores com-
pared to the vehicle group (36.2± 4.6%; p=0.024 
and 33.3± 5.3%; p=0.037).
Next, we investigated whether LPYFDa 
is able to revert the Aβ-induced memory defi-
cits. Therefore, we injected mice with 150 pmol 
LPYFDa or 150 pmol of the non specific control 
peptide scrP in the presence or absence of 30 pmol 
oligomerized Aβ42 into the hippocampus. The 
LPYFDa and the scrP injected mice showed an av-
erage freezing of 61.1± 5.0% and 63.0± 5.5% which 
did not significantly differ from the untreated 
(61.1± 2.4%) or vehicle injected group (58.9± 2.9%).
However, LPYFDa co-injected with Aβ42 
was able to abolish the Aβ42 oligomer-induced  97  
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memory impairment (57.4± 5.2% vs 36.2± 4.46%; 
p=0.039). Co-injection of Aβ with the control 
peptide scrP, which resulted in an average freez-
ing score of 48.0± 4.9%, did not significantly re-
Figure 6.5: Effect of Aβ42 and LPYFDa on contextual fear conditioning. (A) A single i.h. injection of oligomeric Aβ42 led 
to a dose dependent significant decrease in conditioned fear when compared to a vehicle injection. (B) Co-injection of Aβ42 
with LPYFDa prevented the Aβ-induced memory impairment significantly, whereas the non-specific control peptide scrP 
failed to revert memory deficits. Bars indicate the mean relative freezing score in % ± SEM. Differences were determined 
by ANOVA (* = significant at p < 0.05).
verse the Aβ-induced memory deficits (figure 
6.5B). These results indicate that LPYFDa can 
reverse the detrimental effects of Aβ42 oligomers 
and subsequent impaired memory performance.
 Discussion
In the present study we could show 
that Aβ42 oligomers are toxic to primary cortical 
neurons in culture in a dose-dependent man-
ner (figure 6.4A). These results are in line with 
studies by Dahlgren and colleagues, who re-
ported that the oligomeric form of Aβ42 is 10 fold 
more toxic when compared to the fibrillar form 
(Dahlgren et al. 2002). These and our present 
findings support the growing general view that in 
particular oligomeric Aβ42 peptides contribute to 
the progressive neuronal loss and the associated 
memory impairment observed in AD patients. 
Indeed, several studies showed that elevated levels 
of soluble oligomeric Aβ correlate strongly with 
cognitive decline in AD patients (McLean et al. 
1999; Wang et al. 1999). Walsh et al. observed that 
a low-n oligomeric assembly of naturally secreted 
human Aβ alters hippocampal synaptic plasticity 
by inhibiting long-term potentiation (Walsh et al. 
2002). Also the number of spines was dramatical-
ly decreased when neurons were incubated with 
Aβ oligomers, but not with monomers (Walsh et 
al. 2002). However, the loss in dendritic spines 
could be reverted by treating neurons with an 
anti-Ab antibody (Shankar et al. 2007a).
A possibility to counteract the injuri-
ous effects of oligomeric Aβ is by modulating its 
aggregation. Crucial for the aggregation process 
of the Aβ molecule are the hydrophobic residues 
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(amino acids 17-21: LVFFA) within the internal 
region of the Aβ peptide. Experiments by Hilbich 
and colleagues revealed that replacement of those 
hydrophobic residues by hydrophilic residues re-
sults in impaired fibril formation (Hilbich et al. 
1992). These and other findings eventually led to 
the concept of beta-sheet breakers as therapeutic 
strategy for AD as proposed by Soto et al. (Soto 
1999; Soto et al. 1996). The initially synthesized 
compounds were peptides from 11-5 amino acids 
targeting the center region of the Aβ peptide and 
evolved to compounds like LPFFD (iAβ5) and/
or LPYFDa, which are partially homologous to 
this hydrophobic region and bind with a rela-
tively high affinity to Aβ (Hetenyi et al. 2002a; 
Permanne et al. 2002; van Groen et al. 2009) by 
similar intermolecular interactions, leading to a 
competitive replacement of Aβ molecules. A ma-
jor drawback with peptide drugs for neurologi-
cal disorders is their rapid degradation in vivo by 
proteolytic enzymes and their poor blood-brain 
permeability (Adessi and Soto 2002). This issues 
were overcome by chemical modifications, like 
C-terminal amidation and N-terminal carboxyl-
ation, which resulted in increased half life in vivo 
and rapid brain up-take (Permanne et al. 2002). 
Although, we learned a lot about the biochemistry 
in respect to catabolism and brain uptake of cer-
tain aggregation inhibitor peptides, the detailed 
mechanism of action is still poorly understood. 
Therefore, it is important to elucidate and to study 
the three dimensional structure of the Aβ pep-
tide/aggregation inhibiting peptide complex to 
gain more insight into the molecular dynamics of 
the Aβ aggregation process.
We used computational modeling and 
docking experiments to address this question. 
Interestingly our docking results showed that 
LPYFDa binds preferably to the β1 portion of the 
aggregate (table 6.2 and figure 6.3), which has 
a good correlation with the design of this penta-
peptide, since LPYFDa derives from the wild-type 
sequence Leu17-Val-Phe-Phe-Ala21 of Aβ42, which 
is contained in this portion of the aggregate. Our 
docking results did not show any binding prefer-
ence of LPYFDa (nor scrP) for the monomeric or 
the pentameric Aβ.
In the present study we showed that 
the pentapeptide LPYFDa can protect cultured 
neurons from oligomeric Aβ-induced cell death. 
Datki et al. reported similar results on neuro-
nal-like cell lines, e.g. SHSY-5Y cells. They could 
show that a 5-fold molar excess of LPYFDa pro-
tects these cells from toxic effects of fibrillar Aβ 
(Datki et al. 2004; Fulop et al. 2004). In our study 
we could confirm that a molar excess of LPYFDa 
can protect against Aβ42 mediated neurotoxicity. 
Moreover, we could demonstrate a dose depen-
dent protective effect of LPYFDa and that this 
pentapeptide already has significant neuropro-
tective properties even with a 6-fold molar excess 
of oligomeric Aβ42. Our results also in agree-
ment with other studies reporting protection by 
LPYFDa against the rapid neuromodulatory ac-
tion of fibrillar Aβ42 demonstrated by in vitro and 
in vivo electrophysiology (Szegedi et al. 2005).
We found that a single bilateral intra-
hippocampal injection of oligomeric Aβ42 impairs 
memory formation if applied 1 h before the train-
ing session in a contextual fear conditioning par-
adigm. Our findings are in line with several other 
studies, which consistently report on memory 
deficits after intracerebral injections of Aβ42 pep-
tides, although the experimental conditions vary 
in terms of the injected peptide, injection proce-
dure and behavioral tasks employed (Ammassari-
Teule et al. 2002; Christensen et al. 2008; Harkany 
et al. 2001; Malin et al. 2001; Nakamura et al. 
2001; O’Hare et al. 1999). It should be noted that 
these injections obviously lead to Aβ levels be-
yond the basal levels necessary for proper synap-
tic functioning. Garcia-Osta showed that neutral-
ization of endogenous Aβ by an anti-Aβ antibody 
resulted in a memory impairment which implies 
that physiological soluble Aβ levels are required 
for proper memory function (Garcia-Osta and 
Alberini 2009). 99  
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The peptide LPFFD, which was designed 
by the Soto group was able to prevent fibrillogene-
sis in a rat brain model (Soto et al. 1998) and to re-
duce Aβ deposition in transgenic mice (Permanne 
et al. 2002). Most interestingly, iAβ5p was shown 
to reverse the memory impairment caused by in-
trahippocampal injections of Aβ fibrills in rats 
(Chacon et al. 2004). However, these studies did 
not reveal whether impairment of learning and 
memory after oligomeric Aβ injections could be 
counteracted by such compounds. An important 
novelty of our study is that we used Aβ oligomers 
instead of the less effective Aβ fibrills. Therefore, 
an important aim of our study was to establish if 
a compound like LPYFDa is able to prevent Aβ 
oligomer–induced learning and memory deficits. 
We showed that a 5-fold molar excess of LPYFDa 
to Aβ could overcome the detrimental effects of 
Aβ oligomers on memory. Thus, we provide evi-
dence that so-called beta-sheet breaker peptides 
such as LPYFDa bear therapeutic potential against 
Aβ-induced memory impairment. Moreover, it 
was recently demonstrated that intraperitoneally 
administered LPYFDa is able to cross the blood 
brain barrier and protects synapses against excit-
atory action of fibrillar Aβ (Juhasz et al. 2009).
The mechanism how these penta-
peptides exert their protective effects on cell 
death and behavior is not yet fully understood. 
However, it should be noted that the two actions 
of Aβ reported here, namely, the neuronal degen-
eration following application of Aβ oligomers in 
vitro and memory loss following injections of Aβ 
oligomers in vivo may be unrelated. In hippocam-
pal tissue extracted one hour after Aβ injection 
we were unable to detect any caspase-3 cleavage 
which would indicate apoptotic cell death (data 
not shown). Furthermore, there are no studies 
so far that show toxic effects of oligomeric Aβ on 
neurons in vivo. Therefore, the effects on memory 
following an hour post-injection may not have 
a direct correlation with neuronal degenera-
tion, but could simply reflect the effects of Aβ on 
synapses. It is well documented that the main 
effects of Aβ on synapses are inhibition of LTP 
(Chapman et al. 1999a; Kamenetz et al. 2003) and 
elimination of post synaptic glutamate receptors 
(Almeida et al. 2005; Chang et al. 2006; Ting et 
al. 2007). Remarkably, the Aβ induced synaptic 
dysfunction occurs rather rapidly, starting with 
20 minutes after application, and does not need 
chronic exposure (Chen et al. 2000; Chen et al. 
2002; Townsend et al. 2006; Wang et al. 2004).
Furthermore, it is likely that the in-
jected oligomeric Aβ does not remain unchanged 
in terms of its conformation, and the effects on 
memory may be due to changes of Aβ to other 
conformations. The importance of the Aβ confor-
mation on memory was demonstrated by Lesne et 
al (Lesne et al. 2006), who showed that only spe-
cific Aβ protein assemblies in the brain are able to 
impair memory (Lesne et al. 2006).
It remains elusive whether aggregation 
inhibiting peptides like LPYFDa directly bind to 
Aβ, and thereby prevent possible interactions be-
tween Aβ and neuronal membrane proteins, and 
in this way neutralize its toxic effect. We could 
consider two options of interaction with Aβ, 1) 
the pentapeptides bind to the monomeric Aβ, 
thus preventing and/or retarding the formation of 
toxic oligomers, and 2) the pentapeptides bind the 
Aβ oligomers already formed preventing and/or 
modulating, somehow, its neurotoxic properties. 
On the other hand, both above mentioned pos-
sibilities might act simultaneously comprising a 
third possible way of action of this peptide toward 
its neuroprotective effects.
Being aware of the many possible bio-
logical pathways that these peptides might follow 
while inducing neuroprotection, it is interesting 
to see whether these peptides show a preference to 
bind the monomeric Aβ or its soluble oligomers. 
Previous studies using CD spectrometry and 
molecular docking studies have been carried out 
on LPYFDa and other so-called β-sheet breaker 100 
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peptides (Datki et al. 2004; Hetenyi et al. 2002a; 
Hetenyi et al. 2002b; Laczko et al. 2008) but none 
of them so far have demonstrated proof at the mo-
lecular level of the β-sheet breaking properties of 
these peptides. We also might consider the pos-
sibility that these peptides might act as “glue” that 
promote elongation to biologically inert larger 
aggregates, or conversely, bind to the monomeric 
Aβ and this way inhibits oligomer formation. By 
either of these actions, or both, the neurotoxicity 
of Aβ is decreased or reverted.
In summary our findings provide evi-
dence on how and where LPYFD interacts with 
Aβ mono- and oligomers, that LPYFDa neutral-
izes the neurotoxic activity of soluble Aβ oligo-
mers, and in the present conditions can effectively 
prevent the oligomer-induced deficits in memory 
performance. ■
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“Ausencia. Habré de levantar la vasta vida
que aún ahora es tu espejo:
cada mañana habré de reconstruirla.
Desde que te alejaste,
cuántos lugares se han tornado vanos
y sin sentido, iguales
a luces en el día.
Tardes que fueron  nichos de tu imagen,
músicas en que siempre me aguardabas;
palabras de aquel tiempo,
yo tendré que quebrarlas con mis manos.
¿En qué hondonada esconderé mi alma
para que no vea tu ausencia
que como un sol terrible, sin ocaso,
brilla definitiva y despiadada?
Tu ausencia me rodea
como la cuerda a la garganta,
el mar al que se hunde.“
(J.L. Borges)Neuroprotective action & neutralization of aβ42-induced 
memory impairment by a novel in silico designed n-methyl 
amino acids containing peptide
Marcelo F. Masman, Ivica Granic, Sebastian A. Andujar, Pieter J.W. Naude, Ulrich L.M. Eisel, 
Ricardo D. Enriz, Siewert Jan Marrink & Paul G.M. Luiten
Chapter 7
Abstract
We report the in silico design and the neuroprotective properties of Aβ42 derived synthetic N-methyl 
amino acids containing penta-peptide Ac-Lys-(Me)Ile-Ile-(Me)Gly-Leu-NH2. These data demonstrate 
the ability of this novel peptide to interact with different regions of Aβ42 which may be targeted se-
lectively. Furthermore, this study provides proof of principle that this rationally designed peptide has 
protective properties against the neurotoxic effects of oligomeric Aβ42 in vitro and in vivo. This peptide 
can serve as a crucial molecular model design for development of therapeutic molecules for treatment 
of Alzheimer’s disease.
Article in preparation to submission 
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7.1
 Introduction
Alzheimer’s disease  (AD) is a com-
plex multifactorial neurodegenerative syndrome 
characterized by the patient’s memory loss and 
impairment of a wide range of cognitive abili-
ties. This devastating disease affects more than 20 
million people worldwide and, as a consequence 
of the worlds aging population, the prevalence 
of AD is expected to increase to endemic dimen-
sions both in developed and developing nations 
(Blennow et al. 2006; Pratico and Delanty 2000). 
AD is the most extensively studied amyloid-based 
disease, whose main hallmarks are characterized 
by pathological high levels of amyloid deposits in 
frontal brain regions (senile or amyloid or neu-
ritic plaques) and neurofibrillary tangles (Haass 
and Selkoe 2007; Holtzman and Mobley 1991). 
The major components of senile plaques are small 
peptides of 39-43 amino acids called β-amyloid 
(Aβ) which are produced through endoprote-
olysis of the amyloid precursor protein (APP). 
During the pathogenesis of AD the equilibrium 
of Aβ production and Aβ clearance is disturbed, 
which eventually leads to elevated Aβ levels, in-
creased Aβ aggregation and consequently im-
paired memory function (Wasling et al. 2009). 
Recent evidence now indicates that particularly 
soluble oligomeric forms of Aβ42 are to be consid-
ered as the most toxic form of this peptide, and 
correlate well with the progression and cognitive 
decline of the disease (Lesne et al. 2006; Wasling 
et al. 2009)
Due to the high incidence that AD 
has in the human aging population, there is an 
evident need of therapeutic agents that could at 
least significantly delay the course of the disease 
(Hardy and Selkoe 2002; Wolfe 2002). Several 
research strategies currently attempt to develop 
therapies and therapeutic agents that aim to re-
duce Aβ production, enhancing its clearance and/
or preventing or retarding the amyloidogenic 
processes. Amongst them, the use of peptides 
or peptidomimetic molecules derived from the 
Aβ sequence is particularly appealing (Granic 
et al. 2009; Soto et al. 1998; Tjernberg et al. 1996; 
Wolfe 2002). Promising putative treatments may 
be those designed to inhibit steps that precede Aβ 
peptide aggregation, by blocking the production 
of toxic soluble Aβ oligomers in the first place, or 
by reversing, somehow, the toxic effect of these 
soluble oligomers (figure 7.1).
In fact, some short peptides that are de-
rived from the Aβ sequence have already been re-
ported to specifically interact with Aβ and cause 
interferences with its neurotoxic effects. LPFFD 
(Soto et al. 1996; Soto et al. 1998), KLVFF (Hetenyi 
et al. 2002b; Tjernberg et al. 1997; Tjernberg et al. 
1996), RIIGLa (Fulop et al. 2004) and LPYFDa 
(Datki et al. 2003; Datki et al. 2004; Granic et 
al. 2009; Juhasz et al. 2009; Szegedi et al. 2005) 
are some of the promising starting points to de-
velop potential drugs that can somehow reverse 
the negative impacts of soluble Aβ aggregates, al-
though their underlying molecular mechanisms 
remain partly elusive. In order to increase the 
anti-amyloidogenic properties of these peptides, 
a new strategy was recently explored with the 
introduction of N-methyl amino acids in these 
sequences (Cruz et al. 2004; Gordon et al. 2001; 
Gordon et al. 2002). N-Methyl amino acids have 
been used in several systems to control, or prevent 
the aggregation of β-sheet and β-strand peptides 
(Chitnumsub et al. 1999; Clark et al. 1998; Doig 
1997; Hughes et al. 2000; Nesloney and Kelly 1996; 
Rajarathnam et al. 1994). The goal of this modifi-
cation is to block the hydrogen bond network that 
stabilizes the β-sheet amyloid structure and this 
way to inhibit the formation of toxic oligomers 
and/or amyloid aggregates.
In the present study, we report the in silico 
design of a new Aβ-derived synthetic penta-peptide 
Ac-Lys-Ile-Ile-Gly-Leu-NH2 (PN20) and its chemically 
modified version; Ac-Lys-(Me)Ile-Ile-(Me)Gly-Leu-
NH2 (PN22), which contains alternated N-methyl ami-
no acids (scheme 7.1). The protective property of these 106 
ac-lys-(me)ile-ile-(me)gly-leu-nh2 against the neurotoxic effects of aβ42
peptides against the neurotoxic effects of soluble Aβ42 
oligomers was investigated in cultured mouse primary 
cortical neurons (PCN). Furthermore, we explored in 
a previously established in vivo model of Aβ injections 
directly into the hippocampus of mice whether PN22 
exerts beneficial action against the Aβ-induced cogni-
tive deficits (Granic et al. 2009). Ultimately, we intend-
ed to reveal some of the putative mechanism of action 
of these chemically modified peptides by employing 
molecular modeling techniques.
These peptides were designed based on the 
observations of the conformational behavior of the Aβ42 
aggregates  in silico previously reported by Masman 
and coworkers (Masman et al. 2009a). The portion β2 
of these aggregates, specifically the highly hydrophobic 
sequence Ala30-Ile31-Ile32-Gly33-Leu34, was the starting 
point of the present design.
7.1.1  Rational in silico design of pn20 and pn22
In this study we rationally designed two 
novel aggregation modulating peptides (PN20 and 
PN22). Their in silico design was based on the confor-
mational behavior of Aβ42 aggregates, which was previ-
ously reported by Masman and coworkers (Masman et 
al. 2009a). The so-called β2 portion of these aggregates, 
specifically the highly hydrophobic sequence Ala30-
Ile31-Ile32-Gly33-Leu34, was the starting point of this 
design. Due to its hydrophobic nature some chemical 
modifications were applied to the peptides in order to 
increase the solubility of the final peptides. Thus, the 
first modification was the change of the Ala residue 
to Lys. A positively charged residue not only increases 
the water solubility of the peptides but also offers the 
possibility of targeting important negatively charged 
residues that play a crucial role in the stabilization of 
the aggregated Aβ42 oligomers, e.g. Glu22 and Asp23. A 
posteriori, the N- and C-terminal were blocked by acet-
ylation and amidation respectively. This provides some 
advantages: (i) peptide ends are uncharged (no zwit-
terionic), thus we have a better control on the charges 
that take place in a biological medium; (ii) increased 
biological membrane permeability and cell penetra-
tion; (iii) the stability and resistance towards digestion 
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Figure 7.1: Simplified schematic representation of the up-stream amyloid assembly process that leads to neuronal cyto-
toxicity. In disease states, the mechanisms of Aβ production and it clearance is unbalance causing that soluble Aβ mono-
mers undergo aggregation to form various intermediates consisting of different forms of multimeric Aβ oligomers that, 
somehow, performers negative effect on brain cells. Aβ oligomers subsequently assemble to generate insoluble fibrils that 
accumulate in the affected tissues or organs (pathway no shown). Compounds that inhibit formation of these undesirable 
species may, therefore, be capable of protecting tissues or organs from their toxic effects. Two possible inhibition pathways 
are depicted. Pathway 1 shows an up-stream intervention of a putative drug. Thus, this drug may stop or retard the amy-
loigenic process by preventing the conformational change of the Aβ monomers that leads to toxic Aβ aggregates. Pathway 
2 shows the intervention of a putative drug that, somehow, blocks the toxic effects of Aβ oligomers and might also reverse 
the amyloidic assembly process. 107  
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7.2
by aminopeptidases is enhanced; and (iv) peptide ends 
are blocked against synthetase activities. Moreover, 
C-terminal amidation is essential to the biological ac-
tivity of many neuropeptides and hormones (Fricker 
2005; Kim and Seong 2001). These two modifications 
were our guiding principle to the design of PN20.
In fact, a possibility to counteract the detri-
mental effects of oligomeric Aβ is by modulating its ag-
gregation process. A very appealing strategy to endow 
peptides with aggregation modulating properties is 
the incorporation of non-natural amino acids to their 
sequence. Such is the case of N-methyl amino acids 
containing peptides. When the N-methyl amino acids 
residues are located in an alternated fashion into the 
peptide sequence, and the peptide has the possibility to 
form extended conformations, e.g. β-sheets, two differ-
ent “faces” are expressed. On the one hand, one of the 
faces has all the normal H-bonding possibilities that 
a natural peptide has (the so-called “rich H-bonding 
face”). On the other hand, the other face is limited 
on H-bonding possibilities due to the presence of the 
N-methyl groups (scheme 7.1). Thus, the incorporation 
of N-methyl-L-isoleusine and N-methyl-glycine (or sar-
cosine) in position 2 and 4 respectively, by replacement 
of their natural analogs, led us to PN22.
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Scheme 7.1: Schematic representation of the chemical structure of PN20 and PN22. Backbone torsional angles and the 
distance Cα
Lys/Cα
Leu are also shown. For the case of PN22 the “poor and rich H-bonding faces” are shown.
  Material and methods
7.2.1  Molecular modeling
7.2.1.1  Stochastic conformational search. 
EDMC calculations
The conformational space of the penta-
peptides PN20 and PN22 was explored using the 
method previously employed by Liwo et al. (Liwo 
et al. 1996a) which includes the electrostatically 
driven Monte Carlo (EDMC) method (Ripoll 
and Scheraga 1988, 1990) implemented in the 
ECEPPAK package. Conformational energy was 
evaluated using the ECEPP/3 force field (Némethy 
et al. 1992). Hydration energy was evaluated us-
ing a hydration-shell model with a solvent sphere 
radius of 1.4 Å and atomic hydration parameters 
that have been optimized using nonpeptide data 108 
ac-lys-(me)ile-ile-(me)gly-leu-nh2 against the neurotoxic effects of aβ42
(SRFOPT) (Vila et al. 1991; Williams et al. 1992). 
In order to explore the conformational space ex-
tensively, we carried out 20 different runs, each of 
them with a different random number. Therefore, 
we collected a total of 5000 accepted conforma-
tions. Each EDMC run was terminated after 250 
energy-minimized conformations had been ac-
cepted. The parameters controlling the runs 
were the following: a temperature of 298.15 K was 
chosen for the simulations. A temperature jump 
of 50,000 K was used; the maximum number of 
allowed repetitions of the same minimum was 
50. The maximum number of electrostatically 
predicted conformations per iteration was 400; 
the maximum number of random-generated con-
formations per iteration was 100; the fraction of 
random/electrostically predicted conformations 
was 0.30. The maximum number of steps at one 
increased temperature was 20; and the maximum 
number of rejected conformations until a tem-
perature jump was executed was 100. Only trans 
peptide bonds (ω ≈ 180°) were considered. All ac-
cepted conformations were then clustered into 
families using the program ANALYZE (Meadows 
et al. 1994a; Pohorille and Pratt 1990) by applying 
the minimal-tree clustering algorithm for separa-
tion, using all heavy atoms, energy threshold of 
30 kcal mol-1, and RMSD of 0.75 Å as separation 
criteria. This clustering step allows a substantial 
reduction of the number of conformations and 
the elimination of repetitions. A more detailed 
description of the procedure used here is given 
in section 4.4 Computational methods   of  
(Masman et al. 2009b).
7.2.1.2  Molecular dynamics simulations
The most populated conformation of 
PN20 and PN22 obtained from the EDMC were 
embedded in a cubic box containing SPC waters, 
(Berendsen et al. 1981b) leaving at least 10 Å be-
tween the solutes and the edge of the box. The total 
number of water molecules varied between 15630 
and 25919. Cl- ions were added to the systems by 
replacing water molecules in random positions, 
thus making the whole system neutral. Multiple 
simulations were performed for each system, 
starting from different initial random velocity 
distributions. Details of the equilibration proce-
dure can be found in the Suppl. Information. For 
each system 10 ns production runs were obtained 
and analyzed. The coordinates were saved every 2 
ps. Molecular dynamics (MD) simulations were 
performed using the GROMACS 3.3.2 package of 
programs (Van Der Spoel et al. 2005), with the 
OPLS-AA force field (Kaminski et al. 2001). The 
simulations were run under NPT conditions, us-
ing Berendsen’s coupling algorithm (Berendsen et 
al. 1984) for keeping the temperature and pressure 
constant (P = 1 bar, τP = 0.5 ps; T = 310 K, τT = 0.1 
ps). The LINCS algorithm (Hess et al. 1997) was 
used to constrain the lengths of hydrogen con-
taining bonds; the waters were restrained using 
the SETTLE algorithm (Miyamoto and Kollman 
1992). The time step for the simulations was 0.002 
ps and the compressibility 4.8x10-5 bar-1. Van der 
Waals forces were treated using a 1.2 nm cutoff. 
Long-range electrostatic forces were treated using 
the particle mesh Ewald method (PME) (Darden 
et al. 1993a). The analysis of the simulations was 
performed using the analysis tools provided in 
the Gromacs package. The root mean square de-
viation (RMSD) of backbone atoms, the total and 
potential energies were calculated. The root mean 
square fluctuation (RMSF) of the backbone at-
oms and the hydrophilic, hydrophobic and total 
Solvent Accessible Surface Area (SASA) were also 
determined. The total number of hydrogen bonds 
in the peptide group were quantified by counting 
acceptor and donor atom pairs that are not fur-
ther apart than 0.35 nm. All molecular graphical 
presentations were created by VMD (Humphrey 
et al. 1996) and/or UCSF Chimera (Pettersen et al. 
2004a) packages. The standard deviation of every 
given value is shown in between brackets.
7.2.1.3  Docking studies
Two models for Aβ were used as tar-
get systems; the monomeric Aβ42 elucidated by  109  
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Crescenzi et al (monomeric model) (Crescenzi 
et al. 2002), PDB code 1IYT, and the pentam-
eric aggregate Aβ42 developed by Masman et al 
(pentameric model) (Masman et al. 2009a). The 
structures were prepared for docking study as 
follows: for the Aβ42 molecules, water molecules 
were removed from the PDB file and hydrogen 
atoms were added; Gasteiger charges, atomic sol-
vation parameters and fragmental volumes were 
merged to the target system. For all peptides, the 
structure of the most populated family (results 
from the EDMC calculations) was taken as initial 
conformation. Gasteiger charges were assigned 
and non-polar hydrogen atoms were merged. All 
torsions were allowed to rotate during docking. 
The docking energy grid was produced with the 
auxiliary program AutoGrid. The grid dimen-
sions were 61x61x61 for the monomeric model, 
and 90x60x60 for the pentameric model, points 
along the x-, y- and z-axes, with points separated 
by 0.375Å. The grids were chosen to be sufficiently 
large to cover significant portions of the putative 
binding sites. The center of the pentapeptide was 
positioned at the grid center. All graphic manip-
ulations and visualizations were performed by 
means of the AutoDock Tools (Sanner 1999) and 
the Chimera (Pettersen et al. 2004a) programs, 
and ligand docking with AUTODOCK 4 (Morris 
et al. 2009). The Lamarckian genetic algorithm 
was utilized and the energy evaluations were set 
at 2.5x106. A total of 250 accepted conformations 
were collected. Other parameters were set to de-
fault values.
7.2.2  Experimental section
7.2.2.1 Compounds
The peptides Ac-Lys-Ile-Ile-Gly-Leu-
NH2 (PN20), Pro-Asp-Tyr-Leu-Phe-NH2 (scrP) 
and Amyloid β peptide 1−42 (Aβ42) were pur-
chased from EZBiolab Inc.(Carmel, USA). Anti-
Aβ antibody (6E10) was obtained from Covance 
(Emeryville, USA). The peptide Ac-Lys-(Me)Ile-
Ile-(Me)Gly-Leu-NH2 (PN22) was purchased from 
AnaSpec Inc (San Jose, CA, USA). HPLC purity 
higher than 95% was described for all peptides 
used here. Other compounds used in this study 
were purchased from Invitrogen (Carlsbad, USA) 
or Sigma-Aldrich Corporation (St. Louis, USA).
7.2.2.2  Preparation of aβ42-oligomers
Oligomeric Aβ42 was prepared as de-
scribed by Granic and colleagues (Granic et al. 
2009). Also, the aggregational state and the sec-
ondary structure of the oligomeric Aβ42 prepa-
ration were examined by sodium dodecyl sul-
fate (SDS)-PAGE Western blotting and Circular 
Dichroism (CD) spectrometry. For a more de-
tailed description of the methodology used here, 
see Granic et al. (2009).
7.2.3  In vitro testing
7.2.3.1  Primary cortical neuron culture
Primary cortical neurons were prepared 
from embryonic brains (E14) of C57Bl/6J mice. 
The cortices were carefully dissected, meninges 
were removed and the neurons separated by trit-
uration. Cells were plated on poly-D-lysine pre-
coated plates at a density of 1.2 x 105 cells/well (96 
well plates). Neurobasal medium supplemented 
with 2% (v/v) B27-supplement, 0.5 mM glutamine 
and 1% (v/v) penicillin/streptomycin was used 
as a culture medium. After 48 h neurons were 
treated with 10 μM cytosine arabinoside for an-
other 48 h to inhibit non-neuronal cell growth. 
Subsequently, the medium was completely ex-
changed and after 6 days of in vitro culture, the 
neurons were used for experiments.
7.2.3.2  Treatment of cells
Possible toxicity of the penta-peptides 
used here and Aβ42 oligomers was determined by 
incubating neuronal cultures for 24 h with differ-
ent concentrations of the peptide solutions. The 
neuroprotective effect of PN20 and PN22 was as-
sessed by incubating neurons (cultured in 96 well 
plates) for 24 h with 25 µM oligomeric Aβ in the 
presence or absence of different concentrations of 110 
ac-lys-(me)ile-ile-(me)gly-leu-nh2 against the neurotoxic effects of aβ42
PN20 or PN22 peptides. After treatments, the me-
dium was completely exchanged, and 24 h later, 
the cell viability determined by an MTT-assay. 
All treatments were performed in triplicates and 
the experiments were repeated at least two times.
7.2.3.3  Determination of cell viability by mtt-assay
Neuronal viability was determined by 
the colorimetric MTT [3-(4,5-dimethylthiazol-
2-yl-)2,5-diphenyltetrazolium bromide] assay as 
described previously (Mosmann 1983). 1.25 mg/
ml MTT solution was added to each well of a 96 
well plate. After 2 h of incubation, cells were lysed 
in acidic propan-2-ol solution (37% HCl/ pro-
pan-2-ol: 1/166). The absorbance of each well was 
measured with an automated ELISA plate reader 
(Bio-Rad, Munich, Germany) at 595 nm with a 
reference filter at 630 nm.
7.2.4  In vivo testing
7.2.4.1 Animals
Behavioral experiments were performed 
with 9–12 weeks old male C57Bl/6J mice (Harlan, 
Horst, The Netherlands). Individually housed 
mice were maintained on a 12 h light/dark cycle 
(lights on at 7.00 a.m.) with food (Hopefarms, 
standard rodent pellets) and water ad libitum. A 
layer of sawdust served as bedding. The animals 
were allowed to adapt to the housing conditions 
for 1–2 weeks before the experiments started. The 
procedures concerning animal care and treat-
ment were in accordance with the regulations 
of the Ethical Committee for the use of experi-
mental animals of the University of Groningen 
(License number DEC4668D).
7.2.4.2  Animal surgery
Double guide cannulae type C235 
(Plastics One, Roanoke, USA) were implanted in 
the brain using a Kopf stereotactic instrument 
during Hypnorm/Midazolam (10 ml/kg, i.p.) an-
esthesia under aseptic conditions as previously 
described (Nijholt et al. 2008) with anteroposte-
rior (AP) coordinates zeroed at Bregma directed 
toward both dorsal hippocampi (i.h.), AP -1.5 mm, 
lateral 1 mm, depth 2 mm (Franklin and Paxinos 
1997). Each double guide cannula with inserted 
dummy cannula and dust cap was fixed to the 
skull with dental cement (3M ESPE AG, Seefeld, 
Germany). Administration of 1 mg/ml finadyne 
(2.5 mg/kg s.c.) before the surgery served as anal-
gesic. The animals were allowed to recover for 6–7 
days before the behavioral test.
7.2.4.3  Intrahippocampal injections
Bilateral i.h. injections were per-
formed under short isoflurane anesthesia using a 
Hamilton microsyringe fitted to a syringe pump 
unit (TSE systems, Bad Homburg, Germany) at 
a constant rate of 0.3 µl/min (final volume: 0.3 µl 
per side). Oligomerized Aβ42 was injected in a fi-
nal concentration of 30 pmol and PN22 or scrP in 
a final concentration of 150 pmol into the dorsal 
hippocampus. PBS (pH 7.5) served as vehicle. ScrP 
was used as a sequence control peptide. One hour 
after the injection the animals were subjected to a 
training session in a fear conditioning paradigm 
(scheme 7.2). The number of animals per group 
varied from 7 to 10.
7.2.4.4  Fear conditioning
Fear conditioning was performed in a 
plexiglas cage (44x22x44 cm) with constant illu-
mination (12 V, 10W halogen lamp, 100–500 lux). 
The training (conditioning) consisted of a single 
trial. Before each individual mouse entered the 
box, the box was cleaned with 70% ethanol. The 
Scheme 7.2: Schematic outline of the experimental in vivo 
setup. C57BL/6J mice were cannulated 7 days prior i.h. 
injection with oligomerized Aβ42 and/or aggregation in-
hibiting peptides. One hour after the injection the animals 
were trained in a contextual fear conditioning paradigm. 
24 h after the training session memory performance was 
assessed. 111  
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mouse was exposed to the conditioning context 
for 180 s followed by a scrambled footshock (0.7 
mA, 2 s, constant current) delivered through a 
stainless steel grid floor. The mouse was removed 
from the fear conditioning box 30 s after shock 
termination to avoid an aversive association with 
the handling procedure. Memory tests were per-
formed 24 h after fear conditioning. Contextual 
memory was tested in the fear conditioning 
box for 180 s without footshock presentation. 
Freezing, defined as the lack of movement except 
for respiration and heart beat, was assessed as 
the behavioral parameter of the defensive reac-
tion of mice by a time-sampling procedure every 
10 s throughout memory tests. In addition, mean 
activity of the animal during the training and 
retention test was measured with the Ethovision 
system (Noldus, Wageningen, The Netherlands). 
Immediately after the behavioral test mice were 
injected i.h. with methylene blue solution dur-
ing sodium-pentobarbital anesthesia (0.1 ml/ 10g, 
i.p.). Brains were removed and serially sectioned 
at 50 µm. Sections were stained on glass for 5 min 
in 0.1% nuclear fast red solution. To identify the 
location of the injection, sections were analyzed 
using light microscopy. Only data from animals 
in which the proper intrahippocampal site of in-
jection was confirmed, were evaluated.
7.2.5  Statistical analysis
Behavioral data were analyzed by 
analysis of variance (ANOVA) followed by the 
Bonferroni post-hoc test to determine statistical 
significance. For statistical analysis of the MTT 
assays, an unpaired Student’s t test with unequal 
variance was used. A p-value *< 0.05 was consid-
ered to be statistically significant. A p-value **< 
0.005 was considered to be highly significant. 
Data are presented as mean value ± standard er-
ror of the mean (SEM).
 Results
7.3.1  Molecular modeling
7.3.1.1  Stochastic conformational search 
in solution. Edmc calculations
In order to have a better view at the 
molecular level, it is crucial to assess the confor-
mational behavior of PN20 and PN22 in solution. 
Therefore, all peptides were selected for energy 
calculations to determine the relevant conforma-
tions. The results of the theoretical calculations 
are summarized in table 7.1S in appendix A. 
Calculations yielded a large set of conformational 
families for each peptide studied. The total num-
ber of conformations generated was 70236 and 
79077, for PN20 and PN22 respectively, whereof 
5000 conformations for each pentapeptide were 
accepted. In the clustering procedure, an R.M.S.D 
(Root Mean Square Deviation) of 0.75 Å and a ΔE 
of 30 kcal mol-1 were used. The number of families 
after clustering was 703 and 409, for PN20 and 
PN22, respectively. The total number of families 
accepted with a relative population higher than 
  Lys  Ile/(Me)Ile  Ile  Gly/(Me)Gly  Leu 
d C
α
Lys/C
α
Leu    I1  \1  I2  \2  I3  \3  I4  \4  I5  \5 
P
N
2
0
  1  -77.93 -26.75 -77.76 -36.70 -76.80 -39.50  95.11  49.13  -76.76 -34.73 6.39 
2  -89.21 -48.10 -92.61 -50.83 -154.25  138.47 -83.89  67.60  -78.96 -41.85 9.91 
3  -74.25 -24.36 -79.41 -32.43 -76.68 -54.86  150.07  70.85  -71.13 -41.12 4.83 
P
N
2
2
  1  -150.42  75.40  -120.16  79.15  -140.85  73.54 -80.59  71.04  -82.85 -33.07  11.20 
2  -150.36  75.98  -117.73  83.13  -151.48  75.78 -100.57  47.66  -77.99 -34.30  11.47 
3  -150.42  76.58  -116.92  81.14  55.16  68.55 -93.90  58.60  -81.90 -32.94 9.62 
Table 7.1: Backbone tortional angles of the three most populated families for PN20 and PN22 found at the EDMC/
SRFOPT/ECCEP/3 level of theory. All angles values are given in degrees. The distance (d Cα
Lys/ Cα
Leu, Å) between the Cα 
atoms of residue Lys1 and residue Leu5 is also shown.112 
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0.50% was 30 and 11, for PN20 and PN22, resp. 
that sum up to ca 85% of all conformations. All 
low-energy conformers of pentapeptides studied 
here were then compared to each other. The com-
parison involved the spatial arrangements, rela-
tive energy and populations. The PN20 evaluation 
showed that the most populated family (24.20%) 
is also the energetically preferred one, while its 
second most populated family (5.52%) has a rela-
tive energy of 2.55 kcal mol-1 above the global min-
imum. The third most populated family (3.76%) 
shows a relative energy of 1.66 kcal mol-1 above 
the global minimum. On the other hand, the 
most populated family of PN22 (62.38%) is also the 
global minimum, while its second most populated 
family showed a relative energy of 0.57 kcal mol-1 
above the global minimum and a relative popu-
lation of 8.50%. The third most populated fam-
ily (5.20%) has a relative energy of 0.61 kcal mol-1 
above the global minimum. It was observed that 
PN20 possesses a marked tendency to form folded 
conformations while PN22 shows high preference 
to form semi-extended or fully-extended con-
formations. Table 7.1 shows the values of f and 
y torsional angles for the three most populated 
families of PN20 and PN22. Spatial overlapped 
stereoviews of selected conformations, for PN20 
and PN22 are shown in figure 7.2.
7.3.1.2  Molecular dynamics
PN20 and PN22 were examined by MD 
due to the need of exploring their conformation-
al behavior in a more realistic system by means 
of an explicit solvent. Figure 7.3 shows the dis-
tance between the Cα atoms of residues Lys1 and 
Leu5 (d Cα
Lys/ Cα
Leu) as a function of the simula-
tion time for PN20 and PN22. This parameter is 
a clear and easy way of depicting the conforma-
tional preferences of these peptides. In this figure, 
it is observed that PN20 prefers folded conforma-
tion with a d Cα
Lys/ Cα
Leu= 4.22(0.49) Å while PN22 
showed a marked preference to extended confor-
mations (d Cα
Lys/ Cα
Leu= 12.25(1.08) Å).
Figure 7.2: Stereoview of the three most populated families for PN20 and PN22 optimized at EDMC/SRFOPT/ECCEP/3 
level of theory. (A) Overlapped geometries of family 1 (ΔE = 0.00 cal mol-1, white), family 2 (ΔE = 2.55 kcal mol-1, magenta) 
and family 3 (ΔE= 1.66 kcal mol-1, cyan) for PN20. (B) Overlapped geometries of family 1 (ΔE = 0.00 kcal mol-1, white), fam-
ily 2 (ΔE= 0.57 kcal mol-1, magenta) and family 3 (ΔE= 0.61 kcal mol-1, cyan) for PN22. All hydrogen atoms and side-chains 
have been deleted for more clarity. N-Methyl groups are depicted in ball-and-stick model.
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Figure 7.3: Distance between Cα atoms of residues Lys1 
and Leu5 as a function of simulation time. The maximum 
ideal (for a fully extended conformation, where all φ and 
ψ ≈ 180º) distance between the above mentioned atoms is 
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to bind either Site I or Site II. PN20 obviously 
binds both sites unselectively and with more or 
less the same intensity. On the other hand, the 
most populated conformations of PN22 show a 
binding preference for Site I. Thus, the binding of 
     PN20  PN22 
     EB  KB  %P  EB  KB
a  %P 
M
o
n
o
m
e
r
i
c
A
E
4
2
 
S
i
t
e
 
I
  1  -2.23  2.29x10
-2  24.62  -4.03  1.09x10
-3  18.14 
2  -3.17  4.72x10
-3  16.58  -3.67  2.04x10
-3  17.25 
S
i
t
e
 
I
I
  1  -2.77  9.13x10
-3  21.82  -1.11  1.58x10
-1  19.20 
2  -3.28  3.88x10
-3  18.64  -2.08  2.98x10
-2  18.75 
P
e
n
t
a
m
e
r
i
c
 
A
E
4
2
 
TOP 
1  -3.81  1.56x10
-3  21.66  -2.10  2.88x10
-2  25.00 
2  -3.26  4.23x10
-3  18.89  -1.60  6.84x10
-2  19.74 
E1 
1  -3.48  2.73x10
-3  22.12  -2.24  2.23x10
-2  26.51 
2  -4.00  1.17x10
-3  17.31  -1.74  5.23x10
-2  17.67 
E2 
1  -2.54  1.38x10
-2  22.07  -4.24  7.48x10
-4  20.34 
2  -3.46  2.90x10
-3  17.57  -4.71  3.25x10
-4  19.49 
a KB is calculated in with the equation KB=exp((ΔG*1000.)/(Rcal*TK),
where ΔG is the docking energy, Rcal is 1.98719 and TK is 298.15 
Table 7.2: The two most populated families of PN20 and 
PN22 found by docking simulations on the monomeric 
and pentameric Aβ42 peptide and the corresponding bind-
ing energy (EB, kcal mol-1) of the complexes. The binding 
constant (KB, M) and the relative populations (%P) are 
also shown.

Figure 7.4: Density population distribution as a function 
of the binding energy: (A) PN20 and PN22 on the mono-
meric target model. (B) PN20 and (C) PN22 on the penta-
meric aggregate target model. The histogram of the densi-
ty population distribution was fitted to a spline smoothing 
regression.
7.3.1.3  Docking studies
The docking studies performed here 
have been analyzed on the basis of their confor-
mational population distribution as a function of 
the binding energy. The clusterization procedure 
was run with a cut-off of 2.00 Å RMSD. Figure 
7.4 shows the density population distribution for 
PN20 and PN22 on the two target system-models 
used here.
Monomeric Model. Two potential bind-
ing sites were found by using a single blind dock-
ing run (results not shown) on the monomeric 
Aβ42 molecule (PDB code 1IYT). Figure 7.5A 
depicts the location of these potential binding 
sites. Site I encompasses the residues 21-26 con-
taining Glu22 and Asp23, which were previously 
identified as residues for aggregation of the oligo-
mers (Buchete and Hummer 2007; Masman et al. 
2009a). Site II includes residues 6-12 located in the 
portion of the molecule that loses all structural 
organization after oligomerization, thus form-
ing part of the so-called disordered region. The 
docked-conformational population for PN20 and 
PN22 is shown in figure 7.4, panel A. It can be 
observed that PN20 does not show a preference 114 
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plex is the most similar arrangement to the ideal 
case. Even though the quantity of H-bonds was 
less numerous than in the ideal case, the orienta-
tion of the “poor and rich” H-bonding faces ap-
pear similar. Figure 7.7 reveals the atomic details 
of the interactions of the second most populated 
complex (family 2 β2, in table 7.2) found between 
PN22 and the pentameric Aβ42. All the ligand-
target contacts are depicted as wireframe spheres. 
PN22 is located in a transversal direction to the 
Aβ chains, and inside an important channel-like 
hydrophobic pocket formed between the residues 
Ile31 and Met35 of the aggregate. The side-chains 
of PN22 are localized parallel to the Aβ back-
bone. Thus, the side-chains act as hydrophobic 
anchors. Obviously, due to the highly hydropho-
bic nature of both, target and drug molecules, the 
predominant interaction type is the hydrophobic 
contact. Also, it is interesting to mention that the 
N-methyl groups face the Aβ aggregate, this way 
increasing the hydrophobic contact between drug 
and receptor. Accordingly, the “rich H-bonding 
face” is exposed to the surrounding space, where 
the solvent (water) should be.
PN22 on Site II is energetically weaker than the 
one observed on Site I. In table 7.2 the two most 
populated families of the complexes of PN20 and 
PN22 with the monomeric Aβ42 are summarized. 
PN22 showed lower binding energies, while site 
I was in general energetically preferred over site 
II. Figure 7.5B shows the interacting complex of 
PN22 on Site I. Amongst all the interaction ob-
served here, it is important to highlight that the 
NH3
+ group of residue Lys forms a strong salt-
bridge interaction with residue Asp23.
Pentameric Model. The target model 
used here was previously reported by Masman 
and coworkers (Masman et al. 2009a). This Aβ42 
aggregates model contains two β-sheet moieties 
(β1, residues 18-26 and β2, residues 31-42), which 
are proposed as putative binding sites. Moreover, 
a third possible site for interactions with ligand 
molecules is postulated, which involves both 
above mentioned sites (β1 and β2) at the edge of 
the aggregate. This site, here called the TOP site, 
is orientated into the oligomeric axis, in the same 
direction where the oligomers grows by aggre-
gation. Table 7.2 shows the two most populated 
families of the complexes of PN20 and PN22 with 
the pentameric Aβ42. It is observed in figure 7.4B 
that PN20, in contrast with our expectation, has 
no preference to bind any of the sites targeted 
here. PN20 unselectively binds to β1, β2 and TOP 
sites. On the other hand, PN22 displayed a pref-
erence to bind the β2 site compared to the other 
two proposed sites. Figure 7.4C shows that the 
most populated conformations are energetically 
preferred when PN22 binds to site β2, while this 
peptide binds nonspecifically to β1 and TOP sites. 
Figure 7.6A illustrates an ideal H-bonding ar-
rangement for TOP interaction of PN22 with 
an Aβ aggregate. It is depicted that PN22 may 
expose a “rich H-bonding face” to interact with 
the target molecule while exposing a “poor 
H-bonding face” that may stop the aggregation 
process. Figure 7.6B shows the atomic details of 
the interactions of the most populated complex 
(family 1 TOP, in table 7.2). This interacting com-
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Figure 7.5: (A) Location of site I and site II on the mo-
nomeric Aβ42 model. (B) Stereoview of the populated 
complex PN22/Aβ42 monomeric on site I. All ligand-target 
contact are depicted as wireframe spheres. Salt-bridge 
Lys-NH3
+/Asp23 is marked with a block-arrow. 115  
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Figure 7.6: (left) (A) An ideal TOP inter-
action of PN22 with an Aβ42 aggregate. The 
N-methyl amino acid residues are shaded 
in grey. Hydrogen bonds are represented 
as slashed lines (---). (B) A stereoview of 
most populated complex PN22/Aβ42 pen-
tameric model on site TOP. All ligand-
target contact are depicted as wireframe 
spheres.
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Figure 7.7: (down) A stereoview of the 
second most populated complex PN22/
Aβ42 pentameric on site β2. Different 
views are shown: lateral (A), frontal (B), 
zoomed in (C and D). Panel C shows the 
ligand-target contact which are depicted 
as wireframe spheres. Panel D shows a 
stereo-view of PN22 in the channel-like 
hydrophobic pocket formed, mainly by 
residues Ile31 and Met35.116 
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Figure 7.8: Cell viability of primary cortical neurons determined by an MTT-assay. Neuronal survival was determined 
after incubating increasing concentrations of the pentapeptides (A) PN20 and (B) PN22 with or without 25 μM Aβ42 for 24 
h. Bars indicate the mean cell viability in % relative to untreated controls ± SEM. (* = significant at p < 0.05; ** = highly 
significant at p<0.005).
7.3.2  Experimental testing
7.3.2.1  Pn22 is neuroprotective against 
oligomeric aβ42 in vitro
Part of this study was to provide proof 
of principle that the newly designed aggregation 
modulator peptides have the potential to protect 
nerve cells against Aβ-induced toxicity. Thus, we 
tested firstly whether these novel peptides exhib-
ited any toxicity to neuronal cultures by them-
selves, and secondly whether PN20 and PN22 were 
capable to neutralize the toxic effect of oligomeric 
Aβ42. To this purpose primary cortical neurons in 
culture were exposed to different concentrations 
of PN20 or PN22 alone, to Aβ42 alone (25 µM) or to 
pentapeptides and Aβ42 together for 24 h. Neither 
PN20 nor PN22 alone was toxic to neurons at 
any tested concentration (figure 7.8). When ex-
posed to 25 µM oligomeric Aβ42 only 30-40 % of 
the cultured neurons survived a 24 h incubation. 
Furthermore, both PN20 and PN22 were able to 
protect the neurons from Aβ42-induced toxicity in 
a dose dependent manner (figure 7.8). The meth-
ylated PN22 (figure 7.8B) in that respect proved 
to be more effective reaching significance at 8 µM; 
P=0.02 when compared to the non-methylated 
PN20 (figure 7.8A) (reaching significance at 32 
µM; P=0.01). With the highest concentration (250 
µM) of PN20 up to 62.3± 12.9% of the neurons sur-
vived the Aβ treatment. 250 µM of PN22 was even 
more protective against the Aβ42 challenge with 
up to 86.3± 3.7% cell survival.
7.3.2.2  Cognitive deficits induced by oligo-
meric aβ42 can be neutralized by pn22
Based on the in vitro data we selected 
the most effective peptide PN22 and tested wheth-
er PN22 is able to reverse the Aβ-induced memory 
deficits. We further included a scrambled peptide 
(scrP) as a control for sequence specificity of the 
peptides. To that purpose we used an animal 
model in which we injected mice with oligomeric 
Aβ42 into the hippocampus to induce memory 
deficits (Granic et al., 2009).
One hour prior to the training session in 
a contextual fear conditioning paradigm C57BL/6J 
mice received a single injection of oligomeric Aβ42 
(30 pmol) or vehicle with PN22 (150 pmol) or scrP 
(150 pmol). In general the injections did not affect 
locomotion or the shock reaction during training  117  
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(data not shown). The vehicle injected animals 
displayed an average relative freezing behavior, as 
a measure of memory score of 57.1± 2.2%, which 
did not differ from untreated control animals 
(58.1± 3.6 %). The injection of 30 pmol oligomer-
ized Aβ42 led to a significant decrease in freezing 
behavior compared to the vehicle group (33.7± 
6.5% vs 57.1± 2.2; p=0.002) (figure 7.9) indicative 
of impaired memory storage.
The PN22 and the scrP injected mice 
showed an average freezing of 54.9± 5.0% and 
63.0± 5.5% respectively, which did not significant-
ly differ from the untreated control (61.1± 2.4%) or 
vehicle injected group (58.9± 2.9%).
However, PN22 co-injected with Aβ42 
was able to abolish the Aβ42 oligomer-induced 
memory impairment (53.7± 2.8% vs 33.7± 6.5%; 
p=0.01). Co-injection of Aβ with scrP resulted in 
an average freezing score of 48.0± 4.9%, which did 
not significantly reverse the Aβ-induced mem-
ory deficits. These results provide evidence that 
PN22 is capable to neutralize the negative effects 
induced by Aβ42 oligomers on memory perfor-
mance in an in vivo test paradigm.

Figure 7.9: Effect of Aβ42 and PN22 on contextual fear 
conditioning. Co-injection of Aβ42 with PN22 prevented 
the Aβ-induced memory impairment significantly, where-
as the non-specific control peptide scrP failed to revert 
memory deficits. Bars indicate the mean relative freezing 
score in % ± SEM. Differences were determined by ANO-
VA (* = significant at p < 0.05).
 Discussion
Crucial for the aggregation process 
of the Aβ molecule are the hydrophobic residues 
that encompass the β2 region (amino acids 30-42). 
Thus, it was also observed for Aβ42 monomers in 
solution that the sequence I31IGLMVGGVVIA42 
(namely, the β2 portion) may be responsible for 
the higher propensity of this peptide to form 
amyloid aggregates (Sgourakis et al. 2007). 
Therefore, small peptides like PN20 and PN22, 
which are partially homologous to this hydro-
phobic region, bind with a relatively high affin-
ity to Aβ by similar intermolecular interactions, 
leading to a competitive replacement of Aβ mol-
ecules. Interestingly our docking results showed 
that PN22 binds preferably to the β2 portion of 
the aggregate (table 7.2 and figure 7.4C), which 
has a good correlation with the design of this pen-
tapeptide. However, in contrast with our expecta-
tions, PN20 did not show such a binding profile. 
This may be explained by the fact that PN20 dis-
played a complete different conformational be-
havior in solution than PN22 as shown by EDMC 
and MD simulations. PN22 had a strong prefer-
ence for extended conformations, while PN20 
showed a strong affinity to folded conformations. 
This was not only observed in solution but also in 
our docking results. Thus, an extended or semi-
extended conformation was observed for the ma-
jority of the most populated complexes that PN22 
formed, whereas the opposite was the case for 118 
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PN20. It appears to be that an extended or semi-
extended conformation is the possible “biologi-
cally relevant conformation” or “pharmacophoric 
patron” for these peptides.
On the other hand, all the docked 
preferred conformations showed a tendency 
to extended or semi-extended ligand’s orienta-
tion. Moreover, the docking studies could pre-
dict that a modification of PN20 by alternated 
N-methylation, thereby moderately increasing 
its hydrophobicity, improves the interaction 
to the β2 portion of the Aβ42.aggregates. Thus, 
PN22 shows a selective binging to the portion β2. 
Neither PN20 nor PN22 showed a preference to 
bind the monomeric or the pentameric Aβ42 mod-
el, which suggests us that the peptides may bind to 
both forms of Aβ42.
We hypothesize that Site I-bound-PN22, 
especially on Asp23, causes impediment or slow-
ing down of the conformational change that pre-
cedes the aggregation. Consequently, PN22 bind-
ing increases the possibilities of degradation or 
clearance of Aβ monomers (see figure 7.1), since, 
Asp23 plays a crucial role in the stabilization of the 
Aβ aggregates. In general it can be observed that 
PN22 binds stronger and selectively to Site I, to 
the monomeric Aβ42 than PN20.
The present results indicated that pen-
tapeptides PN20 and PN22 can significantly 
preserve cultured neurons from Aβ-induced cell 
death in a dose dependent manner. Moreover, 
the methylated pentapeptide PN22 protected the 
cells more effectively than the non-methylated 
PN20. Similar results on PC12 cells by using dif-
ferent single N-methyl amino acid containing 
peptides were previously reported (Cruz et al. 
2004; Hughes et al. 2000). Peptides endowed with 
N-methyl amino acids have some clear advantag-
es with respect to their potential as a therapeutic 
agent. These peptides remain remarkably stable to 
changes in solvent conditions and resist denatur-
ation by heating, changes in pH (from 2.5 to 10.5), 
and addition of denaturants. Furthermore, this 
kind of peptides despite their hydrophobic com-
position is highly water soluble. A water soluble 
but hydrophobic nature suggest that these pep-
tides might be able to pass spontaneously through 
biological cell membranes (Gordon et al. 2002).
An important aim of our study was to 
establish if a compound like PN22 is able to pre-
vent Aβ–induced learning and memory deficits 
in a mammalian animal model. We showed that 
a 5-fold molar excess of PN22 to Aβ could over-
come the detrimental effects of Aβ oligomers on 
memory when injected into the hippocampal re-
gion. Thus, we provide evidence that N-methyl 
containing peptides such as PN22 bear therapeu-
tic potential against Aβ-induced memory impair-
ment.
The mechanism how these penta-
peptides exert their protective effects on cell 
death and behavior is not yet fully understood. 
However, these peptides directly bind to Aβ 
and thereby may prevent possible interactions 
between Aβ and neuronal membrane proteins 
and in this way neutralize the toxic effect of Aβ 
oligomers. We hypothesize two options of inter-
action notably of PN22 with Aβ that are depicted 
in figure 1. Pathway 1 proposes that PN22 binds 
to the monomeric Aβ thus preventing and/or 
retarding the formation of toxic oligomers, by 
interfering with the conformational change that 
precedes the oligomer formation. Pathway 2 sug-
gests that PN22 binds to the already formed Aβ 
oligomers thereby preventing and/or modulating, 
somehow, its neurotoxic properties. By either of 
these actions, or both, the neurotoxicity of Aβ is 
decreased or reverted and the Aβ clearance/deg-
radation processes be reactivated.
We may conclude that this novel in silico 
designed N-methyl amino acid containing pep-
tide interacts with Aβ42 and that different regions 
of Aβ may be selectively targeted by this peptide. 
Our findings provide evidence on how and where 
PN22 interacts with Aβ42 mono- and oligomers, 
that PN22 can neutralize the neurotoxic effects  119  
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of soluble Aβ42 oligomers in vitro and in vivo. In 
the latter condition we obtained proof of principle 
that this pentapeptide can effectively prevent the 
Aβ oligomer-induced deficits in memory perfor-
mance. More structural evidence is required to 
consolidate the proposed mechanism and to fur-
ther improve our peptide designs. Nevertheless, it 
is clear that these peptides can serve as promising 
molecular designs that hold promise as therapeu-
tic molecules for treatment of AD. ■
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“The brain may take advice, but not the heart, and love, 
having no geography, knows no boundaries: weight and 
sink it deep, no matter, it will rise and find the surface: 
and why not? any love is natural and beautiful that lies 
within a person’s nature; only hypocrites would hold a 
man responsible for what he loves, emotional illiterates 
and those of righteous envy, who, in their agitated con-
cern, mistake so frequently the arrow pointing to heaven 
for the one that leads to hell’
(T. Capote) 
088.1
General discussion & future perspectives
Marcelo F. Masman
Chapter 8
It is well known that the ultimate goal 
of the medicinal chemist is to develop, by rational 
design, a molecule which will produce a desired 
biological activity without producing undesir-
able collateral effects. To be able to achieve such 
an objective a complete description of the phar-
macophore (box 8.1) is extremely important. 
Although the presently available techniques of 
molecular modeling have allowed more “ratio-
nal” and planned investigation with respect to 
those developed in the last century, they are still 
far from perfect. However, computational chemi-
cal techniques are used routinely to identify un-
  The role of computational medicinal chemistry in today’s drug discovery
derlying reasons and explanations for observed 
chemical reactivity, or to assess the probability of 
a molecule to exhibit certain desired properties. 
Thus, in silico (box 8.2) techniques reduce the hu-
man effort, the time consumed in bioassays, and 
the number of experimental animal laboratory 
studies necessary to provide the first steps to-
wards developing a new drug. In order to achieve 
the above mentioned goals, compromises in view 
of the complexity of the biological system and in-
dividual variations must be taken into account. 
Otherwise, a realistic approach of a given system 
may be put at risk.
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Besides being a very interesting source 
of new potential drugs, peptides are still relatively 
large sized systems which seriously limit the com-
plexity of the level of theory that is going to be 
used to attack the problem from the point of view 
of the computational technique. Normally, a hy-
brid methodology that combines molecular dy-
namics with quantum mechanical geometry op-
timization is nowadays used. Complex molecular 
systems can be approached by using this method-
ology in a relatively realistic fashion. Also, a re-
duced model may be generated from the former 
one in order to perform more exact energetic 
determinations by using quantum calculations. 
Thus, the “whole” system can be studied by split-
ting it into several reduced models. It is for this 
reason that this reductionist approach is generally 
called a “divide and conquer” challenge.
On the other hand, the rapidly evolving 
and improving cost-performance relationship is 
placing high-tech computers on the desktop of to-
day’s medicinal chemist. Access to high resolution 
interactive computer graphics, conformational 
energy minimization of relatively larger biologi-
cal systems, classical and quantum molecular 
dynamics, geometrical optimizations, homolo-
gous protein structure generation and sequence 
database searching are examples of some tools 
which can routinely accessed through commer-
cial molecular modeling software packages. All in 
all, these improvements allow us to perform more 
realistic simulations of the biological system un-
der study.
The application of molecular modeling 
techniques in any area of medicinal chemistry 
have been shown to be convenient and necessary 
in order to determine the potential compounds 
to be synthesized and tested. Some great find-
ings have been accomplished regarding drug de-
sign based on molecular modeling. For instance, 
Agouron Pharmaceutical designed Viracept, an 
HIV-1 protease inhibitor, using structure-based 
design tools (Babine et al. 1995). Crixivan (Dorsey 
et al. 1994), another HIV-1 protease inhibitor re-
ceived FDA approval in record time, and is now 
used by over 300,000 patients worldwide. Also, by 
means of structure-based methods, Merck devel-
oped a glaucoma therapeutic agent called Trusopt 
(Greer et al. 1994). Without such calculations, nei-
ther structure based approaches nor de novo drug 
design would be at the stage that they are at pres-
ent. In addition, these techniques helped to design 
several new candidate drugs as mentioned above.
I personally consider from a scientific 
point of view that the use of molecular model-
ing supporting experimental bioassays is not only 
preferable, but also necessary. It has been recog-
nized that scientific knowledge has advanced far 
enough to permit a focus on molecular mecha-
nisms with atomistic details. In today’s drug 
discovery  in silico molecular modeling studies 
are now developed and fully accepted, not as a 
supplement to a checklist procedure, but rather as 
integral part of medicinal chemistry.
Box 8.1: Pharmacophore definitions
- P. Ehrlich, (1909); “a molecular framework that carries 
(phoros) the essential features responsible for a drug’s 
(pharmacon) biological activity”.
- P. Gund, (1977); “a set of structural features in a molecule 
that is recognized at a receptor site and is responsible for 
that molecule’s biological activity”
- IUPAC (1998); “an ensemble of steric and electronic fea-
tures that is necessary to ensure the optimal supramolecu-
lar interactions with a specific biological target and to trig-
ger or block its biological response”.
Box 8.2: In silico is an expression used to mean “per-
formed on computer or via computer simulation.” The 
phrase is coined in analogy to the latin phrases in vivo 
and in vitro which are commonly used in biology and re-
fer to experiments done in living organisms and outside 
of living organisms, respectively. The term in silico does 
not mean anything in latin. The proper latin phrase would 
likely be in simulacro to describe experiments done on the 
likeness (simulacrum) or model of a phenomenon.124 
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8.2
   cAMP signaling pathways as a putative new target of antifungal drugs
Amongst the fungi tested as part of the 
present thesis, Cryptococcus neoformans (box 8.3) 
and  Candida albicans (box 8.4) were the most  
sensitive to the antifungal peptides designed in 
this thesis. It is important to highlight that the 
mechanism of action of these peptides has not 
been determined yet. Nevertheless, as a general 
feature, antimicrobial cationic peptides possess 
a relatively non-specific mechanism of action by 
either acting through a detergent-like disruption 
of the bacterial or fungal cell membrane or by 
the formation of transient transmembrane pores 
(Huang 2000; Shai 2002). The former mecha-
nisms are the ones proposed especially for cell-
penetrating peptides studied in chapter 4, since 
these peptides are long enough to form α-helix 
conformations that may lead to cell membrane 
pore formation. However, peptides derived from 
the α-MSH studied in chapters 2-3 may be too 
short to form cell membrane pores. Nevertheless, 
there is now evidence that the antimicrobial ac-
tivity of α-MSH and derivative peptides is exerted 
through a unique mechanism substantially differ-
ent from that of other natural antimicrobial pep-
tides, at least in the case of C. albicans (Grieco et 
al. 2003).
Previous investigations have yielded 
evidence that the candidacidal effect of α-MSH 
is linked to mechanism of cAMP-inducing activ-
ity. α-MSH seems to increase cAMP production 
in C. albicans and the adenylyl cyclase inhibitor 
ddAdo (dideoxyadenosine) partly reversed the 
candidacidal effect of the peptide (Cutuli et al. 
2000; Grieco et al. 2003). It is remarkable, how-
ever when we carefully look at it, this mechanism 
of action in C. albicans mimics the influence of 
α-MSH in mammalian cells in which the peptide 
binds to G-protein-linked melanocortin recep-
tors, activates adenylyl cyclase, and increases 
cAMP. In support of this, Singh and coworkers 
reported that, by using phosphodiesterase inhibi-
tors, the alteration in the cAMP signaling path-
way affects the cell cycle progression in Candida 
albicans (Singh et al. 2007). Therefore, implication 
of cAMP signaling in both the cell cycle and mor-
phogenesis seems to be a potential target for the 
development of new antifungal drugs. However, 
due to the overall implications that cAMP sig-
naling pathways have in humans, one may ask; 
how selective the designed drugs using this target 
would be? Since, fungal cells seem to have similar 
cAMP signaling pathways as human cells, a com-
pound that targets this pathway would not be, at 
least in principle, a selective enough candidate.
Box 8.3: Cryptococcus neoformans is an encapsulated 
yeast-like fungus that can live in both plants and animals. 
This species belongs to the broad class of organisms called 
“club fungi” or division basidiomycota, which is one the 
five major types of fungi. C. neoformans usually grows 
as a yeast (unicellular) and replicates by budding. Under 
certain conditions, both in nature and in the laboratory, 
C. neoformans can grow as a filamentous fungus. When 
grown as a yeast, C. neoformans has a prominent capsule 
composed mostly of polysaccharides. Infection with C. 
neoformans is termed cryptococcosis. Most infections 
with C. neoformans consist of a lung infection. However, 
fungal meningitis, especially as a secondary infection for 
AIDS patients, is often caused by C. neoformans making it 
a particularly dangerous fungus. Infections with this fun-
gus are rare in those with fully functioning immune sys-
tems. For this reason, C. neoformans is sometimes referred 
to as an opportunistic fungus.
Box 8.4: Candida albicans is a yeast fungus and a causal 
agent of opportunistic oral and genital infections in hu-
mans. Systemic fungal infections, especially candidia-
sis, have emerged as important causes of morbidity and 
mortality in immunocompromised patients (e.g., AIDS, 
cancer chemotherapy and organ or bone marrow trans-
plantation). C. albicans is among the many organisms that 
live in the human mouth and gastrointestinal tract. Un-
der normal circumstances, C. albicans lives in ca 80% of 
the human population with no harmful effects, although 
overgrowth results in candidiasis. 125  
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  Targeting the amyloid hypothesis with aβ-toxicity offsetting peptides
It is controversially discussed wheth-
er the amyloid fibrils are an epiphenomenon 
linked to Alzheimer’s disease (AD) or whether 
fibril formation causes AD (Forman et al. 2007; 
Wisniewski et al. 1997). There is now more con-
sensus, however, based on in vitro and in vivo 
evidence that soluble oligomeric forms of Aβ have 
potent neurotoxic activity and are the primary 
causes of neuronal injury and cell death occur-
ring in AD (Lesne et al. 2006; Lue et al. 1999; 
Naslund et al. 2000; Wasling et al. 2009). On the 
other hand, there is a relatively weak correlation 
between the severity of dementia and the density 
of fibrillar amyloid plaques (Dickson et al. 1995; 
Katzman 1986; Terry et al. 1991) and indeed this 
has been frequently cited as a critical flaw in the 
Aβ hypothesis. However, several studies have 
shown a robust correlation between soluble Aβ 
levels and the extent of synaptic loss and sever-
ity of cognitive impairment (Chang et al. 2006; 
Chapman et al. 1999b; Dineley et al. 2002; Dodart 
et al. 2002; Haass and Selkoe 2007; Jacobsen et al. 
2006; Lesne et al. 2006; Lue et al. 1999; McLean et 
al. 1999; Naslund et al. 2000; Shankar et al. 2008; 
Shankar et al. 2007b; Walsh and Selkoe 2007; 
Wang et al. 1999; Wasling et al. 2009).
It is important to mention that the 
production of Aβ is a normal process (Haass et 
al. 1992a; Seubert et al. 1992; Shoji et al. 1992), 
but in a small number of individuals, the over-
production of all Aβ species, or an increased 
proportion of the 42 amino acids form, appears 
sufficient to cause early onset AD (Bentahir et 
al. 2006; Cai et al. 1993; Citron et al. 1992; Haass 
et al. 1992b; Kumar-Singh et al. 2006; Rovelet-
Lecrux et al. 2006; Seubert et al. 1992; Suzuki et 
al. 1994). Therefore, the mere presence of Aβ does 
not cause neurodegeneration; rather neuronal in-
jury appears to ensue as a result of the ordered 
self-association of Aβ molecules (Busciglio et al. 
1992; Geula et al. 1998; Pike et al. 1991). However, 
it should be appreciated that besides its patho-
logical properties, Aβ may have important roles 
in synaptic plasticity and normal brain function-
ing (Pearson and Peers 2006; Puzzo et al. 2008; 
Wasling et al. 2009). The endogenous level of Aβ 
in the brain is regulated by synaptic activity in 
vivo, suggesting a dynamic feedback loop involv-
ing APP metabolism and Aβ that may modulate 
synaptic activity (Haass and Selkoe 2007). Thus, it 
has been shown that the depletion of endogenous 
Aβ, by a single intrahippocampal administration 
of anti-Aβ-antibody, leads to disrupted memory 
retention in rats (Garcia-Osta and Alberini 2009). 
The advantage of targeting the amy-
loid hypothesis with Aβ-toxicity offsetting pep-
tides (box 8.5), in comparison to other putative 
therapeutic approaches for AD such as vaccina-
tion, is that they specifically target the abnormal 
conformation of Aβ without interfering with any 
possible physiological function of the soluble mo-
nomeric Aβ peptide. Moreover, this type of com-
pounds may not interfere with the metabolism 
of APP, and this is an advantage in comparison 
with the secretase inhibitors (e.g.: β-secretase 
and g-secretase inhibitors). Blocking this secre-
tase system can cause failures of very important 
metabolic pathways. Thus, blocking γ-secretase 
complex, besides lowering Aβ formation in ex-
perimental systems, interferes with receptor/
signalling system of the protein Notch. The re-
duction of Notch activity could interfere with im-
portant cellular proliferation and differentiation 
pathways (Pollack and Lewis 2005).
8.3
Box 8.5: The term Aβ-toxicity offsetting peptides is used 
in this thesis to refer to those peptides that somehow, neu-
tralize the toxic effect of Aβ on neurons. The term “β-sheet 
breakers”, introduced by C. Soto in 1998, have been widely 
used to refer to this kind of peptides, even when the pep-
tides did not show any β-sheet breaking properties. For 
this reason, I propose to use this new terminology to refer 
to this novel class of compounds, in which the effect of the 
peptide is mentioned but not necessarily its way of action. 126 
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On the other hand, it was shown that 
Leu-Pro-Tyr-Phe-Asp-NH2 and PN22 peptides, in 
respectively chapters 6 and 7, may bind the mo-
nomeric form of Aβ42. Nevertheless, this binding 
property may interfere with the conformational 
changes that precede the aggregation process and 
not with the normal physiological functions of 
the soluble monomeric Aβ peptide.
  May anti-amyloid properties lead to antifungal activity?
Some of the Aβ-toxicity offsetting pep-
tides studied here were designed on the basis of 
their capabilities to bind Aβ aggregates by “mim-
icking” Aβ properties and conformational be-
havior (chapters 6 and 7), which might endow 
them anti-amyloid properties. On the other hand, 
the antifungal peptides ported in chapters 2-4 
share some structural similarities with these Aβ-
offsetting peptides. For instance, both types of 
peptides are positively charged and have a com-
promising relationship between hydrophobic/
aromatic residues and charged residues. However, 
they do not necessarily share the same confor-
mational preferences. In general, cell-penetrating 
peptides with antifungal properties (chapter 4) 
showed a preference to form folded conforma-
tions (a-helix-like conformations), while α-MSH 
derived antifungal peptides (chapters 2-3) pre-
ferred extended conformations (β-sheet-like con-
formations). The latter one is another similarity 
shared with the Aβ-toxicity offsetting peptides 
reported in chapter 7. Regarding the above 
mentioned, one may wonder whether anti-amy-
loid properties can lead to antifungal activity?
Within the past two decades, several 
proteins that do not necessarily have similar ami-
no-acid sequences have been reported to form 
amyloid-like aggregates on the surfaces of some 
fungi and bacteria (Claessen et al. 2003; Claessen 
et al. 2002; Gebbink et al. 2005). The functions 
that these aggregated proteins seem to play on the 
surfaces of these microorganisms are multifold. 
For instances, these amyloids play an important 
role in the invasion of abiotic and biotic sub-
strates, reduce the water surface tension allowing 
hyphae to escape aqueous environments, and en-
able hyphae to penetrate solid surfaces (e.g.: host 
cuticle) amongst others. There is also experimen-
tal evidence that the amyloid layer forms a pro-
tective “coat” to allow microorganisms to evade 
the immune system of the host (Wosten and De 
Vocht 2000). Currently, hydrophobins are the 
only proteins known to form amyloids on fun-
gal surfaces (Linder 2009). Other proteins may 
fulfill this role in fungi that do not express hy-
drophobins (e.g.: Candida albicans) (Gebbink et 
al. 2005). Bacteria have been shown to form cell-
surface-located amyloids of two classes of pro-
teins; chaplins and curli/tafi (Claessen et al. 2003; 
Gebbink et al. 2005). Thus, it seems that the pres-
ence of amyloid structures on the cell surface of 
microorganisms is widespread. Therefore, these 
amyloid-like arrangements seem to be a promis-
ing novel target to design compounds capable of 
disrupting the structure of these aggregates and 
through this action to expert their anti-microbial 
properties. In that respect, C. neoformans seems 
to be highly affected by the peptides reported in 
this thesis (chapters 2-4). May be this due to an 
existing amyloid “coat” on the surface of this fun-
gus, which may be disrupted by these peptides? 
Whether this is the case of C. neoformans or 
not, the finding of such structures on the surface 
of pathogenic microorganisms that cause life-
threatening infections, is a novel target to develop 
selective therapeutic agents.
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8.5
  Overall conclusions and perspectives
The work described in this thesis is a 
step forward towards a protein based drug de-
sign in which methods of rational drug design 
and dynamical features of the target have been 
taken into account. Clearly, the in silico design is 
a method that can be used to study complex bio-
logical systems. However, the results of the simu-
lations should be interpreted with caution.
Several new targets to develop putative 
drugs have been mentioned in this thesis, which 
may give the possibility to project future investi-
gation programs, some of them are already being 
in a developing phase. With regards to antifungal 
peptides, new families, based on our results re-
ported in chapter 4, are being designed, synthe-
sized and tested. Regarding the Aβ-toxicity offset-
ting peptides, new structures have been proposed 
as well as peptidomimetic structures currently 
under investigation in our labs. We may conclude 
with the statement that the findings presented in 
this thesis hold great potential for further devel-
opment of a strategy towards therapeutic applica-
tions in two major human health conditions. ■references 129  
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Development of Novel Small-Size Peptides as Putative Therapeutic Drugs
  Rational design of peptide drugs 
using computational techniques. This 
thesis focuses on the development of small pep-
tide molecules with putative therapeutic applica-
tions. In particular, our research has been focused 
on peptides with either antifungal properties 
(chapters 2-4) or with the ability to control pro-
tein deposits that cause the characteristic brain 
damage in Alzheimer’s disease (chapters 5-7). In 
modern medicinal chemistry research, the use of 
computational techniques has become an impor-
tant and almost inevitable step towards the devel-
opment of new drugs. With these techniques it is 
possible, with certain accuracy, to simulate what 
happens between a newly developed drug and its 
target molecule(s), e.g. protein, DNA, cell-mem-
branes, etc. Molecular dynamics is one of the 
computational techniques used in this thesis, and 
perhaps the one most frequently applied in mod-
ern medicinal chemistry. Based on the results of 
these types of calculations, new potential drugs 
were designed to achieve the optimum desired ef-
fects.
  New Peptide Drugs for the 
treatment of fungal infections. Fungal 
infections in humans are common and may af-
fect skin, intestines, heart, and brain, amongst  
other organs. Fungi are difficult to combat and 
can be life threatening, especially in AIDS pa-
tients, cancer patients after chemotherapy, organ 
transplanted patients, diabetes, burns, malnutri-
tion, etc. This is due to the fact that their immune 
system is remarkably weak, creating an ideal situ-
ation for fungi to attack. Fungal infections are dif-
ficult to suppress and a really selective, safe and 
effective drug to treat this type of infections is not 
yet available. Thus, there is a great need of pro-
ducing innovative and selective antifungal drugs. 
Small peptides derived from naturally occurring 
compounds have been taking under study in this 
thesis. The antifungal activities of these peptides 
have been tested in culture for several common 
pathogenic fungi. These antifungal peptides 
showed a promising profile to become a selective 
drug that might exert their effect through interac-
tion with the cell-membrane of the fungal cells.
  Novel peptides to protect 
against Alzheimer’s Disease. Alzheimer’s 
disease is a very complex disease where brain 
damage is associated with an increased degrada-
tion of the human mind and memory. Multiple 
factors play a role in causing the disease, but re-
searchers agree that the production of a specific 
toxic form of the beta-amyloid peptide plays a key 
role. This peptide is not toxic by itself but it be-
comes toxic when several beta-amyloid molecules 
clump together forming what is called soluble ag-
gregates. In this form the beta-amyloid become 
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toxic to nerve cells and a slow but unstoppable 
degradation process begins in brain regions that 
are essential for learning and memory, which in 
the course of years leads to the characteristic de-
mentia. The currently available drugs for treating 
Alzheimer’s disease have little impact and may, at 
best, delay the loss of memory, but do not stop the 
degradation process of the nerve cells. The severi-
ty of the disease and the enormous increase in the 
number of patients suffering from it, are the driv-
ing force of a worldwide search for new and more 
effective drugs. In our own research we focus on 
the development of new peptide compounds that 
prevent or slow down the formation of the toxic 
beta-amyloid soluble aggregates. By the use of 
computational techniques, we have been able to 
explore the self-bound beta-amyloid molecules, 
as well as their interaction with new potential 
drugs. With this important information we have 
designed small peptide drugs aimed at disrupt-
ing the toxic form of amyloid. The anti-amyloid 
potential of these peptides has been tested, in the 
first place, by cultured brain cells which have been 
exposed to toxic beta-amyloid forms. Secondly, 
we have tested these anti-amyloid peptides in the 
‘hippocampus’ of mouse brain, a typical brain 
area affected in the Alzheimer’s patient and which 
is the key structure for the formation of memory. 
Both testing experiments have produced not only 
positive but promising results indicating the po-
tential therapeutic application of these anti-amy-
loid peptides.■ 149  
Ontwikkeling van Innovatieve Kleine Eiwitten voor Therapeutische Toepassingen 
  Rationele ontwerpen van peptide 
medicijnen met behulp van moleculaire 
dynamica.  Dit proefschrift richt zich op de 
ontwikkeling van kleine moleculen voor me-
dicinale en therapeutische toepassingen. Met 
name richt het onderzoek zich op dergelijke kle-
ine eiwit moleculen voor de bestrijding van een 
tweetal ziekte veroorzakers: 1. Schimmelinfecties 
(hoofdstukken 2-4), en 2. Eiwitklontering 
die de oorzaak is van de ziekte van Alzheimer 
(hoofdstukken 5-7). 
In het moderne onderzoek naar nieuwe 
medicijnen wordt gebruik gemaakt van tech-
nieken van de moleculaire dynamica. Met deze 
technieken is het mogelijk om exact te berek-
enen wat er gebeurt tussen een nieuw ontwikkeld 
medicijn en het doeleiwit waar het medicijn op 
aangrijpt. Op grond van de uitkomsten van deze 
berekeningen kan het ontwerp van het nieuwe 
medicijn worden aangepast zodat een optimale 
werking wordt bereikt. Moleculaire dynamica is 
een van de berekeningsmethoden die zijn toege-
past in dit proefschrift. In het moderne onderzoek 
van de medicinale chemie is dit waarschijnlijk de 
meest gebruikte methode voor het ontwerpen en 
berkenen van nieuwe medicijnen.
  Nieuwe Peptide Medicijnen voor 
Schimmelinfecties. Schimmelinfecties bij de 
mens komen veelvuldig voor en kunnen een bed-
reiging vormen voor huid, darmen, inwendige 
organen, hart en hersenen. Schimmels vormen 
moeilijk te bestrijden infecties en kunnen lev-
ensbedreigend zijn met name in omstandigheden 
waarbij de weerstand van het individu is aange-
tast zoals bij HIV besmetting, bij chemotherapie 
van kankerpatienten, na orgaantransplantaties, 
bij diabetes, brandwonden, ondervoeding of ge-
brekkige hygiëne in het algemeen. In dergelijke 
omstandigheden is het immuunsysteem ernstig 
verzwakt en krijgen schimmels de kans om het 
organisme te besmetten. Inwendige of uitwendige 
schimmelinfecties zijn moeilijk te behandelen 
en er is grote behoefte aan nieuwe innnovatieve 
farmaca met afdoende anti-schimmelwerking. 
Kleine peptiden die zijn afgeleid van in de natu-
ur voorkomende verbindingen vormen daarbij 
een veelbelovend perspectief. In het proefschrift 
zijn een aantal van deze kleine peptiden ontwor-
pen en onderzocht op hun vermogen om veel 
voorkomende schimmels te vernietigen. Een aan-
tal van deze peptiden waren daarbij zeer succes-
vol door hun antibiotische effect op de celwanden 
van de schimmelcellen, en hebben de potentie 
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zich verder te ontwikkelen tot schimmelbestrij-
dende medicijnen.
  Innovatieve Kleine Peptiden 
voor Bestrijding van Alzheimer 
Eiwitten. De ziekte van Alzheimer is een zeer 
ingewikkeld ziektebeeld waarbij beschadiging 
van het  hersenweefsel gepaard gaat met een toen-
emende afbraak van het menselijk denkvermogen 
en het geheugen. Uiteindelijk gaan alle ervarin-
gen en herinneringen die gedurende een leven 
lang zijn opgeslagen in onze hersenen verloren. 
Meerdere factoren spelen een rol bij het vero-
orzaken van deze ziekte, maar onderzoekers zijn 
het erover eens dat de vorming van een eiwit in 
de grote hersenen beta-amyloid genaamd hierin 
een sleutelrol speelt. Als afzonderlijk molecuul is 
beta-amyloid niet toxisch, maar als beta-amyloid 
moleculen onderling gaan samenklonteren tot 
meervoudige amyloid moleculen worden ze gifig 
voor de hersencellen en komt een langzaam maar 
niet te stoppen afbraakproces in het brein op 
gang, dat in de loop van jaren tot de kenmerkende 
en steeds verder toenemende dementie leidt. 
Nu beschikbare medicijnen voor behan-
deling van de ziekte van Alzheimer hebben maar 
een gering effect en kunnen in het beste geval de 
achteruitgang van het geheugen enigszins ver-
tragen maar stoppen het afbraakproces niet. De 
ernst van de ziekte en de enorme toename van het 
aantal patiënten lijdende aan deze ziekte in de ko-
mende jaren zijn een drijvende kracht achter een 
wereldwijde zoektocht naar nieuwe en meer effec-
tieve medicijnen.
In ons eigen onderzoek richten wij ons 
op de ontwikkeling van nieuwe peptide medici-
jnen die de vorming van de beta-amyloid klon-
tering kunnen voorkomen, en daarmee de giftige 
werking van meervoudig amyloid kunnen bestri-
jden. Met behulp van moleculaire dynamica tech-
nieken hebben we het proces van amyloid klon-
tering nagebootst. Op basis van deze belangrijke 
informatie hebben we kleine peptide medicijnen 
ontworpen die erop gericht zijn de amyloid-
verbindingen te verbreken en die we anti-amyloid 
peptiden hebben genoemd. 
  Enkele van deze peptiden heb-
ben we in het laboratorium getest op hun effectiv-
iteit om hersenen te beschermen tegen de gifitige 
amyloid klontering. Dit hebben we op verschil-
lende manieren onderzocht. In de eerste plaats 
door gekweekte hersencellen bloot te stellen aan 
geklonterde amyloidmoleculen. Hierop sterven 
de hersencellen, maar toevoeging van onze anti-
amyloid peptiden gaf een effectieve bescherming 
tegen het gifige amyloid. In de tweede plaats heb-
ben we in de hersenen van muizen geklonterd 
amyloid aangebracht in de ‘hippocampus’, een 
hersengebied dat kenmerkend is aangetast in de 
Alzheimerpatiënt. Hierdoor trad in deze dieren 
geheugenverlies op dat werd voorkomen door to-
epassing van de nieuwe anti-amyloid medicijnen. 
We kunnen concluderen dat we er in zijn geslaagd 
om nieuwe moleculen te ontwerpen die potentieel 
in staat zijn om de giftige eigenschappen van beta-
amyloid te bestrijden en de gevolgen hiervan voor 
de aantasting van het geheugen te voorkomen. 
Deze innovatieve peptide ontwerpen zijn veel-
belovend voor een effectieve behandeling van de 
ziekte van Alzheimer. ■  151  
Desarrollo de Nuevos Péptidos de Pequeño Tamaño como Drogas Terapéuticas Putativas
  El diseño racional de drogas pep-
tídicas mediado por técnicas computa-
cionales. Este trabajo de tesis se focaliza en el 
desarrollo de pequeños péptidos con aplicacio-
nes terapéuticas putativas. En particular, hemos 
focalizado nuestros esfuerzos en el diseño de 
estructuras peptídicas que posean, ya sea, activi-
dad antifúngica (capítulos 2-4) o capacidad de 
controlar las deposiciones proteicas que causan 
las lesiones cerebrales características del mal de 
Alzheimer (capítulos 5-7 ). En el campo de la 
química medicinal de hoy el uso de técnicas com-
putacionales es una importante y casi inevitable 
etapa en el desarrollo de nuevas drogas. Con el 
uso de estas técnicas es posible, con cierta exacti-
tud, simular lo que sucede a nivel molecular entre 
una nueva droga y su(s) molécula(s) target(s), por 
ejemplo: proteínas, ADN, membranas celulares, 
etc. Simulaciones de la dinámica molecular es 
una de las técnicas utilizadas en este trabajo de te-
sis y quizás es la técnica más frecuentemente apli-
cada en la química medicinal actual. Novedosas 
estructuras peptídicas han sido diseñadas basán-
donos en los resultados obtenidos con este tipo de 
técnicas. Estas nuevas drogas putativas han sido 
desarrolladas con el objetivo de lograr los ópti-
mos efectos deseados.
  Nuevas dogas peptídicas para el 
tratamiento de infecciones fúngicas. Las 
infecciones fúngicas en humanos son de común 
ocurrencia y pueden afectar piel, intestinos y 
cerebro entre otros órganos. Estos patógenos 
fúngicos son difíciles de combatir y amenazan 
contra la vida de las personas afectadas, especial-
mente en pacientes con SIDA, cáncer, que hayan 
recientemente recibido un órgano trasplantado, 
sufrido quemaduras, malnutrición, etc. Esto es 
debido a que estos pacientes poseen un sistema 
inmunológico marcadamente debilitado, creando 
así una situación ideal de ataque para este tipo 
de microorganismos patógenos. Esta infecciones 
fúngicas son difíciles de suprimir y actualmente 
no disponemos de una droga que sea realmente 
selectiva, segura y efectiva para su tratamiento. 
Es por esto que hay una gran necesidad de pro-
ducir drogas anti-fúngicas que sean innovadoras 
y sobre todo selectivas. En este trabajo de tesis se 
han estudiado pequeños péptidos de ocurrencia 
natural con potencial actividad anti-fúngica. Esta 
actividad ha sido testeada en cultivos celulares de 
diversos patógenos fúngicos comunes. Algunos 
de los péptidos anti-fúngicos reportados aquí 
mostraron una prometedora tendencia a conver-
tirse en drogas selectivas que podrían ejercer sus 
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efectos anti-fúngicos mediante la interacción con 
la membrana celular fúngica.
  Nuevos péptidos que nos prote-
jan contra el mal de Alzheimer. El mal de 
Alzheimer es una enfermedad extremadamente 
compleja en la cual el daño cerebral está asociado 
con una incrementada deterioración de la mente 
y memoria. Múltiples son los factores que juegan 
un rol importante en esta enfermedad, sin em-
bargo es de común acuerdo entre los científicos 
que el rol principal lo juega la presencia de espe-
cificas formas del péptido beta-amiloideo en el 
cerebro de las personas afectadas. Este péptido no 
es toxico por sí mismo, pero su toxicidad es ex-
presada cuando varias moléculas del péptido en 
cuestión se aglomeran para formar los llamados 
agregados en solución. En esta forma el péptido 
beta-amiloideo se torna neuro-toxico desatando 
un lento pero imparable proceso de degradación 
cerebral, afectando principalmente regiones esen-
ciales relacionadas al aprendizaje y a la memoria 
que con el curso de los años lleva a la demencia 
característica de esta enfermedad. Las drogas ac-
tualmente disponibles para su tratamiento tienen 
un impacto muy limitado y a lo sumo sólo retar-
dan la pérdida de memoria, pero no detienen la 
degradación neuronal. La severidad de esta enfer-
medad y el creciente número de pacientes que la 
padece son la fuerza impulsora, a nivel mundial, 
del desarrollo de una droga más efectiva para su 
tratamiento. En nuestro proyecto de investig-
ación nos hemos focalizado en el desarrollo de 
nuevos compuestos peptídicos que prevengan o 
retarden la formación de agregados tóxicos del 
péptido beta-amiloideo. Basándonos en técnicas 
computacional hemos podido explorar los aso-
ciados moleculares del péptido beta-amiloideo, 
como así también las interacciones de estos con 
nuevas potenciales drogas. Con esta importante 
información hemos diseñado pequeños péptidos 
que poseen tendencia a perturbar las formas toxi-
cas del péptido beta-amiloideo. Su potencial anti-
amiloideo ha sido testeado, en primer lugar, en 
cultivos celulares de neuronas las  cuales fueron 
expuestas a las especies toxicas del péptido beta-
amiloideo. Luego, su actividad anti-amiloidea 
fue probada in vivo en el hipocampo de ratones. 
Ambos experimentos no sólo han producido re-
sultados positivos, sino que también muestran re-
sultados prometedores indicando las potenciales 
aplicaciones terapéuticas de estos nuevos pépti-
dos anti-amiloideos.■ 153   
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